



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C12N 15/12, C07K 14/465, 14/47, 16/18, C12N 5/10, A01K 67/027, A61K 38/17, 31/70, 48/00, C12Q 1/68	A1	(11) International Publication Number: WO 97/46679 (43) International Publication Date: 11 December 1997 (11.12.97)
(21) International Application Number: PCT/US97/09709 (22) International Filing Date: 3 June 1997 (03.06.97) (30) Priority Data: 08/657,139 3 June 1996 (03.06.96) US 60/018,614 3 June 1996 (03.06.96) US Not furnished 2 June 1997 (02.06.97) US (71) Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL [US/US]; 332 North Lauderdale Street, Memphis, TN 38105-2794 (US). (72) Inventors: LAHTI, Jill, M.; 110 Plantation Woods Cove, Cor- dova, TN 38108 (US). KIDD, Vincent, J.; 110 Plantation Woods Cove, Cordova, TN 38108 (US). (74) Agents: DAVIS, Michael, D. et al.; Klauber & Jackson, 411 Hackensack Avenue, Hackensack, NJ 07601 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: CYCLIN-C VARIANTS, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF (57) Abstract The present invention includes alternatively and partially spliced cyclin C mRNAs, recombinant DNA and the truncated protein (a truncated cyclin C) they encode. The alternatively spliced mRNAs result from an insertion of unique exons containing premature termination codons. The partially spliced mRNAs result from an insertion of additional coding sequence derived from exons. One aspect of the present invention is the demonstration that at least one of the alternatively spliced cyclin C mRNAs is produced in a cell cycle dependent fashion, as is the novel truncated cyclin box protein that it encodes. Truncated cyclin C acts as an endogenously encoded cyclin C inhibitor by negatively regulating cyclin C/cdk8 complex activity, in much the same way as the cyclin dependent protein kinase inhibitors that inhibit the D-type cyclins, cyclin A and cyclin E.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TC	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

CYCLIN-C VARIANTS, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF

5

RESEARCH SUPPORT

The research leading to the present invention was supported in part by NIH grants CA 67938 and CA 21765. The government may have certain rights in the present invention. Support for this invention was also provided by the AMERICAN
10 LEBANESE SYRIAN ASSOCIATED CHARITIES.

FIELD OF THE INVENTION

This invention relates generally to naturally occurring alternative forms of a protein
15 that interacts with a protein kinase. This interaction has been proposed to be involved in the regulation of RNA transcription. The invention more particularly relates to a truncated form of the protein, a more stable form of the protein, related biomolecules and to methods of making and using the same, including diagnostic and therapeutic uses. The invention further includes corresponding amino acid and nucleotide
20 sequences.

BACKGROUND OF THE INVENTION:

The cell cycle for replicating cells can be divided into two periods: (1) the cell
25 division period, when the cell divides and separates, with each daughter cell receiving identical copies of the DNA; and (2) the period of growth, known as the interphase period. For the cell cycle of eucaryotes, the cell division period is termed the M (*mitotic*) period. The interphase period in eucaryotes is further divided into three successive phases: G1 (*gap 1*) phase, which directly follows the M period; S
30 (*synthetic*) phase, which follows G1; and G2 (*gap 2*) phase, which follows the S phase, and immediately precedes the M period. During the two gap phases no net change in DNA occurs, though damaged DNA may be repaired. On the other hand, throughout the interphase period there is continued cellular growth and continued

synthesis of other cellular components. Towards the end of the G1 phase, the cell passes a restrictive point and becomes committed to duplicate its DNA. At this point, the cell is also committed to divide. During the S phase, the cell replicates DNA. The net result is that during the G2 phase, the cell contains two copies of all of the DNA present in the G1 phase. During the subsequent M period, the cells divide with each daughter cell receiving identical copies of the DNA. Each daughter cell starts the next round of the growth cycle by entering the G1 phase.

The G1 phase represents the interval in which cells respond maximally to extracellular signals, including mitogens, anti-proliferative factors, matrix adhesive substances, and intercellular contacts. Passage through the restrictive point late in G1 phase defines the time at which cells lose their dependency on mitogenic growth factors for their subsequent passage through the cycle and, conversely, become insensitive to anti-proliferative signals induced by compounds such as transforming growth factor, cyclic AMP analogs, and rapamycin. Once past the restrictive point, cells become committed to duplicating their DNA and undergoing mitosis, as noted above, and the programs governing these processes are largely cell autonomous. (See generally, Darnell *et al* (1986) in *Molecular Cell Biology*, pp 146-148, Scientific American Books, New York.)

Regulation of the human cell cycle requires the periodic formation, activation, and inactivation of protein kinase complexes that consist of a regulatory (cyclin) subunit and a catalytic (cyclin dependent kinase or cdk) subunit. Cell cycle-dependent fluctuations in the levels of many of the cyclin proteins contribute to the activation of these protein kinase complexes. For example, cyclin B participates in the regulation of the G2/M transition by its association with its catalytic subunit, p34^{cdc2}, whereas cyclin A, in complexes with both p34^{cdc2} and cdk2, is essential for the completion of S-phase and entry into G2-phase. Complexes formed between the D-type cyclins and either cdk4 or cdk6 integrate growth factor signals and the cell cycle, allow cells to progress through G1-phase. This particular cell cycle pathway is specifically altered

during tumorigenesis, presumably due to its role in responses to mitogenic stimulation. Alterations have been identified in many components of this pathway, including the D-type cyclins, cyclin dependent protein kinases, and cyclin dependent kinase inhibitors (CKIs). Another G1-phase cyclin, cyclin E, in conjunction with its catalytic subunit cdk2, appears to be essential for progression from G1-phase into S-phase and the initiation of DNA replication. Cyclin E and cdk2 do not appear to be directly targeted during tumorigenesis, quite possibly due to their essential nature. (See generally, Sherr, *Cell* 79:551-555 (1994)) and Sherr, *Cell* 73:1059-1065 (1993)).

10 A class of novel polypeptides that are collectively known as cdk inhibitors (CKIs) can negatively regulate cyclin/cdk activity by associating with these complexes. These so-called "cell cycle brakes" act to inhibit cyclin/cdk complexes by binding specifically to either the cyclin or the cdk, but generally not both. CKI activity is cell cycle regulated allowing these proteins to function as inhibitors of their cognate

15 cyclin/cdk complexes for very limited periods during the cell cycle. The cdk inhibitors isolated thus far include p21^{Cip1, Waf1, Sdi1, Cap20}, p27^{Kip1}, p57^{Kip2}, and a small family of inhibitors of cdk4 (INK4), which include p16^{INK4a}, p15^{INK4b}, p18^{INK4c}, and p19^{INK4d}. In some cases (i.e., p21^{Cip1, Waf1, Sdi1, Cap20}) this inhibitory activity may be conditional, and these proteins may also act to positively regulate cyclin/cdk

20 complexes by functioning as "bridge" molecules that maintain complex formation and enzyme activity. The p21, p27, and p57 proteins have been found in association with multiple cyclins (including D, E, and A), while the INK4 inhibitors specifically interact with complexes containing the D-type cyclins and cdk4 or cdk6. Because these proteins are important in cell cycle control, many are targeted for inactivation by

25 both tumor viruses and genetic alterations during oncogenesis. Loss of specific CKI function can result in unregulated DNA replication, and aid in the generation of further mutations due to accumulating DNA damage. To date, mutations and/or deletions of the p16^{INK4a} gene have been observed in a broad range of tumor types, strongly supporting its role as a tumor suppressor. (See generally, Sherr *et al.*, *Genes*

30 *& Devel.* 9:1149-1163 (1995)) and Morgan, *Nature* 374:131-134 (1995)).

Cyclin C was originally isolated from both human and *Drosophila* cDNA libraries by virtue of its ability to complement a CLN1-3 defective *S. cerevisiae* strain (Lew *et al.*, *Cell* 66:1197-1206 (1991); Leopold *et al.*, *Cell* 66:1207-1216 (1991); Lahue *et al.*, (1991)). The CLN1-3 yeast cyclins function during the G1-phase of the cell cycle by helping convey external growth signals to the nucleus and promote cell cycle progression (Cross, *Mol. Cell Biol.* 10:6482-6490 (1990). Thus, it was postulated that cyclin C was, itself, a G1-phase cyclin regulatory partner. The recent discovery of a cdk partner for cyclin C, cdk8, indicates that, like other G1-phase cyclins, cyclin C functions to regulate a specific cdk, in a cell cycle dependent manner (Tassan *et al.*, *Proc. Natl. Acad. Sci., USA* 92: 8871-8875 (1995)). Cyclin C not only associates with cdk8 *in vitro*, thereby activating the kinase, but also associates with cdk8 *in vivo*. Furthermore, the high degree of sequence identity between mammalian cyclin C and cdk8 with the *S. cerevisiae* *SRB10* and *SRB11* gene products, indicate that this complex plays an important role in the regulation of transcription (O'Neill *et al.*, *Nature*, 374:121-122 (1995); Liao *et al.*, *Nature* 374:193-196 (1995)). In yeast, the *SRB10* and *SRB11* gene products, a cdk and a regulatory cyclin partner respectively, are associated *in vivo* with RNA polymerase II. This cyclin/cdk complex is involved in both positive and negative regulation of transcription. The complex also may play a particularly important role in relaying extracellular growth signals to the transcription apparatus by either directly, or indirectly, phosphorylating the C-terminal domain (CTD) of RNA polymerase II (Tassan *et al.*, *supra*).

The human cdk 8 catalytic partner of cyclin C maps to human chromosome 13q12, a region associated with the *BRCA2* breast cancer susceptibility gene, but the significance of this observation is unknown. The *CCNC* gene encoding human cyclin C has recently been cloned and localized to human chromosome 6q21 (Demetrick *et al.*, *Cytogenet. Cell Genet.* 69:190-192 (1995); Li *et al.* (1996a)). This region of chromosome six is often deleted or altered during tumorigenesis, suggesting that the *CCNC* gene might be a candidate tumor suppressor (Kowalczyk *et al.*, (1985); Prigogina *et al.* (1988)). The integrity of the *CCNC* gene was examined in a subset of

acute lymphoblastic leukemias (ALLs) with 6q21 deletions, and one allele of this gene was consistently deleted (>90% of primary tumors) (Li *et al.*, (1996a)).

However, careful examination of the remaining *CNC* allele by single-strand conformational polymorphism (SSCP) revealed no further physical alterations.

- 5 Similar results involving the frequent deletion of cyclin dependent protein kinase inhibitors, such as p27^{Kip1}, have been demonstrated by others. It is possible that these genes exert their effects in tumors due to haploinsufficiency of the corresponding proteins, or that they are not the actual tumor suppressors, but share close physical linkage with the target genes (Pietenpol *et al.*, *Cancer Res.* 55:1206-1210 (1995); Li
10 *et al.* (1996)).

- The existence of a specific and unique cyclin dependent protein kinase partner, cdk8, for cyclin C indicates that cyclin C functions like other cyclins, *i.e.*, to regulate a kinase catalytic domain. It has been proposed that the cyclin C-cdk8 complex
15 regulates RNA transcription during the cell cycle. However, to date, no factor analogous to a cdk inhibitor has been identified that, in turn, specifically regulates cyclin C/cdk8 complex activity.

- The citation of any reference herein should not be deemed as an admission that such
20 reference is available as prior art to the instant invention.

SUMMARY OF THE INVENTION

- One aspect of the present invention describes a novel amino acid polymer that
25 specifically regulates cyclin C/cdk8 complex activity and thereby plays an important role in the regulation of RNA transcription. The amino acid polymer functions in a manner that is analogous, at least in result, to other cdk inhibitors, by disabling the active cyclin C/cdk8 complex during a portion of the cell cycle. Much like the p16^{INK4}-related proteins and other CKIs such as p21^{Waf1/Cip1}, p27^{Kip1}, and p57^{Kip2}, the

amino acid polymer functions as inhibitor of its associated protein kinase at specific times during the cell cycle.

The present invention includes an amino acid polymer that hinders the formation of an active cyclin C-cdk8 complex. In some embodiments, the amino acid polymer also possesses a specific binding affinity for cdk8. In one aspect of the invention the amino acid polymer is a protein. In another aspect of the invention the amino acid polymer is an active fragment of the protein. The present invention includes agonists, and mimics of the amino acid polymer.

10

In some embodiments of this aspect of the present invention, the amino acid polymer is a truncated form of cyclin C. In one embodiment the amino acid polymer is a truncated form of cyclin C that comprises at least about 20% or alternatively at least about 30% of the amino acid sequence encoded by the cyclin-box region. In another embodiment the amino acid polymer is a truncated form of cyclin C that comprises at least about 40% or alternatively at least about 50% of the amino acid sequence encoded by the cyclin-box region. In a preferred embodiment the amino acid polymer is a truncated form of cyclin C that comprises at least about 60% or alternatively at least about 70% of the amino acid sequence encoded by the cyclin-box region. In the another preferred embodiment of this aspect of the invention, the amino acid polymer has the amino acid sequence of SEQ ID NO:4 (see, Figure 1B).

15

20

In one embodiment of the invention the amino acid polymer is derived from *Avian* cells. In a preferred embodiment the amino acid polymer is derived from mammalian cells. In one such embodiment, the amino acid polymer is a human protein that has all of the intronic sequences removed with the exception of the introns located between exon 7 and 9 (exon 8 is included). In a particular embodiment of this type, the human amino acid polymer has an amino acid sequence of SEQ ID NO:52.

25

Another aspect of the present invention, includes an isolated amino acid polymer corresponding to a human cyclin C that does not encode a PEST sequence rich carboxyterminal domain. In one such embodiment, the amino acid polymer contains additional coding sequence between sequences derived from exons 11 and 12 in the human cyclin C cDNA. In a particular embodiment, the amino acid polymer has an amino acid sequence of SEQ ID NO:50. Such an amino acid polymer can have greater stability than the native human cyclin C since the PEST sequence has been shown to be involved in the rapid turnover of many proteins.

10 A further aspect of the invention includes the use of detectable labels, such as but not limited to an enzyme, a radioactive element, a bioluminescent, a chromophore that absorbs in the ultraviolet and/or visible and/or infrared region of the electromagnetic spectrum, and a fluorophore. The present invention includes the amino acid polymer labeled with such a detectable label.

15

The present invention includes antibodies to all of the amino acid polymers of the instant invention. In a preferred embodiment of this aspect of the invention, there are antibodies for truncated cyclin C which have a greater affinity for the truncated protein than for the full-length form of cyclin C so that the truncated cyclin C may be distinguished from the full-length form of cyclin C. In one such embodiment, the antibody is raised against a peptide comprising all or a portion of amino acids 167-178 of SEQ ID NO:52.

In another embodiment, the antibody is for an amino acid polymer of the present invention that corresponds to a human cyclin C that does not encode a PEST sequence rich carboxyterminal domain. Preferably such an antibody has a greater affinity for the amino acid polymer than for human cyclin C. In one such embodiment, the antibody is raised against a peptide comprising all or a portion of amino acids 286-325 of SEQ ID NO:50.

30

The antibodies of the present invention may be selected from polyclonal antibodies, monoclonal antibodies or chimeric (bispecific) antibodies and all such variants are considered to be included herein. Either type of antibody can further comprise a detectable label as described above.

5

A related aspect of the present invention includes an immortal cell line that produces a monoclonal antibody against the amino acid polymers of the instant invention. In one embodiment the immortal cell line produces a monoclonal antibody against a truncated cyclin C. In one such embodiment the immortal cell line produces a monoclonal antibody against the truncated cyclin C having the amino acid sequence of SEQ ID NO:4 and/or SEQ ID NO:52. Alternatively, the immortal cell line can produce a monoclonal antibody to SEQ ID NO:50.

10

The present invention also includes methods for isolating the amino acid polymers from bacterial, insect or animal cells.

15

One aspect of the present invention includes the isolated nucleic acids that encode the amino acid polymers of the present application. In some embodiments the nucleic acid is an mRNA, in other embodiments it is a recombinant DNA molecule, or a degenerate variant thereof. In one such embodiment, the isolated nucleic acid encodes the amino acid sequence of SEQ ID NO:4.

20

In one particular embodiment of this type, the nucleic acid has the coding sequence for the amino acid sequence of SEQ ID NO:4 contained in SEQ ID NO:2. In another embodiment, the isolated nucleic acid encodes the amino acid sequence of SEQ ID NO:52. In one particular embodiment of this type, the nucleic acid has the coding sequence for the amino acid sequence for SEQ ID NO:52 contained in SEQ ID NO:51. In yet another embodiment, the isolated nucleic acid encodes the amino acid sequence of SEQ ID NO:50. In one particular embodiment of this type, the nucleic

25

acid has the coding sequence for the amino acid sequence for SEQ ID NO:50 contained in SEQ ID NO:49.

The present invention also includes the corresponding DNAs, including cDNAs and
5 mRNAs. Nucleic acids that hybridize to the nucleic acids of the present invention under standard and/or stringent hybridization conditions are also included in the present invention.

Nucleotide probes are also included in the present invention. Such nucleotide probes
10 may be used for screening for the nucleic acids of the present invention. All of the nucleotide probes of the present invention may be labeled with a detectable label as described above.

In one embodiment the nucleotide probe comprises all or a portion of the nucleotide
15 sequence of nucleotides 885-928 of SEQ ID NO:49. In another embodiment, the nucleotide probe comprises all or a portion of the nucleotide sequence of nucleotides 527-771 of SEQ ID NO:51. In still another embodiment, the nucleotide probe comprises all or a portion of the nucleotide sequence of SEQ ID NO:53. In still
another embodiment, the nucleotide probe comprises all or a portion of the nucleotide
20 sequence of nucleotides 357-429 of SEQ ID NO:2

One aspect of the present invention includes expression vectors that contain a nucleic
acid of the present invention which is operatively linked to an expression control
sequence. These expression vectors may be homologously recombined in a
25 chromosome in a cell. In some embodiments of this aspect of the invention, the cell contains a nucleic acid that has been disrupted, and the cell is unable to express a functional form of the amino acid polymer of the present invention. In one such embodiment of this aspect of the invention, the cell is a chicken DT40 cell.

In other embodiments of this aspect of the invention, the cell is mammalian and can be placed into a mammalian blastocyst. The blastocyst can then be re-implanted into a pseudopregnant female mammal to generate a transgenic animal. In one embodiment of this aspect of the invention, the transgenic animal contains a nucleic acid that has been disrupted, and the transgenic animal cannot express a functional form of the amino acid polymer of the present invention. In more preferred embodiments the transgenic animal is a mouse that can be used as an animal model. When the transgenic mouse contains a disrupted nucleic acid as described above, the transgenic animal is a "knockout" mouse.

10

The present invention also includes a pharmaceutical composition for treating oncogenesis containing a therapeutically effective amount of an amino acid polymer of the present invention, or an agent capable of promoting the production and/or activity of the amino acid polymer, or an agent capable of mimicking the activity of the amino acid polymer, or an agent capable of inhibiting the production and/or activity of the amino acid polymer, and mixtures thereof.

15

An alternative aspect of the present invention includes antisense nucleic acid that functions by hybridizing to the mRNA encoding the amino acid polymers of the present invention. In some embodiments the antisense nucleic acid is RNA. In other embodiments the antisense nucleic acid is DNA. The present invention also includes a recombinant DNA molecule having a DNA sequence which, on transcription, produces an antisense ribonucleic acid against an mRNA coding for an amino acid polymer of the present invention.

25

In still another aspect of the present invention there is a ribozyme that catalyzes the cleaving of a precursor RNA as part of the process of converting the precursor RNA to an mRNA transcript encoding truncated cyclin C. The precursor RNA contains the exons that encode *cyclin C*, and one or more introns that have one or more sites for cleaving the introns from the precursor RNA. The ribozyme acts at a particular site of

30

the precursor RNA, a site which is not cleaved during the process of converting the precursor RNA to an mRNA transcript encoding the full-length *cyclin C*. In one embodiment the ribozyme is a *Tetrahymena*-type ribozyme. In another embodiment the ribozyme is a Hammerhead-type ribozyme. The present invention also includes a
5 recombinant DNA molecule which, upon transcription, produces the ribozyme. In preferred embodiments the site of cleavage of the RNA precursor for the ribozyme is in the cyclin-box region.

Test kits are also included in the present invention. Test kits contain markers with
10 specific affinities for particular target molecules and directions for using the kit. More particularly, these test kits are for identifying target molecules which are the amino acid polymers and nucleic acids of the present invention. Markers may be labeled with the detectable labels of the present invention. In one embodiment, a nucleic acid of the present invention is identified in a biological sample using a kit containing a
15 marker that is a detectably labeled nucleotide probe of the present invention. In another embodiment, an amino acid polymer of the present invention is identified in a biological sample using a kit containing a marker that is an antibody of the present invention. In a preferred embodiment of this type, the marker is an antibody that is specific for truncated cyclin C. In some embodiments, the markers are in packaged in
20 predetermined amounts. In other embodiments a standard target molecule, known to react with the marker, is included in the kit. Other kits may contain additional reagents that react with the marker to bestow or enhance its detectability and/or buffering materials.

25 One preferred set of directions is for using a kit to detect the presence of an amino acid polymer of the present invention by the steps of:
(a) contacting a biological sample obtained from a cell, in which the presence of the amino acid polymer is suspected, with a marker that is an antibody for the amino acid polymer, under conditions that allow binding of the amino acid polymer to the
30 antibody to occur; and

(b) detecting whether the binding has occurred. Detection of binding indicates the presence of the amino acid polymer in the sample.

Another preferred set of directions is for using a kit of the present invention to detect the presence of an alternatively spliced mRNA of the present invention by the steps of:

(a) contacting a biological sample obtained from a cell, in which the presence of the alternatively spliced mRNA is suspected, with a marker that is a nucleotide probe for the alternatively spliced mRNA, under conditions that allow hybridization to occur; and

(b) detecting whether hybridization has occurred. Detection of hybridization indicates the presence of the alternatively spliced mRNA in the sample.

These directions are not meant to be solely for kits, but rather also function as teachings for the skilled artisan to practice the methodology with the appropriate reagents, even in the absence of the kits themselves.

The invention also includes the full-length form of *Avian cyclin C* having the amino acid sequence of SEQ ID NO:3 (see, Figure 1A and Figure 1C) antibodies raised against it and nucleic acids that code for the amino acid sequence of SEQ ID NO:3. More specifically, the invention includes the nucleic acid having the DNA sequence of SEQ ID NO:1 (see, Figure 1A and Figure 1C). In a related embodiment, the nucleic acid has an RNA sequence corresponding to SEQ ID NO:1. The invention includes the use of these biomolecules to perform targeted disruption of the *cyclin C* gene in chicken DT40 cells via homologous recombination. Targeted disruption is a very powerful molecular genetic tool used in drug development. The chicken DT40 cell line is a valuable system for the ready isolation of mutant cells, that is technically less difficult and less time consuming than the murine model.

The present invention also includes methodology for distinguishing the G2/M phase (late G2 phase and M phase) from the G1/S phase (late G1 phase and S phase) in the cell cycle of a given cell. This methodology relies on the presence of the truncated cyclin C and one of the alternatively spliced mRNA *e.g.*, CmRNA1, CmRNA2, or an mRNA-encoding the amino acid sequence of SEQ ID NO:52 during the G2/M phase and their absence during the G1/S phase. Monitoring either the alternatively spliced mRNA or truncated cyclin C alone or together may be used to distinguish these phases. Directions and kits described above for identifying truncated cyclin C or the alternatively spliced mRNA may be used for this purpose.

10

The present invention also includes a method of preventing and/or treating oncogenesis by administering to an animal a therapeutically effective amount of the truncated cyclin C, an agent capable of promoting the production and/or activity of the truncated cyclin C, an agent capable of mimicking the activity of the truncated cyclin C, an agent capable of inhibiting the production of truncated cyclin C, and mixtures thereof.

15

The present invention also includes a method of promoting cell growth by administering to a subject animal a nucleic acid encoding the amino acid sequence of SEQ ID NO:50 or the amino acid polymer itself. This longer lived form of a cyclin C should be more effective since less protein will be needed to be administered or synthesized.

20

Another aspect of the invention is an *in vitro* method for detecting or diagnosing the presence of a disease associated with elevated or decreased levels of the truncated cyclin C in a mammalian subject having the steps of: (a) evaluating the level of the truncated cyclin C in a biological sample from a mammalian subject and (b) comparing the level detected in step (a) to a level of the truncated cyclin C present in normal subjects or in the subject at an earlier time. An increase in the level of the truncated cyclin C as compared to normal levels indicates a disease associated with

30

elevated levels of truncated cyclin C, and decreased level of truncated cyclin C as compared to normal levels indicates a disease associated with decreased levels of truncated cyclin C.

- 5 A variation of this aspect of the invention tests for the presence of truncated cyclin C during the different phases of the cell cycle. The presence of truncated cyclin C during the G1/S phase or its absence during the G2/M phase is indicative of a diseased state.
- 10 An *in vitro* method for monitoring a therapeutic treatment of a disease associated with elevated or decreased levels of truncated cyclin C in a mammalian subject is also disclosed. This test evaluates the levels of the truncated cyclin C in a series of biological samples obtained at different time points from a mammalian subject undergoing a therapeutic treatment for a disease associated with elevated or decreased
- 15 levels of truncated cyclin C.

- The present invention also includes methods of delivering a recombinant DNA molecule, encoding the amino acid polymers of the present invention, to a target cell which comprises providing a virus-derived vector that has been modified to comprise
- 20 the recombinant DNA molecule and causing the vector to transfect the cell. Appropriate virus derived vectors include but are not limited to adenovirus, adeno-associated virus and retrovirus derived vectors. In one embodiment of this invention, the recombinant DNA is designed to be transcribed in the target cell constitutively. In another embodiment, the recombinant DNA is designed to be
- 25 transcribed in the target cell under regulatable conditions. In preferred embodiments, the target cell is a human cell.

These and other aspects of the present invention will be better appreciated by reference to the following drawings and Detailed Description.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-1C depict nucleotide sequence(s) and predicted ORFs of the avian cyclin C and alternatively spliced cyclin C cDNAs. (Figure 1A) The avian cyclin C cDNA sequence (SEQ ID NO:1) and its predicted ORF (SEQ ID NO:3). The cyclin-box region is shaded. The translational start site for the cyclin C protein is indicated by the bold M. The location of introns within the coding regions is shown by the arrowheads above the DNA sequence. The termination codon is indicated by an asterisk. (Figure 1B) The alternatively spliced exon is shown by the large, bolded arrowheads. The nucleotide sequence (SEQ ID NO:2) and corresponding ORF of this alternatively spliced region is shown in bold italics. The termination codons are denoted by asterisks. The alternatively spliced region rejoins the normal cyclin C sequence after the second large, bolded arrowhead above the DNA sequence. GenBank acquisition numbers for these sequences are as follows: cyclin C (U40873), alternatively spliced cyclin C (U40874). (Figure 1C) The predicted protein sequence of the avian cyclin C cDNA is shown in comparison to the corresponding human (line 2) and *Drosophila* (line 3) protein sequences. Identity is denoted by a hyphen (-) and gaps are denoted by periods (.). The conserved cyclin-box region is shown in shadowed boxes. The human cyclin C protein contains 20 additional amino acid residues at its aminotermius, unlike the avian or *Drosophila* proteins which do not contain this region.

Figure 2 depicts a schematic representation of the avian cyclin C gene. The location of the translational start site of the cyclin C protein is shown by the ATG. Similarly, the termination codon for the protein is shown by the TAA. Restriction endonuclease sites are indicated above the gene structure. The orientation of the gene is indicated above the schematic by 5' and 3'. A comparison of the isolated cyclin C mRNAs with the positions of the exons and introns of the gene is shown below the gene. The normal translational start codon shared by all of these mRNAs is indicated by the ATG. Both cyclin C mRNAs 1 and 2 contain exon 4a, and, therefore contain

premature in-frame termination codons indicated by the TGA and TAA. Cyclin C mRNA 3 is the only mRNA capable of encoding an intact cyclin C ORF.

Polyadenylation of these mRNAs is indicated by the AAA sequence. GenBank accession numbers for the avian genomic cyclin C sequences are as follows: Exon 2,

- 5 U40875; Exon 3, U40876; Exon 4, U40877; Exon 4a, U40878; Exon 5, U40879; Exon 6, U40880; Exon 7, U40881; Exon 8, U40882; Exon 9, U40883; Exon 10, U40884; Exon 11, U40885; Exon 12, U40886.

- Figures 3A-3B depict RT-PCR analysis of the various cyclin C mRNAs (1, 2, and 3; as depicted in Fig. 2) from avian cell lines and tissues. The source of the cell line or tissue is indicated above each lane. Controls include DT40 cell RNA in the absence of PCR primers (RNA only) and the chicken cyclin C cDNA (C-cDNA) as a positive control. The sizes of the RT-PCR reaction products that were sequenced are shown to the left of each panel. (Figure 3A) RT-PCR primers corresponding to the 5' portion of exon 4a and the 3' portion of exon 7. (Figure 3B) RT-PCR primers corresponding to the 3' portion of exon 4a and the 5' portion of exon 2.

- Figures 4A-4D depict Northern blot analysis of alternatively spliced cyclin C mRNA expression in synchronized DT40 cells. RNA isolated from elutriated and nocodazole-blocked DT40 (B-cells) was transferred to a membrane and hybridized with either, (Figure 4A) the alternatively spliced cyclin C PCR probe (described in Materials and Methods), (Figure 4B) hybridization of the same RNA samples with the avian cyclin C probe, (Figure 4C) a chicken cyclin B2 cDNA probe, or (Figure 4D) the same RNAs stained with EtBr. The location of the major alternatively spliced cyclin C transcript (1.7 kb; CmRNA-2, having SEQ ID NO:2) is shown by the arrow. The location of the cyclin B2 mRNA is also appropriately indicated.

- Figures 5A-5B depict expression of a smaller, 19 kDa cyclin C-related protein in avian cells. (Figure 5A) To determine whether the *Drosophila* cyclin C antibody would recognize the avian proteins, it was used to immunoprecipitate either the full-

length normal cyclin C transcript or the alternatively spliced cyclin C transcript, which produces a truncated cyclin C protein. These cyclin C proteins were generated by *in vitro* transcription translation (IVTT) and then immunoprecipitated as described by others (Leclerc *et al.*, *Molec. Biol. Cell*, 7:505-513 (1996). (Figure 5B) The same

5 *Drosophila* cyclin C antibody was used to detect either (1) the *in vitro* transcribed translated normal (C) or alternatively spliced (Δ C) transcripts, (2) total cell lysate from nocodazole blocked DT40 cells, or (3) the same DT40 cell lysate after preincubation with a GST-cyclin C fusion protein corresponding to the avian gene. Incubation of the cyclin C antibody with the GST-cyclin C fusion protein acts as a

10 competitor. Competition with this GST-cyclin C protein is indicated below the lanes with a (+). The location of the normal ~30 kDa cyclin C protein, as well as the ~19 kDa truncated cyclin C-box protein is marked on the side of the panels.

Figure 6 shows the comparison of normal human cyclin C protein sequence and

15 alternatively spliced form 1 (human cyclin C alternatively spliced form with an additional exon between 11 and 12). Single letter amino acid sequence of normal human cyclin C (top line) and alternatively spliced form 1 (bottom line). Identical residues are indicated by (-). Gaps in the sequence are indicated by (/).

20 Figure 7 shows the nucleotide sequence comparison of human cyclin C and alternatively spliced human cyclin C form 1 (as defined in Figure 6). The nucleotide sequence of human cyclin C is shown on the top line. Alternatively spliced form 1 on the bottom line. Identical nucleotides are indicated by (-) and gaps are shown by (/).

25 Figure 8 shows the comparison of normal human cyclin C protein sequence and partially spliced form 1. Single letter amino acid sequence of normal human cyclin C (top line) and partially spliced form 1 (bottom line). Identical residues are indicated by (-). Gaps in the sequence are indicated by (/). The predicted termination codon is shown by *.

Figure 9 shows the nucleotide sequence comparison of human cyclin C and partially spliced human cyclin C form 1. The nucleotide sequence of human cyclin C is shown on the top line. Partially spliced form 1 on the bottom line. Identical nucleotides are indicated by (-) and gaps are shown by (/) and ::: indicates the location of an
5 approximately 600 nucleotides of unsequenced DNA presumed to contain exon 8.

DESCRIPTION OF THE INVENTION

The present invention describes a novel amino acid polymer a truncated cyclin C that
10 plays an important role in the regulation of RNA transcription by acting to attenuate the cyclin C/cdk8 complex activity. The present invention includes nucleic acids that specifically encode such an amino acid polymer including two particular alternatively spliced cyclin C mRNAs (CmRNA-1, CmRNA-2) a DNA having a nucleotide sequence of SEQ ID NO:2, and a corresponding RNA to that recombinant DNA. The
15 present invention further includes methods of making, detecting, isolating, and using the amino acid polymer as a cell cycle marker protein. The present invention more specifically includes a truncated human cyclin C. The human truncated cycling C has the amino acid sequence of SEQ ID NO:52. In addition, the present invention includes an alternatively spliced human mRNA which encodes a cyclin C containing
20 additional codes sequences derived from exons 11 and 12 in the human cyclin C cDNA. The alternatively spliced human mRNA encodes an amino acid polymer having an alternative carboxy-terminal end, relative to cyclin C. This protein is more long-lived than cyclin C and may be used as a stable analog of human cyclin C. Antibodies raised against the amino acid polymers of the present invention, their use
25 for detection of the amino acid polymers of the present invention, corresponding antisense nucleic acids and ribozymes are also disclosed.

An amino acid polymer that binds cdk8 and hinders the
cyclin C/cdk8 complex activity

As noted above, the present invention provides an amino acid polymer (a cyclin C/cdk8 inhibitor) that hinders the formation of an active cyclin C/cdk8 complex. In some embodiments of the present invention the amino acid polymer also has a binding affinity for cdk8. In a specific embodiment, the cyclin C/cdk8 inhibitor is a truncated cyclin C with a sequence set forth in SEQ ID NO:4 (see, Figure 1B). In another specific embodiment, the truncated cyclin C has an amino acid sequence of SEQ ID NO:52.

10

The term "hinders" as used herein, is meant to encompass a mild inhibition, a complete inhibition and all intermediary states of inhibition.

The phrase "hinders the formation of an active cyclin C-cdk8 complex" as used herein, includes inhibiting the formation of a cyclin C-cdk8 complex, by for example binding cdk8 in a competitive manner with cyclin C; inhibiting the activity of an existing cyclin C-cdk8 complex, for example by forming a tertiary complex with cyclin C and cdk8; and any combination of these two inhibitory mechanisms.

20 The term "amino acid polymer" as used herein, is used interchangeably with the term "polypeptide" and denotes a polymer comprising amino acids connected by peptide bonds.

The term "cyclin C/cdk8 inhibitor" is used herein to denote "the amino acid polymer" which corresponds to the "truncated cyclin C" of the present invention. One such specific amino acid polymer of the invention is the truncated cyclin C having the amino acid sequence set forth in SEQ ID NO:4. Another is the truncated cyclin C having an amino acid sequence of SEQ ID NO:52.

25

For cyclin C, the "cyclin box region" extends from amino acid 9 to amino acid 175. The exact requirements for a functional cyclin box region (which is necessary for physical interaction of a cdk with an appropriate cyclin) are loosely defined by a region of shared protein sequence homology. However, it should be recognized that

5 there is no evidence that this entire region is required for many of the cyclin-cdk interactions; only cyclin A/ckd2 has been examined (Lees *et al.*, *Mol. Cell. Biol.* 13:1194-1201 (1993)). In fact, studies by Lee *et al.* (*Proc. Natl. Acad. Sci., USA* 93:3859-3263 (1996)) demonstrate that a novel 35 kDa protein (p35) found in post-mitotic neurons can bind to a cdk and regulate its function, much like a

10 "conventional" cyclin. However, p35 has very limited sequence homology to any of the members of the cyclin gene family (*i.e.*, cyclin A, cyclin B, cyclin C, cyclin D1, D2, D3, cyclin E, cyclin E, and cyclin G).

The invention further provides an antigenic fragment of the cyclin C/ckd8 inhibitor, which can be used, *e.g.*, after conjugation with a carrier protein, to generate antibodies

15 to the cyclin C/ckd8 inhibitor. Furthermore, as set forth below, the present invention contemplates the cyclin C/ckd8 inhibitor containing synthetic amino acids, derivitized by acetylation or phosphorylation, or substituted with conservative amino acids that provide the same biochemical properties

20

A molecule is "antigenic" when it is capable of specifically interacting with an antigen recognition molecule of the immune system, such as an immunoglobulin (antibody) or T cell antigen receptor. An antigenic polypeptide contains at least about 5, and preferably at least about 10, amino acids. An antigenic portion of a molecule can be

25 that portion that is immunodominant for antibody or T cell receptor recognition, or it can be a portion used to generate an antibody to the molecule by conjugating the antigenic portion to a carrier molecule for immunization. A molecule that is antigenic need not be itself immunogenic, *i.e.*, capable of eliciting an immune response without a carrier.

30

Proteins having a slightly altered amino acid sequence from that described herein and presented in FIGURE 1B (SEQ ID NO:4), but displaying substantially equivalent activity are contemplated by the present invention. These modifications may be deliberate, for example, such as modifications obtained through site-directed
5 mutagenesis, or may be accidental, such as those obtained through mutations in hosts that are producers of the complex or its named subunits.

The amino acid residues described herein are preferred to be in the "L" isomeric form and include both naturally occurring amino acids as well as amino acid analogs such
10 as norleucine. However, residues in the "D" isomeric form can be substituted for any L-amino acid residue, as long as the desired functional property is retained by the polypeptide. NH_2 refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxyl group present at the carboxyl terminus of a polypeptide.

15

It should be noted that all amino acid residue sequences are represented herein by formulae whose left and right orientation is in the conventional direction of amino-terminus to carboxyl-terminus. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a
20 further sequence of one or more amino-acid residues

The amino acid polymers of the present invention may be obtained in several ways including by isolation from animal cells, by synthetic means such as solid-phase peptide synthesis or by isolation from recombinant cells that contain one or more
25 copies of a DNA transcript encoding the cyclin C/cdk8 inhibitor.

The term "polypeptide" is used in its broadest sense to refer to a compound of two or more subunit amino acids, amino acid analogs, or peptidomimetics. The subunits may be linked by peptide bonds. In another embodiment, the subunit may be linked
30 by other the bonds, *e.g.* ester, ether, etc. As used herein the term "amino acid" refers

to either natural and/or unnatural or synthetic amino acids, including glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics. A peptide of three or more amino acids is commonly called an oligopeptide if the peptide chain is short. If the peptide chain is long, the peptide is commonly called a polypeptide or
5 a protein.

Synthetic polypeptides, prepared using the well known techniques of solid phase, liquid phase, or peptide condensation techniques, or any combination thereof, can include natural and unnatural amino acids. Amino acids used for peptide synthesis
10 may be standard Boc (N^{α} -amino protected N^{α} -t-butyloxycarbonyl) amino acid resin with the standard de-protecting, neutralization, coupling and wash protocols of the original solid phase procedure of Merrifield (*J. Am. Chem. Soc.* **85**:2149-2154 (1963)), or the base-labile N^{α} -amino protected 9-fluorenylmethoxycarbonyl (Fmoc) amino acids first described by Carpino *et al.* (*J. Org. Chem.* **37**:3403-3409 (1972)).
15 Both Fmoc and Boc N^{α} -amino protected amino acids can be obtained from Fluka, Bachem, Advanced Chemtech, Sigma, Cambridge Research Biochemical, Bachem, or Peninsula Labs or other chemical companies familiar to those who practice this art. In addition, the method of the invention can be used with other N^{α} -protecting groups that are familiar to those skilled in this art. Solid phase peptide synthesis may be
20 accomplished by techniques familiar to those in the art and provided, for example, in Stewart and Young, 1984, Solid Phase Synthesis, Second Edition, Pierce Chemical Co., Rockford, IL; Fields *et al.*, *Int. J. Pept. Protein Res.* **35**:161-214 (1990), or using automated synthesizers, such as sold by ABS. Thus, polypeptides of the invention may comprise D-amino acids, a combination of D- and L-amino acids, and various
25 "designer" amino acids (*e.g.*, β -methyl amino acids, $C\alpha$ -methyl amino acids, and $N\alpha$ -methyl amino acids, etc.) to convey special properties. Synthetic amino acids include ornithine for lysine, fluorophenylalanine for phenylalanine, and norleucine for leucine or isoleucine. Additionally, by assigning specific amino acids at specific coupling steps, α -helices, β turns, β sheets, γ -turns, and cyclic peptides can be generated.

In one aspect of the invention, the peptides may comprise a special amino acid at the C-terminus which incorporates either a CO_2H or CONH_2 side chain to simulate a free glycine or a glycine-amide group. Another way to consider this special residue would be as a D or L amino acid analog with a side chain consisting of the linker or bond to the bead. In one embodiment, the pseudo-free C-terminal residue may be of the D or the L optical configuration; in another embodiment, a racemic mixture of D and L-isomers may be used.

The present invention further provides for determination of the structure of the amino acid polymers of the present invention, which can be provided in sufficient quantities by recombinant expression (*infra*) or by synthesis. This is achieved by assays based on the physical or functional properties of the product, including radioactive labeling of the product followed by analysis by gel electrophoresis, immunoassay, etc.

The structure of the amino acid polymers of the present invention can be analyzed by various methods known in the art. Structural analysis can be performed by identifying sequence similarity with other known proteins. The degree of similarity (or homology) can provide a basis for predicting structure and function of the cyclin C/cdk8 inhibitor, or a domain thereof. In a specific embodiment, sequence comparisons can be performed with sequences found in GenBank, using, for example, the FASTA and FASTP programs (Pearson *et al.*, *Proc. Natl. Acad. Sci., USA* 85:2444-48 (1988)).

The protein sequence can be further characterized by a hydrophilicity analysis (*e.g.*, Hopp *et al.*, *Proc. Natl. Acad. Sci., USA* 78:3824 (1981)). A hydrophilicity profile can be used to identify the hydrophobic and hydrophilic regions of the cyclin C/cdk8 inhibitor.

Secondary structural analysis (e.g., Chou *et al.*, *Biochemistry* 13:222 (1974)) can also be done, to identify regions of the cyclin C/cdk8 inhibitor that assume specific secondary structures.

- 5 Manipulation, translation, and secondary structure prediction, as well as open reading frame prediction and plotting, can also be accomplished using computer software programs available in the art.

By providing an abundant source of the recombinant cyclin C/cdk8 inhibitor, the
10 present invention enables quantitative structural determination of cyclin C/cdk8 inhibitor, or domains thereof. In particular, enough material is provided for nuclear magnetic resonance (NMR), infrared (IR), Raman, and ultraviolet (UV), and circular dichroism (CD) spectroscopic analysis. In particular NMR provides very powerful structural analysis of molecules in solution, which more closely approximates their
15 native environment (Marion *et al.*, *Biochem Biophys. Res. Comm.* 113:967-974 (1983); Bar *et al.*, *J. Magn. Reson.* 65:355-360 (1985); Kimura *et al.*, *Proc. Natl. Acad. Sci., USA* 77:1681-1685 (1980)). Other methods of structural analysis can also be employed. These include but are not limited to X-ray crystallography (Engstrom, *Biochem Exp Biol* 11:7-13 (1974)).

20

More preferably, co-crystals of cyclin C/cdk8 inhibitor as a complex with cdk8 and/or
the cyclin C/cdk8 complex can be studied. Analysis of co-crystals provides detailed information about binding, which in turn allows for rational design of ligand agonists and antagonists. Computer modeling can also be used, especially in connection with
25 NMR or X-ray methods (Fletterick, R. and Zoller, M. (eds.), 1986, *Computer Graphics and Molecular Modeling*, in *Current Communications in Molecular Biology*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York).

Nucleic Acids Encoding the Cyclin C/cdk8 inhibitor

The present invention includes isolation of mRNA encoding an cyclin C/cdk8 inhibitor factor of the invention, as well as all of the mRNAs encoding the amino acid polymers of the present invention, including naturally occurring forms of the amino acid polymers, and any antigenic fragments thereof from any animal, particularly mammalian or avian, and more particularly human, source.

In the practice of the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (herein "Sambrook et al., 1989"); *DNA Cloning: A Practical Approach*, Volumes I and II (D.N. Glover ed. 1985); *Oligonucleotide Synthesis* (M.J. Gait ed. 1984); *Nucleic Acid Hybridization* [B.D. Hames & S.J. Higgins eds. (1985)]; *Transcription And Translation* [B.D. Hames & S.J. Higgins, eds. (1984)]; *Animal Cell Culture* [R.I. Freshney, ed. (1986)]; *Immobilized Cells And Enzymes* [IRI. Press. (1986)]; B. Perbal, *A Practical Guide To Molecular Cloning* (1984); F.M. Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc. (1994).

20

Therefore, if appearing herein, the following terms shall have the definitions set out below.

As used herein, the term "gene" refers to an assembly of nucleotides that encode a polypeptide, and includes genomic DNA nucleic acids which can contain a complete set of introns and exons, and cDNA.

A "vector" is a replicon, such as plasmid, phage or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment.

30 A "replicon" is any genetic element (e.g., plasmid, chromosome, virus) that functions

as an autonomous unit of DNA replication *in vivo*, i.e., capable of replication under its own control.

A "cassette" refers to a segment of DNA that can be inserted into a vector at specific
5 restriction sites. The segment of DNA encodes a polypeptide of interest, and the cassette and restriction sites are designed to ensure insertion of the cassette in the proper reading frame for transcription and translation.

A cell has been "transfected" by exogenous or heterologous DNA when such DNA
10 has been introduced inside the cell. A cell has been "transformed" by exogenous or heterologous DNA when the transfected DNA effects a phenotypic change. Preferably, the transforming DNA should be integrated (covalently linked) into chromosomal DNA making up the genome of the cell.

15 "Heterologous" DNA refers to DNA not naturally located in the cell, or in a chromosomal site of the cell. Preferably, the heterologous DNA includes a gene foreign to the cell.

A "nucleic acid molecule" refers to the phosphate ester polymeric form of
20 ribonucleosides (adenosine, guanosine, uridine or cytidine; "RNA molecules") or deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxythymidine, or deoxycytidine; "DNA molecules"), or any phosphoester analogues thereof, such as phosphorothioates and thioesters, in either single stranded form, or a double-stranded helix. Double stranded DNA-DNA, DNA-RNA and RNA-RNA helices are possible.
25 The term nucleic acid molecule, and in particular DNA or RNA molecule, refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, *inter alia*, in linear or circular DNA molecules (e.g., restriction fragments), plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA
30 molecules, sequences may be described herein according to the normal convention of

giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (*i.e.*, the strand having a sequence homologous to the mRNA). A "recombinant DNA molecule" is a DNA molecule that has undergone a molecular biological manipulation.

5

A nucleic acid molecule is "hybridizable" to another nucleic acid molecule, such as a cDNA, genomic DNA, or RNA, when a single stranded form of the nucleic acid molecule can anneal to the other nucleic acid molecule under the appropriate conditions of temperature and solution ionic strength (*see* Sambrook et al., *supra*).

- 10 The conditions of temperature and ionic strength determine the "stringency" of the hybridization. For preliminary screening for homologous nucleic acids, low stringency hybridization conditions, corresponding to a T_m of 55°, can be used, *e.g.*, 5x SSC, 0.1% SDS, 0.25% milk, and no formamide; or 30% formamide, 5x SSC, 0.5% SDS. Moderate stringency hybridization conditions correspond to a higher T_m ,
15 *e.g.*, 40% formamide, with 5x or 6x SCC. High stringency hybridization conditions correspond to the highest T_m , *e.g.*, 50% formamide, 5x or 6x SCC. Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate stringency for hybridizing nucleic acids depends on the
20 length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of T_m for hybrids of nucleic acids having those sequences. The relative stability (corresponding to higher T_m) of nucleic acid hybridizations decreases in the following order: RNA:RNA, DNA:RNA, DNA:DNA.
25 For hybrids of greater than 100 nucleotides in length, equations for calculating T_m have been derived (*see* Sambrook et al., *supra*, 9.50-9.51). For hybridization with shorter nucleic acids, *i.e.*, oligonucleotides, the position of mismatches becomes more important, and the length of the oligonucleotide determines its specificity (*see* Sambrook et al., *supra*, 11.7-11.8). Preferably a minimum length for a hybridizable

nucleic acid is at least about 18 nucleotides; preferably at least about 36 nucleotides; and more preferably the length is at least about 48 nucleotides.

In a specific embodiment, the term "standard hybridization conditions" refers to a T_m of 55°C, and utilizes conditions as set forth above. In a preferred embodiment, the T_m is 60°C; in a more preferred embodiment, the T_m is 65°C.

"Homologous recombination" refers to the insertion of a foreign DNA sequence of a vector in a chromosome. Preferably, the vector targets a specific chromosomal site for homologous recombination. For specific homologous recombination, the vector will contain sufficiently long regions of homology to sequences of the chromosome to allow complementary binding and incorporation of the vector into the chromosome. Longer regions of homology, and greater degrees of sequence similarity, may increase the efficiency of homologous recombination.

Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, terminators, and the like, that provide for the expression of a coding sequence in a host cell. In eukaryotic cells, polyadenylation signals are control sequences

A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined for example, by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase.

A coding sequence is "under the control" of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then trans-RNA spliced and translated into the protein encoded by the coding sequence.

5

As used herein, the term "sequence homology" in all its grammatical forms refers to the relationship between proteins that possess a "common evolutionary origin," including proteins from superfamilies (*e.g.*, the immunoglobulin superfamily) and homologous proteins from different species (*e.g.*, myosin light chain, etc.) (Reeck *et al.*, *Cell* 50:667 (1987)).

10

Accordingly, the term "sequence similarity" in all its grammatical forms refers to the degree of identity or correspondence between nucleic acid or amino acid sequences of proteins that do not share a common evolutionary origin (*see* Reeck *et al.*, *supra*).

15

However, in common usage and in the instant application, the term "homologous," when modified with an adverb such as "highly," may refer to sequence similarity and not a common evolutionary origin.

20

In a specific embodiment, two DNA sequences are "substantially homologous" or "substantially similar" when at least about 50% (preferably at least about 75%, and most preferably at least about 90 or 95%) of the nucleotides match over the defined length of the DNA sequences. Sequences that are substantially homologous can be identified by comparing the sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, *e.g.*, Maniatis *et al.*, *supra*; DNA Cloning, Vols. I & II, *supra*; Nucleic Acid Hybridization, *supra*.

25

Similarly, in a particular embodiment, two amino acid sequences are "substantially homologous" or "substantially similar" when greater than 30% of the amino acids are

30

identical, or greater than about 60% are similar (functionally identical). Preferably, the similar or homologous sequences are identified by alignment using, for example, the GCG (Genetics Computer Group, Program Manual for the GCG Package, *Version* 7, Madison, Wisconsin) pileup program.

5

The term "corresponding to" is used herein to refer to similar or homologous sequences, whether the exact position is identical or different from the molecule to which the similarity or homology is measured. The term "corresponding to" refers to the sequence similarity, and not the numbering of the amino acid residues or

10 nucleotide bases.

A gene encoding an amino acid polymer of the present invention, whether genomic DNA or cDNA, can be isolated from any source, particularly from a human cDNA or genomic library. Methods for obtaining the gene are well known in the art, as
15 described above (*see, e.g.,* Sambrook et al., *supra*). Accordingly, any animal cell potentially can serve as the nucleic acid source for the molecular cloning of the gene. The DNA may be obtained by standard procedures known in the art from cloned DNA (*e.g.,* a DNA "library"), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired cell (*See, for example,*
20 Sambrook et al., *supra*; Glover, D.M. (ed.), 1985, DNA Cloning: A Practical Approach, MRL Press, Ltd., Oxford, U.K. Vol. I, II). Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions; clones derived from cDNA will not contain intron sequences other than those portions included by alternative splicing. Whatever the source, the gene should be molecularly
25 cloned into a suitable vector for propagation of the gene.

Identification of the specific DNA fragment containing the desired gene may be accomplished in a number of ways. For example, if an amount of a portion of the gene or its specific RNA, or a fragment thereof, is available and can be purified and
30 labeled, the generated DNA fragments may be screened by nucleic acid hybridization

to a labeled probe (Benton *et al.*, *Science* 196:180 (1977); Grunstein *et al.*, *Proc. Natl. Acad. Sci., USA* 72:3961 (1975)). For example, a set of oligonucleotides corresponding to the partial amino acid sequence information obtained for an amino acid polymer of the present can be prepared and used as probes for DNA encoding that protein, or as primers for cDNA or mRNA (*e.g.*, in combination with a poly-T primer for RT-PCR). Preferably, a fragment is selected that is highly unique to the particular amino acid polymer. Those DNA fragments with substantial homology to the probe will hybridize. As noted above, the greater the degree of homology, the more stringent hybridization conditions can be used. In a specific embodiment, high stringency hybridization conditions are used to identify an homologous mRNA for the particular mRNAs of the present invention.

Further selection can be carried out on the basis of the properties of the gene and its alternative splice sites, *e.g.*, if the alternative splice sites facilitate the formation of an mRNA that encodes a protein product having the isoelectric, electrophoretic, amino acid composition, or partial amino acid sequence of the amino acid polymers as disclosed herein. Thus, the presence of the gene may be detected by assays based on the physical, chemical, or immunological properties of its expressed product. For example, cDNA clones, or DNA clones which hybrid-select the proper mRNAs, can be selected which produce a protein that, *e.g.*, has similar or identical electrophoretic migration, isoelectric focusing or non-equilibrium pI gel electrophoresis behavior, proteolytic digestion maps, or antigenic properties as known for the particular amino acid polymer. For example, the ability of a cyclin C/cdk8 inhibitor to bind to cdk8 and to hinder the active cyclin C/cdk8 complex is indicative of its identity as an cyclin C/cdk8 inhibitor of the present invention.

The present invention also relates to cloning vectors containing genes encoding analogs and derivatives of the amino acid polymers of the present invention, that have the same or homologous functional activity as the particular amino acid polymer, and homologs thereof from other species. The production and use of derivatives and

- analogous related to amino acid polymers of the present invention are within the scope of the present invention. In a specific embodiment, the derivative or analog is functionally active, *e.g.*, capable of exhibiting one or more functional activities associated with a wild-type cyclin C/cdk8 inhibitor of the invention. Derivatives can be made by altering the encoding nucleic acid sequences by substitutions, additions or deletions that provide for functionally equivalent molecules. Preferably, derivatives are made that have enhanced or increased functional activity relative to the native cyclin C/cdk8 inhibitor, or have greater stability than the amino acid polymer.
- 10 Due to the degeneracy of nucleotide coding sequences, other DNA and/or mRNA sequences which encode substantially the same amino acid sequence as an amino acid polymer of the present invention may be used in the practice of the present invention. These include but are not limited to allelic genes, homologous genes from other species, and nucleotide sequences comprising all or portions of nucleic acids encoding
- 15 such amino acid polymer which are altered by the substitution of different codons that encode the same amino acid residue within the sequence, thus producing a silent change. Likewise, such derivatives include, but are not limited to, those containing, as a primary amino acid sequence, all or part of the amino acid sequence of an amino acid polymer of the present invention, *e.g.*, as set forth in SEQ ID NO:4, SEQ ID
- 20 NO:50, or SEQ ID NO:52, including altered sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a conservative amino acid substitution. Substitution of one or more amino acid residues within the sequence by an amino acid of a similar polarity, which acts as a functional equivalent, may result in a silent alteration. Substitutes for an amino acid
- 25 within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. Amino acids containing aromatic ring structures are phenylalanine, tryptophan, and tyrosine. The polar neutral amino acids include glycine, serine,
- 30 threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged

(basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Such alterations will not be expected to affect apparent molecular weight as determined by polyacrylamide gel electrophoresis, or isoelectric point.

5

Particularly preferred substitutions are:

- Lys for Arg and vice versa such that a positive charge may be maintained;
- Glu for Asp and vice versa such that a negative charge may be maintained;
- Ser for Thr such that a free -OH can be maintained; and
- 10 - Gln for Asn such that a free NH_2 can be maintained.

Amino acid substitutions may also be introduced to substitute an amino acid with a particularly preferable property. For example, a Cys may be introduced a potential site for disulfide bridges with another Cys. A His may be introduced as a particularly
15 "catalytic" site (*i.e.*, His can act as an acid or base and is the most common amino acid in biochemical catalysis). Pro may be introduced because of its particularly planar structure, which induces β -turns in the protein's structure.

The genes encoding the amino acid polymer derivatives and analogs of the invention
20 can be produced by various methods known in the art. The manipulations which result in their production can occur at the gene or protein level. For example, a cloned gene sequence can be modified by any of numerous strategies known in the art (Sambrook et al., 1989, *supra*). The sequence can be cleaved at appropriate sites with restriction endonuclease(s), followed by further enzymatic modification if desired,
25 isolated, and ligated *in vitro*. In the production of the gene encoding a derivative or analog of an amino acid polymer of the present invention, care should be taken to ensure that the modified gene remains within the same translational reading frame as the native nucleic acid, uninterrupted by translational stop signals, in the region where the desired activity is encoded.

30

- Additionally, a nucleic acid sequence encoding an amino acid polymer of the present invention can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to
- 5 facilitate further *in vitro* modification. Preferably, such mutations enhance the functional activity of the mutated gene product. Any technique for mutagenesis known in the art can be used, including but not limited to, *in vitro* site-directed mutagenesis (Hutchinson, *et al.*, *J. Biol. Chem.* **253**:6551 (1978); Zoller *et al.*, *DNA* **3**:479-488 (1984); Oliphant *et al.*, *Gene* **44**:177 (1986); Hutchinson *et al.*, *Proc. Natl.*
- 10 *Acad. Sci., USA* **83**:710 (1986)), use of TAB® linkers (Pharmacia), etc. PCR techniques are preferred for site directed mutagenesis (see Higuchi, 1989, "Using PCR to Engineer DNA", in *PCR Technology: Principles and Applications for DNA Amplification*, H. Erlich, ed., Stockton Press, Chapter 6, pp. 61-70).
- 15 In a specific embodiment, a truncated cyclin C fusion protein can be expressed. A truncated cyclin C fusion protein comprises at least a functionally active portion of a another protein joined via a peptide bond to at least a functionally active portion of a truncated cyclin C polypeptide. The sequences of the other protein can be amino- or carboxy-terminal to the truncated cyclin C sequences. A recombinant DNA molecule
- 20 encoding such a fusion protein comprises a sequence encoding at least a functionally active portion of the other protein joined in-frame to the truncated cyclin C coding sequence, and preferably encodes a cleavage site for a specific protease, *e.g.*, thrombin or Factor Xa, preferably at the junction of the other protein and the truncated cyclin C. In a specific embodiment, the other protein is glutathione-S-transferase (GST) and the
- 25 fusion protein is a GST-truncated cyclin C fusion protein that bind directly to cdk8 *in vitro*, including radiolabeled cdk8. In another embodiment, the other protein is green fluorescent protein (GFP) and the fusion protein is a GFP-truncated cyclin C fusion protein.

The identified and isolated gene can then be inserted into an appropriate cloning vector. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used. The insertion into a cloning
5 vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site desired may be produced by ligating nucleotide sequences
10 (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated. Preferably, the cloned gene is contained on a shuttle
15 vector plasmid, which provides for expansion in a cloning cell, *e.g.*, *E. coli*, and facile purification for subsequent insertion into an appropriate expression cell line, if such is desired. For example, a shuttle vector, which is a vector that can replicate in more than one type of organism, can be prepared for replication in both *E. coli* and *Saccharomyces cerevisiae* by linking sequences from an *E. coli* plasmid with
20 sequences from the yeast 2 μ plasmid.

Expression of the Amino Acid Polymers of the Present Invention

The nucleotide sequence coding for an amino acid polymer of the present invention, or antigenic fragment, derivative or analog thereof, or a functionally active derivative,
25 including a chimeric protein, thereof, can be inserted into an appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. Such elements are termed herein a "promoter." Thus, the nucleic acid encoding an amino acid polymer of the invention is operationally associated with a promoter in an expression vector of the invention.
30 Both cDNA and genomic sequences can be cloned and expressed under control of

such regulatory sequences. An expression vector also preferably includes a replication origin.

The necessary transcriptional and translational signals can be provided on a recombinant expression vector, or they may be supplied by the native gene encoding the amino acid polymer and/or its flanking regions.

Potential host-vector systems include but are not limited to mammalian cell systems infected with virus (*e.g.*, vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (*e.g.*, baculovirus); microorganisms such as yeast containing yeast vectors; or bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA.

The expression elements of vectors vary in their strengths and specificities.

Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.

15

A recombinant protein of the present invention, or functional fragment, derivative, chimeric construct, or analog thereof, may be expressed chromosomally, after integration of the coding sequence by recombination. In this regard, any of a number of amplification systems may be used to achieve high levels of stable gene expression (See Sambrook et al., 1989, *supra*)

20

The cell into which the recombinant vector comprising the nucleic acid encoding the amino acid polymer is cultured in an appropriate cell culture medium under conditions that provide for expression of amino acid polymer by the cell.

25

Any of the methods previously described for the insertion of DNA fragments into a cloning vector may be used to construct expression vectors containing a gene consisting of appropriate transcriptional/translational control signals and the protein coding sequences. These methods may include *in vitro* recombinant DNA and synthetic techniques and *in vivo* recombination (genetic recombination).

30

Expression of the amino acid polymer may be controlled by any promoter/enhancer element known in the art, but these regulatory elements must be functional in the host selected for expression. Promoters which may be used to control cyclin C/cdk8 inhibitor gene expression include, but are not limited to, the SV40 early promoter
5 region (Benoist *et al.*, *Nature* **290**:304-310 (1981)), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto *et al.*, *Cell* **22**:787-797 (1981)), the herpes thymidine kinase promoter (Wagner *et al.*, *Proc. Natl. Acad. Sci., USA* **78**:1441-1445 (1981)), the regulatory sequences of the metallothionein gene (Brinster *et al.*, *Nature*, **296**:39-42 (1986)); prokaryotic expression vectors such as the
10 β -lactamase promoter (Villa-Kamaroff *et al.*, *Proc. Natl. Acad. Sci., USA* **75**:3727-3731 (1978)), or the *tac* promoter (DeBoer *et al.*, *Proc. Natl. Acad. Sci., USA* **80**:21-25 (1983)); see also "Useful proteins from recombinant bacteria" in *Scientific American* **242**:74-94 (1980); promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase)
15 promoter, alkaline phosphatase promoter; and the animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift *et al.*, *Cell* **38**:639-646 (1984); Ornitz *et al.*, *Cold Spring Harbor Symp. Quant. Biol.* **50**:399-409 (1986); MacDonald, *Hepatology* **7**:425-515 (1984)); insulin gene control region
20 which is active in pancreatic beta cells (Hanahan, *Nature* **315**:115-122 (1985)), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl *et al.*, *Cell*, **38**:647-658 (1984); Adames *et al.*, *Nature* **318**:533-538 (1984); Alexander *et al.*, *Mol. Cell. Biol.* **7**:1436-1444 (1984)), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder *et al.*, *Cell*,
25 **45**:485-495 (1986)), albumin gene control region which is active in liver (Pinkert *et al.*, *Genes and Devel.* **1**:268-276 (1987)), alpha-fetoprotein gene control region which is active in liver (Krumlauf *et al.*, *Mol. Cell. Biol.* **5**:1639-1648 (1985); Hammer *et al.*, *Science* **235**:53-58 (1987)), alpha 1-antitrypsin gene control region which is active in the liver (Kelsey *et al.*, *Genes and Devel.*, **1**:161-171 (1987)), beta-globin gene control
30 region which is active in myeloid cells (Mogam *et al.*, *Nature* **315**:338-340 (1985));

Kollias *et al.*, *Cell* 46:89-94 (1986)), myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead *et al.*, *Cell* 48:703-712 (1987)), myosin light chain-2 gene control region which is active in skeletal muscle (Sani, *Nature* 314:283-286 (1985)), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason *et al.*, *Science* 234:1372-1378 (1985)).

Vectors are introduced into the desired host cells by methods known in the art, *e.g.*, transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, lipofection (lysosome fusion), use of a gene gun, or a DNA vector transporter (see, *e.g.*, Wu *et al.*, *J. Biol. Chem.* 267:963-967 (1984); Wu *et al.*, *J. Biol. Chem.* 263:14621-14624 (1988); Hartmut *et al.*, Canadian Patent Application No. 2,012,311, filed March 15, 1990).

15 Transgenic Animal Models of truncated cyclin C Activity

As noted above, the functional activity of truncated cyclin C or the stabilized cyclin C exemplified by the amino acid polymer having the amino acid sequence of SEQ ID NO:50 can be evaluated transgenically. In this respect, a transgenic mouse (or other animal) model can be used. A DNA fragment encoding truncated cyclin C (hereafter referred to as the "*truncated cyclin C* gene") for example, can be introduced transgenically using standard techniques, either to provide for over expression of the protein, or to complement animals defective in the protein. Transgenic vectors, including viral vectors, or cosmid clones (or phage clones) corresponding to the wild type locus of candidate gene, can be constructed using the isolated DNA fragment encoding truncated cyclin C, as described below. Cosmids may be introduced into transgenic mice using published procedures (Jaenisch, *Science* 240:1468-1474 (1988)).

Alternatively, *truncated cyclin C* genes can be tested by examining their phenotypic effects when expressed in antisense orientation in wild-type animals. In this

approach, expression of the wild-type allele is suppressed, which leads to a mutant phenotype. RNA-RNA duplex formation (antisense-sense) prevents normal handling of mRNA, resulting in partial or complete elimination of wild-type gene effect. This technique has been used to inhibit TK synthesis in tissue culture and to produce

5 phenotypes of the *Kruppel* mutation in *Drosophila*, and the *Shiverer* mutation in mice (Izant *et al.*, *Cell* **36**:1007-1015 (1984); Green *et al.*, *Annu. Rev. Biochem.* **55**:569-597 (1986); Katsuki *et al.*, *Science* **241**:593-595 (1988)). An important advantage of this approach is that only a small portion of the gene need be expressed for effective inhibition of expression of the entire cognate mRNA. (This technique is particularly

10 advantageous in the present invention, since in some embodiments the full-length form of cyclin C is expressed and only the truncated cyclin C is eliminated.) The antisense transgene will be placed under control of its own promoter or another promoter expressed in the correct cell type, and placed upstream of the SV40 polyA site. This transgene can be used to make transgenic mice, or by using gene knockout

15 technology.

Antibodies to the Amino Acid Polymers of the Present Invention

According to the present invention, amino acid polymers of the present invention produced recombinantly or by chemical synthesis, and fragments or other derivatives

20 or analogs thereof, including fusion proteins, may be used as an immunogen to generate antibodies that recognize specific and unique portions of these polypeptides. Such antibodies include but are not limited to polyclonal, monoclonal (Kohler *et al.*, *Nature* **256**:495-497 (1975); Kozbor *et al.*, *Immunology Today* **4**:72 (1983); Cole *et al.*, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96

25 (1985); PCT/US90/02545; Cote *et al.*, *Proc. Natl. Acad. Sci., USA* **80**:2026-2030 (1983)), chimeric (Morrison *et al.*, *J. Bacteriol.* **159**:870 (1984); Neuberger *et al.*, *Nature* **312**:604-608 (1984); Takeda *et al.*, *Nature* **314**:452-454 (1985)), single chain (U.S. Patent 4,946,778), Fab fragments, and an Fab expression library. The antibodies of the invention may be cross reactive over species, *e.g.*, they may

30 recognize homologous proteins from different species. Polyclonal antibodies have

greater likelihood of cross reactivity. Alternatively, an antibody of the invention may be specific for a single form of an amino acid polymer of the present invention such as an antibody specific for the human truncated cyclin C.

- 5 For the production of polyclonal antibody, various host animals can be immunized by injection, including but not limited to rabbits, mice, rats, sheep, goats, etc. In one embodiment, for example the cyclin C/cdk8 inhibitor polypeptide or fragment thereof can be conjugated to an immunogenic carrier, *e.g.*, bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH). Various adjuvants may be used to increase the
- 10 immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (*bacille Calmette-Guerin*) and *Corynebacterium*
- 15 *parvum*.

- In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, *e.g.*, radioimmunoassay, ELISA (enzyme-linked immunosorbant assay), "sandwich" immunoassays,
- 20 immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, *in situ* immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (*e.g.*, gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc.
- 25 In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present
- 30 invention. For example, to select antibodies which recognize a specific epitope of an

amino acid polymer of the present invention, one may assay generated hybridomas for a product which binds to the amino acid polymer fragment containing such epitope. For selection of an antibody specific to such an amino acid polymer from a particular species of animal, one can select on the basis of positive binding with the amino acid
5 polymer expressed by or isolated from cells of that species of animal.

The foregoing antibodies can be used in methods known in the art relating to the localization and activity of the amino acid polymer, *e.g.*, for Western blotting, imaging the polypeptide *in situ*, measuring levels thereof in appropriate physiological
10 samples, etc.

Inhibition of Cyclin C/cdk8 inhibitor Expression

The present invention extends to the preparation of antisense nucleotides and ribozymes that may be used to interfere with the expression of the cyclin C/cdk8
15 inhibitor at the translational level. This approach utilizes antisense nucleic acid and ribozymes to block translation of a specific mRNA, either by masking that mRNA with an antisense nucleic acid or cleaving it with a ribozyme. Such approaches also may be used to interfere with the expression of the stabilized human cyclin C exemplified by the amino acid polymer having an amino acid sequence of SEQ ID
20 N(0):50

Antisense nucleic acids are DNA or RNA molecules that are complementary to at least a portion of a specific mRNA molecule (*see* Weintraub, 1990; Marcus-Sekura, *Anal. Biochem.* 172:298 (1988)). In the cell, they hybridize to that mRNA, forming a
25 double stranded molecule. The cell does not translate an mRNA in this double-stranded form. Therefore, antisense nucleic acids bind mRNA and thereby interfere with the expression of the protein encoded by the mRNA. Oligomers of about fifteen nucleotides and molecules that hybridize to the AUG initiation codon will be particularly efficient, since they are easy to synthesize and are likely to pose
30 fewer problems than larger molecules when introducing them into organ cells.

Antisense methods have been used to inhibit the expression of many genes *in vitro* (Marcus-Sekura, *supra*; Hambor *et al.*, *J. Exp. Med.* **168**:1237 (1988)). Preferably synthetic antisense nucleotides contain phosphoester analogs, such as phosphorothiolates, or thioesters, rather than natural phosphoester bonds. Such phosphoester bond analogs are more resistant to degradation, increasing the stability, and therefore the efficacy, of the antisense nucleic acids.

Ribozymes are RNA molecules possessing the ability to specifically cleave other single stranded RNA molecules in a manner somewhat analogous to DNA restriction endonucleases. Ribozymes were discovered from the observation that certain mRNAs have the ability to excise their own introns. By modifying the nucleotide sequence of these RNAs, researchers have been able to engineer molecules that recognize specific nucleotide sequences in an RNA molecule and cleave it (Cech, *J. Am. Med. Assoc.* **260**:3030 (1988)). Because they are sequence-specific, only mRNAs with particular sequences are inactivated.

Investigators have identified two types of ribozymes, *Tetrahymena*-type and "hammerhead"-type (Hasselhoff and Gerlach, 1988). *Tetrahymena*-type ribozymes recognize four-base sequences, while "hammerhead"-type recognize eleven- to eighteen-base sequences. The longer the recognition sequence, the more likely it is to occur exclusively in the target mRNA species. Therefore, hammerhead-type ribozymes are preferable to *Tetrahymena*-type ribozymes for inactivating a specific mRNA species, and eighteen base recognition sequences are preferable to shorter recognition sequences.

Therapeutic Methods and Gene Therapy

Various diseases or disorders mediated by inappropriate cell cycle activity due to increased or decreased activity of the cyclin C/cdk8 inhibitor of the invention may be addressed by introducing genes that encode either antisense or ribozyme molecules that inhibit expression of the cyclin C/cdk8 inhibitor (where the disease or disorder is

associated with excessive cyclin C/cdk8 inhibitor activity), or the cyclin C/cdk8 inhibitor (where the disease or disorder is associated with decreased cyclin C/cdk8 inhibitor activity). In addition, *in vitro* or *in vivo* transfection with one of the foregoing genes may be useful for evaluation of cell cycle activity in an animal
5 model, which in turn may serve for drug discovery and evaluation.

In a specific embodiment, the present invention is directed to the treatment of tumors and other cancers by modulating the activity of a truncated cyclin C, *e.g.*, by enhancing or inhibiting expression of the cyclin C/cdk8 inhibitor to increase or
10 decrease its activity. In specific embodiments, the invention provides for introducing an antisense nucleotide or a ribozyme specific for the alternatively spliced mRNA to inhibit truncated cyclin C activity. In this instance, increased expression of genes indirectly under control of truncated cyclin C may be necessary to restore appropriate cell cycle and growth characteristics to a transformed cell, in which case a transgene
15 vector of the invention for expression of truncated cyclin C can be used. Under other circumstances, control of proliferation of a cancer cell is accomplished by maintaining an active cyclin C/cdk8 complex, thereby regulating uncontrolled cell proliferation characteristic of cancer cells. As the present invention provides for detecting the level and activity of truncated cyclin C in cells, such as cancer cells, specifically
20 tumor cells, the need to increase or decrease the activity of truncated cyclin C in a given cell can be readily determined.

Examples of tumors that can be treated according to the invention include sarcomas and carcinomas such as, but not limited to: fibrosarcoma, myxosarcoma, liposarcoma,
25 chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma,
30 papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary

carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, 5 craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, and retinoblastoma.

In another embodiment, dysproliferative changes (such as metaplasias and dysplasias) are treated or prevented in epithelial tissues such as those in the cervix, esophagus, 10 and lung. Thus, the present invention provides for treatment of conditions known or suspected of preceding progression to neoplasia or cancer, in particular, where non-neoplastic cell growth consisting of hyperplasia, metaplasia, or most particularly, dysplasia has occurred (for review of such abnormal growth conditions, see Robbins and Angell, 1976, *Basic Pathology*, 2d Ed., W.B. Saunders Co., Philadelphia, pp. 15 68-79). Hyperplasia is a form of controlled cell proliferation involving an increase in cell number in a tissue or organ, without significant alteration in structure or function. As but one example, endometrial hyperplasia often precedes endometrial cancer. Metaplasia is a form of controlled cell growth in which one type of adult or fully differentiated cell substitutes for another type of adult cell. Metaplasia can occur in 20 epithelial or connective tissue cells. Atypical metaplasia involves a somewhat disorderly metaplastic epithelium. Dysplasia is frequently a forerunner of cancer, and is found mainly in the epithelia; it is the most disorderly form of non-neoplastic cell growth, involving a loss in individual cell uniformity and in the architectural orientation of cells. Dysplastic cells often have abnormally large, deeply stained 25 nuclei, and exhibit pleomorphism. Dysplasia characteristically occurs where there exists chronic irritation or inflammation, and is often found in the cervix, respiratory passages, oral cavity, and gall bladder. For a review of such disorders, see Fishman *et al.*, *Medicine*, 2d Ed., J. B. Lippincott Co., Philadelphia (1985).

In one embodiment, a gene for regulation of truncated cyclin C (*e.g.*, an antisense gene) is introduced *in vivo* in a viral vector. Such vectors include an attenuated or defective DNA virus, such as but not limited to herpes simplex virus (HSV), papillomavirus, Epstein Barr virus (EBV), adenovirus, adeno-associated virus (AAV), and the like. Defective viruses, which entirely or almost entirely lack viral genes, are preferred. Defective virus is not infective after introduction into a cell. Use of defective viral vectors allows for administration to cells in a specific, localized area, without concern that the vector can infect other cells. Thus, in a specific embodiment, tumors can be specifically targeted. Examples of particular vectors include, but are not limited to, a defective herpes virus 1 (HSV1) vector (Kaplitt *et al.*, *Molec. Cell. Neurosci.* 2:320-330 (1991)), an attenuated adenovirus vector, such as the vector described by Stratford-Perricaudet *et al.* (*J. Clin. Invest.*, 90:626-630 (1990)), and a defective adeno-associated virus vector (Samulski *et al.*, *J. Virol.* 61:3096-3101 (1987); Samulski *et al.*, *J. Virol.*, 63:3822-3828 (1989)).

Preferably, for *in vitro* administration, an appropriate immunosuppressive treatment is employed in conjunction with the viral vector, *e.g.*, adenovirus vector, to avoid immuno-deactivation of the viral vector and transfected cells. For example, immunosuppressive cytokines, such as interleukin-12 (IL-12), interferon- γ (IFN- γ), or anti-CD4 antibody, can be administered to block humoral or cellular immune responses to the viral vectors (*see, e.g.*, Wilson, *Nature Medicine* (1994)). In addition, it is advantageous to employ a viral vector that is engineered to express a minimal number of antigens.

In another embodiment the gene can be introduced in a retroviral vector, *e.g.*, as described in Anderson *et al.*, U.S. Patent No. 5,399,346; Mann *et al.*, *Cell* 33:153 (1983); Temin *et al.*, U.S. Patent No. 4,650,764; Temin *et al.*, U.S. Patent No. 4,980,289; Markowitz *et al.*, *J. Virol.* 62:1120 (1988); Temin *et al.*, U.S. Patent No. 5,124,263; International Patent Publication No. WO 95/07358, published March 16, 1995, by Dougherty *et al.*; and Kuo *et al.*, *Blood* 82:845 (1993).

Targeted gene delivery is described in International Patent Publication WO 95/28494, published October 1995.

Alternatively, the vector can be introduced *in vivo* by lipofection. For the past decade,
5 there has been increasing use of liposomes for encapsulation and transfection of
nucleic acids *in vitro*. Synthetic cationic lipids designed to limit the difficulties and
dangers encountered with liposome mediated transfection can be used to prepare
liposomes for *in vivo* transfection of a gene encoding a marker (Felgner *et al.*, *Proc.*
Natl. Acad. Sci., USA **84**:7413-7417 (1987); see Mackey *et al.*, *Proc. Natl. Acad. Sci.,*
10 *USA* **85**:8027-8031 (1988)). The use of cationic lipids may promote encapsulation of
negatively charged nucleic acids, and also promote fusion with negatively charged
cell membranes (Felgner *et al.*, *Science* **337**:387-388 (1989)). The use of lipofection
to introduce exogenous genes into the specific organs *in vivo* has certain practical
advantages. Molecular targeting of liposomes to specific cells represents one area of
15 benefit. It is clear that directing transfection to particular cell types would be
particularly advantageous in a tissue with cellular heterogeneity, such as pancreas,
liver, kidney, and the brain. Lipids may be chemically coupled to other molecules for
the purpose of targeting (see Mackey *et al.*, 1988, *supra*). Targeted peptides, *e.g.*,
hormones or neurotransmitters, and proteins such as antibodies, or non-peptide
20 molecules could be coupled to liposomes chemically.

It is also possible to introduce the vector *in vivo* as a naked DNA plasmid. Naked
DNA vectors for gene therapy can be introduced into the desired host cells by
methods known in the art, *e.g.*, transfection, electroporation, microinjection,
25 transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a
gene gun, or use of a DNA vector transporter (see, *e.g.*, Wu *et al.*, *J. Biol. Chem.*
267:963-967 (1992); Wu *et al.*, 1988, Hartmut *et al.*, *supra*).

Detection of an Amino Acid Polymer of the Present Invention

As suggested earlier, the diagnostic method of the present invention comprises examining a cellular sample or medium by means of an assay including an effective amount of a binding partner of the amino acid polymer, such as an anti-cyclin C/cdk8 inhibitor antibody, preferably an affinity-purified polyclonal antibody, and more preferably a mAb, or oligonucleotide containing the specific sequence.

The present invention also relates to a variety of diagnostic applications, including methods for detecting the presence of stimuli such as the earlier referenced polypeptide ligands, by reference to their ability to elicit the activities which are mediated by the present cyclin C/cdk8 inhibitor. As mentioned earlier, the cyclin C/cdk8 inhibitor can be used to produce antibodies to itself by a variety of known techniques, and such antibodies could then be isolated and utilized as in tests for the presence of particular transcription activation activity in suspect target cells.

The procedures and their application are all familiar to those skilled in the art and accordingly may be utilized within the scope of the present invention. For example, a "competitive" procedure is described in U.S. Patent Nos. 3,654,090 and 3,850,752. A "sandwich" procedure is described in U.S. Patent Nos. RE 31,006 and 4,016,043. Still other procedures are known such as the "double antibody," or "DASP" procedure.

The labels most commonly employed for these studies are radioactive elements, enzymes, chemicals which fluoresce when exposed to ultraviolet light, and others.

A number of fluorescent materials are known and can be utilized as labels. These include, for example, fluorescein, rhodamine, auramine, Texas Red, AMCA blue and Lucifer Yellow. A particular detecting material is anti-rabbit antibody prepared in goats and conjugated with fluorescein through an isothiocyanate.

An amino acid polymer of the present invention or its binding partner(s) can also be labeled with a radioactive element or with an enzyme. The radioactive label can be detected by any of the currently available counting procedures. The preferred isotope may be selected from ^3H , ^{14}C , ^{32}P , ^{35}S , ^{36}Cl , ^{51}Cr , ^{57}Co , ^{58}Co , ^{59}Fe , ^{90}Y , ^{125}I , ^{131}I , and
5 ^{186}Re .

Enzyme labels are likewise useful, and can be detected by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques. The enzyme is conjugated to the selected particle by reaction
10 with bridging molecules such as carbodiimides, diisocyanates, glutaraldehyde and the like. Many enzymes which can be used in these procedures are known and can be utilized. The preferred are peroxidase, β -glucuronidase, β -D-glucosidase, β -D-galactosidase, urease, glucose oxidase plus peroxidase and alkaline phosphatase. U.S. Patent Nos. 3,654,090; 3,850,752; and 4,016,043 are referred to by way of
15 example for their disclosure of alternate labeling material and methods.

Other means for detecting specific binding are well known in the art, including biosensors such as the BIAcore™ system (Pharmacia Biosensor AB, Uppsala, Sweden), or optical immunosensor systems. These systems can be grouped into four
20 major categories: reflection techniques; surface plasmon resonance; fiber optic techniques, and integrated optic devices. Reflection techniques include ellipsometry, multiple integral reflection spectroscopy, and fluorescent capillary fill devices. Fiber-optic techniques include evanescent field fluorescence, optical fiber capillary tube, and fiber optic fluorescence sensors. Integrated optic devices include planar
25 evanescent field fluorescence, input grading coupler immunosensor, Mach-Zehnder interferometer, Hartman interferometer and difference interferometer sensors.

Holographic detection of binding reactions is accomplished detecting the presence of a holographic image that is generated at a predetermined image location when one reactant of a binding pair binds to an immobilized second reactant of the binding pair
30 (see U.S. Patent No. 5,352,582, issued October 4, 1994 to Lichtenwalter *et al.*).

Examples of optical immunosensors are described in general in a review article by G.A. Robins (Advances in Biosensors). Vol. 1, pp. 229-256, 1991. More specific description of these devices are found for example in U.S. Patents 4,810,658; 4,978,503; 5,186,897; R.A. Brady *et al.* (*Phil. Trans. R. Soc. Land. B* 316:143-160 (1987)) and G.A. Robinson *et al.* (*in* Sensors and Actuators, Elsevier, 1992).

The following examples are presented in order to more fully illustrate the preferred embodiments of the invention. They should in no way be construed, however, as limiting the broad scope of the invention.

10

EXAMPLES

Various references cited herein are listed after the Examples, *infra*.

Example 1

15 ALTERNATIVELY SPLICED CYCLIN C mRNA IS WIDELY EXPRESSED, CELL CYCLE REGULATED, AND ENCODES A TRUNCATED CYCLIN BOX PROTEIN.

Introduction

20 Screening of an avian T-cell cDNA library results in the isolation of a cyclin C homologue as well as an abundant, yet distinct, cyclin C-related cDNA. The predicted open reading frame (ORF) of the cyclin C cDNA predicted a 283 amino acid protein that is >99% identical to the human protein and 72% identical to the *Drosophila melanogaster* protein. However, the predicted ORF of the cyclin C-
25 related cDNA predicts a much smaller 105 amino acid protein that is identical to cyclin C well into the cyclin-box region (amino acid residue 98), where it abruptly diverges and then terminates. Using PCR analysis of cDNA derived from a range of cell lines and tissues, alternative splicing of the avian cyclin C gene is demonstrated. This alternatively spliced cDNA is the result of the insertion of a unique exon
30 containing premature termination codons within the cyclin-box region of the normal

protein. (The cyclin box region includes amino acids 9-175 as determined by
homology with other cyclins *i.e.*, cyclin A, cyclin B, cyclin D1, cyclin E, etc.).
Furthermore, a smaller ~19 kDa protein that co-migrates with the *in vitro* transcribed
and translated truncated cyclin C protein is detected in normal and virally-transformed
5 avian cells with a *Drosophila melanogaster* cyclin C antibody (Leclerc *et al.*, *supra*).

Steady-state levels of the normal cyclin C mRNA and protein do not vary during the
cell cycle. However, expression of alternatively spliced cyclin C mRNA and protein
is regulated in a cell cycle-dependent manner with a peak in G2/M and early G1-
10 phase, similar to the expression of cyclin B2 (Gallant *et al.*, *J. Cell Biol.* 117:213-224
(1992)). The expression of highly conserved cyclin C and truncated cyclin C ORFs in
a variety of virally-transformed cell lines and normal tissues indicates that both cyclin
C and truncated cyclin C are important in regulating transcription (Leclerc *et al.*
supra; Maldonado *et al.*, *Nature* 381:86-89 (1996)). The truncated cyclin C protein
15 functions as endogenously encoded cyclin C inhibitor by negatively regulating cyclin
C/cdk8 complex activity, in much the same way as the cyclin dependent protein
kinase inhibitors function to inhibit the D-type cyclins, cyclin A and cyclin E (Sherr *et al.*,
Genes & Devel 9:1149-1163 (1995)).

20

MATERIALS AND METHODS

Isolation and characterization of the chicken cyclin C cDNAs and genomic clones.

Chicken cyclin C cDNAs are isolated from a chicken UG9 T-cell cDNA library (Lahti
et al., *Proc. Natl. Acad. Sci., USA* 88: 10595-10960 (1991)) by low-stringency
hybridization with a human cyclin C cDNA (Lew *et al.*, *supra*). Twenty cDNAs are
25 isolated from a screen of ~80,000 cDNAs, and they are subsequently grouped
according to size, and later, nucleotide sequence differences. DNA sequence is
determined as previously described (Bunnell *et al.*, *Proc. Natl. Acad. Sci. USA*
87:7467-7471 (1990); Kidd *et al.*, *Cell Growth & Differ.* 2:85-93 (1991); Xiang *et al.*,
J. Biol. Chem. 269:15786-15794 (1994)). The corresponding chicken gene is isolated
30 by screening a Cornish White Rock chicken cosmid library (Stratagene) with the full-

length chicken cyclin C cDNA as previously described (Eipers *et al.*, *Genomics* 13:613-621 (1992)). *EcoRI* fragments containing the entire gene are subcloned into a pKS plasmid vector (Stratagene), and the resulting plasmid, as well as cosmid, DNA used for double strand DNA sequence analysis. Using oligonucleotide primers

5 designed for sequencing the cDNA clones, all exons and intron/exon boundaries are sequenced in both directions as described (Xiang *et al.*, *supra*). Oligonucleotides are spaced approximately 80-100 bp apart spanning the cDNA. All DNA sequence data is analyzed using the IntelliGenetics program. The following oligonucleotides are used for this analysis: C-1, 5' TCCAGCAGAAGGATGCAA 3'; C-2, 5'

10 CTCCAGCACACAGTCAAC 3'; C-3, 5' AGGTGAACATCTTAAATT 3'; C-4, 5' TAGGAGCCATTAATACTG 3'; C-5, 5' GACCACTTTGACTCAAGA 3'; C-6, 5' CTGCAGAATCACTATACA 3'; C-7, 5' GTCCATTTCATGAACACA 3'; C-8, 5' AGCCATCTCTTTCCTCTC 3'; C-9, 5' CAAGCTAGAGCTATCATG 3'; C-10, 5' CGCTCCTTCAGTAGATCTTG 3'; C-11, 5' TTGAAATTTCTGTCTGAA 3'; C-12,

15 5' AAACCTCTTCGGGAAGGC 3'; C-13, 5' ATCAACAGATAGCTCAGC 3'; C-14, 5' GTCTTCTTGGCCCATATC 3'; C-15, 5' GTAGACTGTAGCAGTGGC 3'; C-16, 5' GCATCCAAAGTAGAGGAG 3'; C-17, 5' CCTTTGCTCCAATATGTG 3'; C-18, 5' TAGAGAATATTGGCTTGAG 3'; C-19, 5' TAGTGCGAGCTCTGCCAGA 3'; C-20, 5' GAGATAGAATTACATTC 3'; C-21, 5' CTA AAAAGTATAGATCCAGT 3';

20 C-22, 5' TAGTGGGAGCTCTGCCAGAAGTTCC 3'; C-23, 5' AACTTCTGGCAGAGCTCGCAC 3'; C-24 5' CAATGGATTTTGGATAAAC 3'; C-25 5' CTCTACTTTGGATGCCAA 3'; C-26, 5' GAGTTTGGTGTGTTTCA 3'; C-27 5' GCTCTATGCAGGTGGATT 3'; C-28, 5' GAAACTACAGGTGCTGAG 3'; C-29, 5' AGCTATCATGAAAGGAGG 3'; C-30, 5' AGGATAGTGAATGACACA 3'; C-31,

25 5' ATAATCAGGGTTATTCTG 3'; C-41-1, 5' GCACCTTATTGAAGCTCT 3'; C-41-2, 5' GTTTGCCAACAACCTACA 3'; C-41-3, 5' GATAAAACCAGCGCACCT 3'; C-41-4, 5' CTGAAGATTAGTTTGCCA 3'.

RT-PCR analysis of cyclin C gene expression.

Total RNA from chicken UG9 T-cells and DT40 B-cells is isolated by hot phenol extraction as described (Bunnell *et al.*, *supra*). Poly(A)⁺ RNAs corresponding to avian liver and brain are obtained from Clontech. One microgram (μ g) of RNA is
5 analyzed from both cell lines and tissues by reverse transcriptase - polymerase chain reactions (RT-PCR) as previously described by others (Kinzler *et al.* 1991). Cyclin C-specific oligonucleotides are used to generate both the complementary DNA (cDNA) and the PCR products. The sequences of these oligonucleotides are as follows: CPP-1, 5' AGCGCACCTTATTGAAGCTCTT 3'; CPP-2, 5' AGGCAAGCTAG-
10 AGCTATCATGA 3'; CPP-3, 5' AGATCTACTGAAGGAGCGCCAA 3'; CPP-4, 5' AGATTAGTTTGCCAACAACCTACA 3'. The resulting RT-PCR products are run on 1% agarose-TBE gels and the fragments excised by electroblotting, as previously described (Kinzler *et al.*, *Science* **253**:661-665 (1991)). The isolated fragments are then purified and ligated into the TA vector (Invitrogen). The resulting clones are
15 screened for inserts, the plasmids purified, and double-strand DNA sequence analysis performed as described above.

Cell cycle synchronization of DT40 cells, RNA and protein isolation, Northern blotting, immunoprecipitations, and Western blotting.

20 DT40 cells are synchronized by a two-step process. Because these B-cells are normally grown in suspension culture (Buerstedde *et al.*, *Cell* **67**:179-188 (1991)), their sensitivity to cell cycle drugs is somewhat limited. To overcome this problem a G1-phase enriched cell population is first elutriated by centrifugal elutriation. Elutriation conditions are as follows: Cells are grown in culture to a concentration of
25 $0.5 - 1 \times 10^6$. These cells are then centrifuged gently and resuspended in 40-50 ml culture media containing 50% of the normal serum concentration. The elutriator (J6-M1 centrifuge) is prewashed with the same media (50% serum), and the centrifuge speed set to 2000 rpm. The pump is set at 8 ml/min. The cell suspension is then applied to the elutriator. The elutriator is washed by using the media containing 50%
30 serum for 10 min. The pump is increased from 8 ml/min to 11 ml/min. Cells are

- collected to 100 ml. The collected cells are centrifuged and resuspended in regular culture media at a concentration of 0.5×10^6 / ml. The elutriated cells are analyzed by fluorescence activated cell sorting (FACS) to confirm their position in the G1-phase of the cell cycle (Dolznig *et al.*, *Cell Growth & Differ.* 6:1341-1352 (1995).
- 5 Nocodazole (Sigma) is then added to a final concentration of 0.5 $\mu\text{g/ml}$ to block the cells for 10-12 hrs. The synchrony of these cells blockage at metaphase is again confirmed by FACS analysis. The nocodazole-treated cells are washed twice with phosphate-buffered saline (PBS) to remove the drug and to release them from the chemical block. The cells are then added back to regular cell culture media and time
- 10 points collected at 2 hr intervals. RNA is extracted from cells collected at these defined 2 hr intervals following their release from nocodazole, as described previously (Dolznig *et al.* 1995). Northern blot analysis of this total RNA is performed following transfer to a Duralose membrane with a PCR probe generated from intron 4 through intron 4a, which contains exon 4a, but does not contain any other region of the normal
- 15 cyclin C mRNA (See Fig. 2). The sequence of the oligonucleotides used for generating this exon 4a-specific probe is as follows: Primer 1 (intron 4 derived) 5'-GACTTGCTGGCTGCCTCATA- 3', Primer 2 (intron 4a derived) 5'-ATATATGAAAGGTATTACAGCCACAA-3' This probe is labeled with [^{32}P]-dCTP (NEN), the blot hybridized, washed and visualized as previously described
- 20 (Lahti *et al.* (1991); Li *et al.*, *Gene* 153: 237-242 (1995). The same blot is hybridized with a chicken cyclin B2 cDNA as a positive control (Gallant *et al.*, *supra*) and a β -actin cDNA probe as a control to demonstrate equal loading of RNA. This gel is also stained with ethidium bromide for the same purposes. A polyclonal antisera made to the *Drosophila melanogaster* cyclin C protein (Leclerc *et al.*, *supra*) is used for the
- 25 immunoprecipitation and Western blotting experiments. This antibody is affinity-purified by using a gel-purified full-length form of cyclin C. The previously reported protocols for both immunoprecipitation and Western blotting using this cyclin C antibody are followed (Leclerc *et al.*, *supra*).

RESULTS

Avian cyclin C cDNAs and their predicted open reading frames.

Screening of the chicken UG9 T-cell cDNA library yielded >20 positive cDNA clones. Restriction analysis of miniprep DNA from these lambda phage clones indicates that they contain inserts ranging in size from 1.8 to ~2.2 kb (data not shown). The inserts from these phage are subsequently cloned into a pKS plasmid vector, and the corresponding nucleotide sequence determined. Two distinct classes of cDNA sequences emerge; one corresponding to the previously reported cyclin C sequences from *Drosophila* and human, and the other containing a 73 bp insertion between codons 98 and 99 of the predicted ORF from the normal cyclin C homologue (Figure 1A and 1B, SEQ ID NO:2). This insertion results in the addition of seven unique amino acids to the first 98 of the cyclin C protein and the termination of the predicted protein due to a chain terminating codon immediately after residue 105 (SEQ ID NO:4, see Figure 1B). An additional in-frame termination codon is found 42 bp downstream of the first. The alternative cDNA sequence then rejoins the predicted sequence of the normal cyclin C cDNA, but due to the 73 bp size of the insertion a frame-shift occurs in the remaining cyclin C coding region. The predicted ORF of the avian cyclin C cDNA produces a 283 amino acid protein (SEQ ID NO:3) and is virtually identical to the predicted ORF of the human protein, containing only one amino acid difference at amino acid residue 110 of chicken (130 of human); a serine residue instead of an alanine residue (Figure 1C). In avians, both the cyclin C and cyclin C-related cDNAs predict ORFs that start at a methionine residue that is identical to that used in the *Drosophila* cyclin C mRNA (Figure 1A and Figure 1C).

Location of the 73 bp cyclin C cDNA insertion within the avian cyclin C gene.

The corresponding cyclin C gene is isolated by screening a chicken genomic cosmid library with the avian cDNA insert. Six positive cosmid clones are identified and analyzed further by restriction endonuclease mapping and DNA sequencing. The mosaic structure of the avian cyclin C gene is shown in Figure 2. The location of

introns that interrupt the coding sequence in the avian gene is identical to intron positions within the human gene [Figures 1 and 2; (Li *et al.*, *Genomics* 32:253-259 (1996a))]. Intron distances in the avian cyclin C gene are established by PCR. To determine whether the 73 bp insertion found in the cyclin C-related cDNA is a part of the normal gene, and its location, specific oligonucleotide primers are made corresponding to the 5' and 3' ends of this sequence. The 73 bp sequence found in the alternative cyclin C cDNA corresponds to an identical 73 bp sequence (exon 4a) located between exons 4 and 5 of the normal cyclin C gene, the same location predicted by the cyclin C-related cDNA sequence (Figures 1 and 2). This sequence is not contiguous with either exons 4 or 5 in the genomic clones, indicating that it is an alternatively spliced exon located within the normal avian cyclin C gene.

Identification of alternate cyclin C mRNAs.

If the variant avian cyclin C cDNA arises from the insertion of an additional exon by alternative splicing, it would indicate that production of such an alternatively spliced cyclin C-related mRNA is an important mechanism for regulating cyclin C/cdk8 kinase activity in cells. To examine the expression of this cyclin C-related mRNA in various avian cell lines and tissues a specific RT-PCR primer set to amplify a region extending from the alternatively spliced exon (exon 4a) through exon 7 is designed (Fig. 2). This primer set should amplify a 360 bp region of cyclin C-related mRNA, while it would produce a ~5 kb fragment from genomic DNA due to the introns located between these exons. The results of this experiment using UG9 and DT40 cell lines (which are both virally-transformed tumor cell lines), as well as normal liver and brain tissue poly(A⁺) RNA, demonstrates that all cell lines and tissues examined express the alternatively spliced 360 bp product (Figure 3A). This product co-migrates with the positive control generated from the cyclin C-related cDNA and it is not found in negative controls. In addition, an unknown, but prominent, band of ~600 bp was observed as well (Figure 3A). To determine the origin of this band, as well as verify the nature of the 360 bp product, the 360 bp and 600 bp RT-PCR fragments are excised from gels and subcloned into the transactivator (TA) vector for DNA

sequence analysis. This DNA sequence analysis verifies the identity of the 360 bp product as the alternatively spliced intron in all cell lines and tissues (data not shown). However, the larger 600 bp band contains the intronic sequence normally found between exons 4a and 5 in its entirety, but none of the intronic sequences found
5 between the other exons included in this PCR product.

These results indicate that as many as three different cyclin C mRNAs might be present in these various cells (CmRNA-1, CmRNA-2, and CmRNA-3, Fig. 2). Only one of these transcripts, CmRNA-3, (having SEQ ID NO:1) would encode the entire
10 cyclin C protein. To confirm this, a second set of oligonucleotide primers specific to the 5' end of exon 4a, or the adjacent intron found 5' of this exon, and extending to exon 2 is designed. If, indeed, the region between exons 4 and 5 is normally transcribed and produces two cyclin C-related mRNAs, two distinctly sized fragments of 310 bp and ~1.6 kb should be observed. The size of the PCR product predicted
15 from genomic DNA for the same region is > 4 kb. As expected, the 310 bp and ~1.6 kb products are observed when RT-PCR reactions are performed with the various avian cell line and tissue RNAs (Figure 3B). However, possibly the size and/or secondary structure of the larger RT-PCR fragment (~1.6 kb) limits the sensitivity of its detection. Once again, these bands are excised and cloned into the TA vector and
20 their respective DNA sequences are determined. The smaller 310 bp fragment contains sequence from exons 2, 3, 4, and 4a, but no intronic sequences. Conversely, the larger 1.6 kb fragment contains these same exonic regions as well as the intronic sequence located between exons 4 and 4a. Attempts to detect additional introns of the cyclin C gene encoded in mRNAs by RT-PCR were unsuccessful, suggesting that this
25 is a specific event involving only this region. These experiments confirm that in avians, cyclin C gene expression is complex and involves the production of multiple mRNA species, some of which may produce truncated cyclin C proteins.

Expression of the alternatively spliced cyclin C mRNA and its corresponding protein during the cell cycle.

To determine the biological significance of the expression of the alternatively spliced cyclin C mRNAs their expression is examined by Northern (Figure 4) and Western (Figure 5) blotting of RNA and protein, respectively. The RNA and protein used in these analyses are prepared from synchronized DT40 cells. Synchronous cell cycle progression of DT40 cells is achieved as described in Materials and Methods. RNA is then extracted from these cells and used for detection of the exon 4a containing cyclin C-related mRNA species with a PCR-generated probe. This probe includes only exon 4a and its immediately flanking introns, and therefore should not detect the normal, completely processed cyclin C mRNA. The nature of the probe used for detecting the alternatively spliced cyclin C mRNA is important, since the alternatively spliced cyclin C mRNA varies from the normal mRNA by only 73 bp, and both species are detected as a co-migrating band when analyzed by Northern blotting with the cyclin C cDNA (Figure 4). Examination of the Northern blot probed with the exon 4a-specific probe reveals that the abundance of a major, alternatively spliced 1.7 kb cyclin C-related mRNA which varies markedly during the cell cycle, reaches maximal levels during G2/M and early G1 phase of the cell cycle (Figure 4A). Conversely, expression of the mRNA encoding the normal cyclin C protein is invariant during the cell cycle (Figure 4B). Additionally, levels of the truncated cyclin C mRNA (CmRNA-2) are comparable to the normal cyclin C mRNA only during G2/M phase, since the steady-state levels of the C mRNA-2 species diminish substantially during the remainder of the cell cycle. This pattern of RNA expression is similar to that observed for cyclin B2 on the same blot (Figure 4C). Identical loading of RNA for each time point was demonstrated by EtBr staining (Figure 4D) and β -actin hybridization. The alternatively spliced cyclin C mRNA (CmRNA-2) is found to be more abundant than any of the other RNA products detected by RT-PCR containing intronic sequences (CmRNA-1 and CmRNA-3), since the major mRNA transcript is ~1.7 kb in size. Thus, expression of the alternatively spliced cyclin C is cell cycle-specific and contributes to the function and/or regulation of the normal cyclin C/cdk8

complex during G2/M and early G1-phase. The cell cycle regulation of the CmRNA-2 species is definitely more dramatic than that observed for either avian or human cyclin C [Figure 4B and (Lew *et al.*, *supra*).

- 5 Western blot analysis of cyclin C proteins from synchronized DT40 B-cells reveals a relatively abundant ~19 kDa protein in G2/M-phase blocked cells (Figure 5B). The cyclin C antibody used in these experiments is generated to the *D. melanogaster* cyclin C protein, which is highly related to both the human and avian homologues [Figure 1 and (Leclerc *et al.*, *supra*)]. This antibody recognized both the normal and
- 10 truncated cyclin C IVTT (*in vitro* transcription translation (IVTT) products when used for immunoprecipitation of these proteins (Figure 5A). A ~30 kDa cyclin C protein is detected in DT40 cell lysates from cells synchronized in G2/M-phase by nocodazole treatment (Figure 5B). These cyclin C proteins co-migrate with the IVTT products corresponding to the normal and truncated avian cyclin C cDNAs, which are detected
- 15 in this experiment by Western blot analysis using the affinity purified *Drosophila* cyclin C antibody (Figure 5B). Specificity of the cyclin C antibody recognition of the 19 and 30 kDa cyclin C protein species is demonstrated by competition with an avian cyclin C-GST fusion protein (Figure 5B). Detection of both the 30 kDa and the 19 kDa cyclin C proteins is dramatically inhibited by this preincubation, demonstrating
- 20 the specificity of the cyclin C antibody interactions. In addition, this particular antibody has been extensively characterized in another study (Leclerc *et al.*, *supra*). The 19 kDa cyclin C-related protein species is not detected in either asynchronous or late G1/early S-phase (G1/S phase), consistent with the reports of others (Leclerc *et al.*, *supra*). Thus, it appears that the 19 kDa cyclin C-related protein corresponds to
- 25 the CmRNA-2 species.

DISCUSSION

- Expression of the cyclin C gene is complex. In avians, two mRNAs encoding
- 30 truncated cyclin box proteins are produced in a cell cycle dependent fashion. In

addition, a ~19 kDa protein is detected by cyclin C antisera during G2/M phase, and early G1-phase but not during late G1- or S-phase, in avian cell lines and normal tissues. The 19 kDa protein co-migrates with a similarly sized protein produced by *in vitro* transcription and translation (IVTT) of an alternatively spliced avian cyclin C-related mRNA. Expression of this alternatively spliced cyclin C mRNA is regulated during the cell cycle, peaking during G2/M phase. The recent discovery of a putative cyclin C cdk partner, cdk8, suggests that, like other G1 cyclins, the truncated cyclin C functions to regulate a specific Cdk, in a cell cycle dependent manner (Tassan *et al.*, *supra*; Leclerc *et al.*, *supra*). Cyclin C not only associates with cdk8 *in vitro*, leading to its activation, but they are also associated *in vivo*. Furthermore, the high degree of sequence identity between mammalian cyclin C and cdk8 with the *S. cerevisiae* *SRB10* and *SRB11* gene products, respectively, indicates that this complex might play an important role in the regulation of transcription. In yeast, the *SRB10* and *SRB11* gene products are associated *in vivo* with RNA polymerase II, and this cyclin/cdk complex is essential for integrating growth regulatory signals with gene transcription (O'Neill *et al.*, *supra*; Liao *et al.*, *supra*; Maldonado *et al.*, *supra*; Leclerc *et al.*, *supra*).

One function of a truncated cyclin C protein would be analogous to endogenous CKIs, binding to and inactivating cdk8 during a portion of the cell cycle. Thus, much like the p16^{INK4}-related proteins, p21^{Waf1/Cip1}, p27^{Kip1}, and p57^{Kip2}, a truncated cyclin C protein could inactivate its associated protein kinase at specific times during the cell cycle (Sherr *et al.*, (1995)). Such a truncated cyclin C protein would function as an endogenously encoded CKI that is regulated via splicing of the cognate gene. This is supported by the observed cell cycle dependent regulation of the expression of the truncated cyclin C mRNA and protein species. In fact, two of the three isolated cyclin C mRNA species (CmRNA-1 and CmRNA-2) from various avian cell lines and tissues encode this truncated product. By CmRNA-2 encoding a CKI-like protein, the appearance of abundant levels of this mRNA during G2/M and early G1-phase would also support a role for the active cyclin C/cdk8 protein kinase complex during late G1-

and S-phase, coincidental with the transcription of genes by activated RNA polymerase II (Akoulitchiev *et al.*, *Nature* 377: 557-560 (1995); Leclerc *et al.*, *supra*; Maldonado *et al.*, *supra*). Others have shown alternatively spliced cyclin E transcripts in tumor cells, but these types of mRNA transcripts could not be found in normal cells, and they did not produce a corresponding protein in the tumor cell lines in which they were detected (Keyomarsi *et al.*, *Oncogene* 15:2612-2624 (1995); Ohtsubo *et al.*, *Mol. Cell. Biol.* 15:2612-2624 (1995)). In addition, an alternatively spliced cyclin D1 mRNA transcript has been found, disrupting the normal ORF in the extreme carboxyl terminal region (Betticher *et al.*, *Oncogene* 11:1005-1011 (1995)).

Such alternatively spliced cyclin D1 mRNAs were found to be invariably expressed in a number of normal and tumor cell lines, but there was no demonstration of a specific protein associated with this altered transcript. In addition, these studies did not elucidate the possible role, if any, for such a transcript. One possible explanation put forth by the authors suggests that such changes in the carboxyl terminus of cyclin D1 may affect protein stability and/or antigenicity; however, the altered portion of the protein does not overlap the critical cyclin-box, or other regions that may be required for its function (Betticher *et al.*, *supra*). Similarly, the alternatively spliced cyclin E mRNA's did not appear to encode a protein, and these transcripts were not expressed in normal cells.

Unlike the alternatively spliced cyclin D1 and cyclin E transcripts, the truncated cyclin C mRNA is specifically regulated during the cell cycle and it encodes a protein. Its widespread expression, in both virally transformed cell lines and normal tissues, suggests that its function is not tumor-specific.

25

Example 2

THE TRUNCATED CYCLIN C PROTEIN FUNCTIONS AS A CYCLIN
DEPENDENT KINASE INHIBITOR.

30

Introduction

The truncated cyclin box protein retains its ability to bind to the catalytic subunit through interactions between the cyclin box and cdk (Parry *et al.*, *EMBO J.*

14:503-511 (1995)) and thereby competes for binding to cdk8 with the wild-type

- 5 cyclin C protein during specific intervals of the cell cycle. The truncated cyclin C protein functions in such a manner as to resemble other CKIs, although it is the first example of the utilization of a portion of the same cyclin protein coding region as a CKI within either the cyclin or cdk gene families.

10 *In vitro* analysis of normal and truncated cyclin C protein function, and generation of antibodies.

To determine whether a truncated cyclin C protein is produced *in vivo*, antibodies generated to the first 98 amino acids of cyclin C are utilized. Two commercial polyclonal rabbit anti-human cyclin C antibodies corresponding to different

- 15 aminoterminal peptides of the human protein have been reported (Upstate Biotechnology, Inc. and Pharmingen). At least one of these reagents (Upstate Biotechnology, Inc.) will immunoprecipitate the full-length and truncated avian cyclin C proteins generated by [³⁵S]-methionine labeled IVTI reactions using these cDNAs (Fig. 3). Western blots are performed using cell lysates (Xiang *et al.*, *supra*) and are
- 20 detected with using chemoluminescence with horseradish peroxidase-conjugated secondary antibodies (Leclerc *et al.*, *supra*). Additional antibodies to either glutathione-S-transferase (GST) or 6-Histidine fusion proteins containing the aminoterminal domain, or the carboxyl terminal domain specific to the full-length form of cyclin C (which will not react with the truncated cyclin C protein), are
- 25 generated by using the carboxyl-terminal region of cyclin C (amino acids 99-183) which are not found in the truncated cyclin C protein. Similarly, cdk8-specific antibodies are generated by use of GST or 6-Histidine fusion constructs. A human cdk8 cDNA has been obtained by RT-PCR and is analyzed by DNA sequence analysis. The avian homologue is isolated and analyzed in a similar manner (Parry *et al.*, *supra*; Pelech *et al.*, *TIBS* 17:233-238 (1992)). Rabbit polyclonal antibodies are
- 30

generated and affinity purified as previously described (Parry *et al.*, *supra*). Antisera's that specifically recognize the cdk8 and cyclin C' proteins by both Western blotting and immunoprecipitation, using the IVTT cdk8, cyclin C, and truncated cyclin C polypeptides, are obtained and used to examine the expression and function of the truncated cyclin C protein in DT40 cells that are synchronously progressing through the cell cycle. This is an especially important point since cyclin C expression is not regulated during the cell cycle (Lew *et al.*, *supra*) but the expression of the truncated cyclin C mRNA (CmRNA-2) is regulated during the cell cycle.

Both cyclin C and cdk8 antibodies are used to analyze cellular protein kinase activity as described by Tassan *et al.* (*supra*). DT40 cells are synchronized by either nocodazole or aphidicolin block of elutriated cell fractions, as described previously. The cyclin C antibodies are also used to detect similar truncated cyclin C protein made in either human or murine cell lines. Specific details of these experiments are provided below. These experiments conclusively demonstrate the existence of the truncated cyclin C protein and confirm that its expression parallels the cell cycle regulated expression of its corresponding mRNA.

The truncated cyclin C protein functions as an effective inhibitor of the normal cyclin C'cdk8 protein kinase complex *in vitro* in the Sf9 insect cell expression system. The infection and/or coinfection of insect Sf9 cells with baculovirus vectors encoding human and murine cell cycle gene products has elucidated specific functional interactions between a number of cell cycle proteins (Kato *et al.*, *Genes & Devel.* 7:331-342 (1993); Lee *et al.*, *Mol. Biol. Cell.* 3:73-84 (1992); Parker *et al.*, *Proc. Natl. Acad. Sci., USA* 89:2917-2921 (1992); Parker *et al.*, *Science* 55:1211-1214 (1995)). The Sf9 expression system successfully expressed many cell cycle related products, including cyclins A, B, D1, D2, D3 and E, and the cell cycle protein kinases cdk2, cdk4, cdk6, PCTAIRE 1 and PITSLRE β 1. Expression of the full-length form of cyclin C and cdk8 in these cells creates an active cyclin/cdk protein kinase complex (Kato *et al.* (1993)). It is important to note that the avian cyclin C and truncated

cyclin C proteins are highly homologous to the human cyclin C protein (99% identity for the former and at least 94% identity for the latter). Baculovirus expression constructs containing the truncated cyclin C protein and cdk8, as well as versions of each of the cyclin C proteins and the cdk8 kinase containing a small portion of hemagglutinin (HA) protein sequence attached to the carboxyl-terminus (e.g., HA-tagged cyclin C and truncated cyclin C constructs) are constructed by the methods used for other cyclins and cdks by Meloche *et al.* (*Mol. Biol. Cell.* 3:63-71 (1992)). The cyclin C and cdk8 proteins, the (His)₆- or HA-tagged proteins are affinity purified from nickel columns or from HA epitope affinity columns, respectively, as described by Meloche *et al.* (*supra*). Additional purifications, when needed, rely upon anion-exchange and gel filtration chromatography as described by Rosenblatt *et al.*, *Proc Natl Acad. Sci. USA* 89:2824-2828 (1992). Column fractions can be assayed by SDS-PAGE and Western blotting with an appropriate antibody. Fractions of cyclin C or truncated cyclin C proteins are assayed for ability to phosphorylate histone H1 in the presence and absence of the cdk8 catalytic subunit. This is done by infection of Sf9 cells with each component separately (i.e., kinase or cyclin) and subsequently mixing equivalent amounts of protein from the lysates for a kinase assay, or by co-infection of Sf9 cells with multiple constructs (i.e., kinase and cyclin) and direct assay of a predetermined amount of cell lysate (Desai *et al.*, *Mol Biol Cell*, 3:571-582 (1992); Kato *et al.* (1993); Rosenblatt *et al.*, *supra*). The ability to inhibit protein kinase activity assayed as described by others for previously identified CKIs can be demonstrated by adding the truncated cyclin C protein to active cyclin C/cdk 8 complexes (Guan *et al.*, *Genes & Devel.* 8:2939-2952 (1994); Hirai *et al.*, *Cell Biol.* 15:2672-2681 (1995); Koh *et al.*, *Nature* 375:506-510 (1995); Polyak *et al.*, *Genes & Devel.* 8:9-22 (1994); Polyak *et al.*, *Genes & Devel.* 8:9-22 (1994); Serrano *et al.*, *Nature* 366:704-707 (1993)). Intrinsic cellular factors are provided in the reactions by mixing mammalian cell lysates, or specific immunoprecipitated proteins containing associated factors, with insect cell lysates containing the expressed kinase and/or cyclin and assaying for kinase activity, as described (Kato *et al.* (1993); Matsushime *et al.*, *supra*). In other words, the purified cyclin and cdk produced by baculovirus

infection of insect Sf9 cells are added back to total cell lysates. Thus, the baculovirus encoded cyclin or cdk can be readily purified using techniques that are well-established (Kato et al. (1993).

5 *In vivo* analysis of the function of the normal and truncated cyclin C proteins.

- The analysis of the truncated cyclin C protein function is augmented by examining the function of this protein in eukaryotic expression systems and cell lines. The effect of regulated expression of the truncated cyclin C protein on the normal growth of several different mammalian cell types are studied by using the available chicken clone
- 10 encoding the truncated cyclin C protein since it is identical in sequence to the human cyclin C protein for 98 of its 105 amino acid residues. Additionally, as described below, the cognate human homologue of the chicken mRNA is isolated. The human cDNA is used in both the *in vitro* studies described above and the *in vivo* studies outlined below. For stable expression of the cyclin C proteins in mammalian cells,
- 15 the preferred approach is a tightly regulated, inducible expression system. These systems permit selection of stable integrants while keeping gene expression extinguished. Thus, even if expression of either cyclin C or its truncated form is deleterious to cell viability, stable cell lines are established.
- 20 A human T-cell line (Jurkat) and an epithelial cell line (HeLa) are obtained that express exogenous proteins under the control of a tetracycline-responsive promoter (Resnitzky *et al.*, *Mol. Cell. Biol.* 14:1669-1679 (1994)). The tetracycline-responsive promoter is created by fusing the tetracycline repressor with the activation domain of VP16 (a herpes simplex viral protein), thereby creating a tetracycline-controlled
- 25 transactivator (tTA) that is constitutively expressed in cells. This tTA stimulates transcription of the gene of interest from a minimal promoter sequence containing tetracycline operator sequences, which are carried on a second plasmid. (This vector and its use in protein expression in human cells is described in detail by Gossen *et al.*, *Proc. Natl. Acad. Sci., USA* 89:5547-5551 (1992)). Thus, expression of an
- 30 exogenous gene is regulated by decreasing the concentration of tetracycline in the

media. The tetracycline-responsive promoter expression system has been successfully used to regulate exogenously introduced G1-phase cyclins (D1 and E) in mammalian cells, as well as to regulate the developmentally controlled and tissue-specific genes in mice (Resnitzky *et al.*, *Mol. Cell. Biol.*, 14:1669-1679 (1994); Gu *et al.*, *Science* 265:103-106 (1994)). Alterations in the endogenous levels of either cyclin C or the truncated cyclin C protein result in significant changes in cell growth due to alterations of the cell cycle. Enhanced expression of either of these proteins, particularly the truncated protein, may also result in increased or decreased cell growth, or alternatively, programmed cell death. Changes in cell cycle progression and growth parameters are monitored by flow cytometry, growth curve analysis, and BudR incorporation, as described previously (Lahti *et al.*, *Mol. Cell. Biol.* 15:1-11 (1995)). Concomitantly, the effect of sustained cyclin C or truncated cyclin C overexpression on RNA polymerase II CTD phosphorylation are examined as described previously (Akoulitchev *et al.*, *supra*; Leclerc *et al.*, *supra*; Maldonado *et al.*, *supra*). To measure the extent of apoptosis, parameters of programmed cell death can be assayed, including the appearance of apoptotic nuclei, DNA fragmentation (as sensitively assayed by fluorescently labeled nick-translated DNA (Lahti *et al.* (1995)), and DNA ladder formation.

20 The existence of a novel mRNA transcript generated from the normal cyclin C locus which is widely expressed, cell cycle regulated, and encodes a truncated cyclin C protein suggests that its function may be linked to the normal protein kinase activity of the cyclin C/cdk8 complex. Furthermore, the avian truncated cyclin C protein interacts with CDK8. These experiments were performed by mixing lysates

25 containing 35S-methionine labeled *in vitro* transcribed and translated cyclin C proteins (both the normal and truncated proteins were used in these studies) with rabbit reticulocyte lysates containing radioactive CDK8. After a one hour incubation at room temperature, antibodies to either cyclin C or CDK8 were added to the lysates. The immunoprecipitates were collected on protein A beads and analyzed by SDS-

30 PAGE on 12.5% acrylimide gels. After electrophoresis the gels were dried and

autoradiographed. Both CDK8 and the cyclin C proteins were present in the immunoprecipitates, demonstrating the interaction of both cyclin C and truncated cyclin C with CDK8.

- 5 Utilization of a single gene to differentially express multiple mRNA transcripts during distinct intervals of the cell cycle has not been associated with other cyclins. These observations indicate that the further examination of the expression and function of this truncated cyclin C protein, as well as the normal cyclin C protein, yields valuable information regarding cyclin C function and the function of the truncated cyclin C
- 10 protein, as well as possible insights into the mechanism involved in the inactivation of cyclin/cdk complexes.

Example 3

CYCLIN C mRNAs AND PROTEINS IN MAMMALS

15

Introduction

- The truncated cyclin C protein exists in humans and has a similar or identical function as the avian truncated cyclin C. In addition, a human cyclin C with an alternative carboxy terminal end is identified. Finally, the in vitro and in vivo systems
- 20 established in this example can be used to functionally examine any genetic alterations identified in the CCNC locus in human tumors

- Both the predicted ORF of the cyclin C protein and the mosaic structure of the gene is absolutely conserved between human and chicken (Li *et al.* (1996a). Antibodies that
- 25 recognize the aminoterminal region of cyclin C, and, as a result, the truncated cyclin C protein, allow identification of a similar truncated protein to be made in mammals. Several different human cell lines (including HeLa and WI38 normal diploid fibroblasts) are synchronized with either drugs (such as nocodazole or aphidicolin), serum depletion, or centrifugal elutriation as described. Cell cycle synchrony is
- 30 verified by flow cytometry analysis. Synchronized cells are used for these

- experiments since expression of the alternatively spliced avian transcript, and truncated protein, is cell cycle regulated. Total cell protein lysates are isolated from each fraction of cells and analyzed by Western blotting for the presence of a truncated cyclin C protein using the cyclin C amino-terminal antibody. Detection of the normal wild-type cyclin C protein provides an internal control for these experiments. As a complementary approach metabolically labeled synchronized cells are made by pulsing with [³⁵S]-methionine prior to immunoprecipitating the cyclin C proteins as described.
- 10 Several distinct, but complementary, approaches are taken to isolate a cDNA clone encoding this protein. The first, and most direct, approach involves the use of reverse transcriptase-polymerase chain reaction (RT-PCR). Total RNA and/or poly(A)⁺ RNA from different human cell lines are converted to cDNA using cyclin C specific gene primers and then subjected to nested PCR (Li *et al.*; Li *et al.* (1996a)). cDNA are
- 15 synthesized from primers originating from the 3' end of the mRNA (corresponding to exons 10-12) of the C'CN' gene (which encodes cyclin C). Placement of the oligonucleotides for cDNA synthesis at this position allows identification of an alternatively spliced transcript in human cells, since the alternatively spliced avian mRNA contains an insertion of an exon between exons 4 and 5 of the gene. Due to
- 20 the identity of the human and avian genes (Li *et al.* (1996a, b)), oligonucleotides for the nested PCR reactions within exons 3/4 and 5/6 are generated. The highly conserved nature of both the genes and their polypeptides, indicates that exon 4a is similar in size (73 bp) in humans. In the event this exon is not as highly conserved in humans, the placement of the oligonucleotides for the nested PCR reactions within
- 25 exons 4 and 5 (inversely orientated to generate an appropriate PCR product) ensures its isolation. Alternatively, cDNA libraries generated from RNA isolated from G2/M and early G1-phase synchronized cells are screened with the human cyclin C cDNA (Lew *et al.*, *supra*; Li *et al.* (1996a)). The inserts from any resulting positive clones are analyzed by DNA sequence analysis using oligonucleotide sequencing primers
- 30 located in exons 4 and 5 which are oriented towards one another. Such primers

currently exist, and are used in the analysis of the human *CCNC* gene (Li *et al.* (1996a). Oligonucleotides from other regions of the gene and restriction enzyme analysis using enzymes that cut frequently are also used to identify the genomic exon encoding an alternatively produced transcript from a different location within the human gene.

Human cyclin C variant transcripts were isolated by screening a human testis cDNA library with a human cyclin C cDNA probe containing the entire coding sequence for the human cyclin C protein. In addition to the normal cyclin C cDNA, two other classes of cDNA clones have been isolated. One of these represents an alternatively spliced human mRNA. This transcript is generated by the insertion of additional coding sequence between sequences derived from exons 11 and 12 in the human cyclin C cDNA (Figure 7). The protein encoded by this mRNA has an alternative carboxy-terminal end (Figure 6). This substitution changes the stability of the protein since the alternatively spliced transcript no longer encodes a protein with a PEST sequence rich carboxyl-terminal domain. (PEST sequences have been shown to be involved in the rapid turnover of many proteins including other G1 cyclins).

A second class of cDNA clones represents a partially spliced mRNA. All of the intronic sequences have been removed from these transcripts with the exception of the introns located between exon 7 and 9 (exon 8 is included) (Figure 9). Extensive analysis of other cDNA clones has revealed that this is the only partially spliced cyclin C transcript found in the cells, indicating it has biological significance. This transcript is predicted to encode a truncated cyclin C protein (Figure 8), similar in nature although slightly larger than that found in avians.

Example 4**ELIMINATION OF FULL-LENGTH AND/OR TRUNCATED CCNC PRODUCTS.**

The linking of cyclin C to cell cycle specific regulation of RNA polymerase II indicates that the extracellular growth signals and nuclear transcription complexes are coordinated, at least in part, to the action of the cyclin C/cdk 8 protein kinase complex. Such a link could be integral for normal cell growth, and any alteration of this pathway could prove to have devastating consequences. A strong correlation between deletion of the human cyclin C (CCNC) gene and deletion and/or translocation of the 6q21 chromosome region in human acute lymphoblastic leukemia (ALL) has also been established (Li *et al.* (1996a). However, the complete loss and/or functional alteration of both CCNC gene alleles has not been observed. This could be explained by the essential function of this gene product. The existence of the widely expressed and cell cycle regulated alternatively spliced transcript, encoding a truncated cyclin C protein of the present invention, suggests that the CCNC gene is normally regulated in a complex manner. More importantly, this truncated cyclin C protein may, in fact, directly inhibit normal cyclin C protein function by competing for binding to the cdk8 subunit during specific intervals of the cell cycle. Elucidation of the requirements for both normal cyclin C and the truncated cyclin C protein in vertebrate cells provides valuable insights regarding their normal function as well as their possible involvement in tumorigenesis. This can be accomplished by specific ablation of either the normal or truncated cyclin C protein via targeted disruption of the gene. In addition, further analysis of the truncated cyclin C protein in human tumor cells, with emphasis on determining its integrity within these cells, is warranted, particularly since the truncated protein functions as a CKI of the normal cyclin C/cdk8 complex. The studies described herein address questions regarding the requirements, and function, of both the normal and truncated cyclin C proteins. Experiments are performed to investigate the role of the truncated cyclin C protein regarding tumor suppression in malignancies with deletions of one CCNC gene allele, as well as to determine the extent that alterations in the level of either cyclin C or the

truncated cyclin C proteins affect parameters of cell growth. Genetic alterations identified in the CCNC gene locus in human tumors as a result of these studies are then functionally examined as outlined above.

- 5 Another approach for examining the functional relationship between the normal cyclin C, or the truncated cyclin C and the *in vivo* protein kinase catalytic subunit, cdk8, involves gene targeting in cultured vertebrate cells. Elimination of the various CCNC gene products specifically, or in combination, allow the assessment of their normal function in a manner that is distinct, but complementary, to the *in vitro* reconstitution and tightly regulated overexpression studies described above.
- 10

Targeted disruption of the CCNC gene regions encoding cyclin C and/or the truncated cyclin C protein in avian cells.

- Further evidence that the truncated cyclin C protein functions as an inhibitor of normal cyclin C/cdk 8 complexes is derived from studies where truncated cyclin C is specifically eliminated from vertebrate cells. Concomitantly, the effect of cyclin C deficiency or elimination is examined. Targeted disruption of a specific gene via homologous recombination has become a very powerful tool in molecular genetics (Capecchi *et al.*, *Science* **244**:1288-1292 (1989); Doetschman *et al.*, *Proc. Natl. Acad. Sci., USA* **85**:8583-8587). Mouse models of disease can now be produced. The approximate ratio of specifically targeted gene disruption events to random integration events after transfection of DNA constructs into mammalian cells is $1:10^3$ to $1:10^5$ (Serrano *et al.* (1993)). A chicken B cell line, DT40, incorporates foreign DNA by specific targeted integration at frequencies that are similar to those seen for random integration (Buerstedde *et al.*, *supra*). This was not a gene-specific event, since targeted integration occurred at identically elevated frequencies at four different genetic loci (Buerstedde *et al.*, *supra*). Therefore, the chicken DT40 cell line provides a valuable system for the ready isolation of mutant cells that is technically less difficult and less time consuming than the murine model. To perform these studies the chicken homologue of the particular gene of interest needs to be isolated
- 15
- 20
- 25
- 30

and characterized. The chicken cyclin C cDNA, truncated cyclin C cDNA, and their cognate gene have been isolated and are part of the present invention, as are polyclonal antisera that recognize both the normal and truncated cyclin C proteins by immunoprecipitation. The chicken cell system described here provides a practical
5 advantage to murine systems due to the ease of generation and decreased complexity of DT40 cell culture. In addition, this cell system has already been used to eliminate both alleles of cyclin D1 and it has been demonstrated that the corresponding alteration in cell cycle progression can be evaluated. This system can be used to disrupt both products of the avian *C'NC'* gene (the normal cyclin C mRNA and the
10 alternatively spliced mRNA encoding a truncated cyclin C protein), individually and in tandem, in the DT40 cell line to determine whether cell growth parameters and/or programmed cell death (PCD) are affected.

Complete characterization of the avian *C'NC'* gene indicates that the positions of all
15 intron/exon positions are absolutely conserved. Specific disruption of the alternatively spliced cyclin C transcript is achieved by disruption of exon 4a, which encodes the alternatively spliced region of this cell cycle regulated transcript. Simultaneous disruption of both cyclin C and the alternatively spliced cyclin C is achieved by disrupting either exon 1, 2, 3, or 4, which are shared between the two
20 transcripts and encode essential portions of their open reading frames. Specific disruption of cyclin C can be achieved by targeting any region of exons 5-11, which contain essential portions of the cyclin C open reading frame (ORF), but are not required for expression of the truncated cyclin C protein. Targeted disruption of the gene can involve the insertion of neomycin (*neo*), hygromycin (*hyg*), (*puromycin*), or
25 (*histidinol*) (*his*) selectable marker gene cassettes into unique exonic restriction sites. These genes are derived from bacteria that are resistant to the corresponding drug. Since these antibiotic resistance genes are encoded by the expression vector containing the cyclin sequences, and are not naturally found in eucaryotic cells, those cells that survive drug treatment will contain an expression vector that also contains

the cyclin gene. The availability of at least four distinct selectable markers allow the generation of multiple disruption plasmids.

Two disruption plasmids containing either a *neo* or *hyg* cassette are prepared which target both full-length and truncated cyclin C proteins. To create these constructs a
5 ~1 kb *EagI-KpnI* restriction fragment containing exons 1-2 is removed and replaced with the selection cassettes, resulting in the disruption of a major portion of the cyclin box domain. Additional constructs are made that can target exon 4a specifically, by deletion of this exon and its immediately adjacent intronic regions using restriction
10 enzymes that remove only this region from a large 7 kb *EcoRI* fragment containing exons 3 - 7. Finally, disruption of only the cyclin C protein, but not the truncated cyclin C protein corresponding to the ORF encoded by exons 1 - 4a, can be achieved by similar deletion of a region of the avian *CCNC* gene containing exon 7 by using
15 two *EcoRI* fragments (~2 kb), containing exons 7 - 9, from a larger 13 kb *BamHI-SacI* fragment which contains exons 4 - 12 of the gene (Figure 2). These selectable marker gene cassettes have been used to disrupt the avian *CCND1* gene, and are used to replace this region and disrupt the normal cyclin C protein. As performed previously for the avian *CCND1* gene, targeted disruption of the *CCNC* gene and its encoded products are verified by Southern and Northern blotting, and by either
20 immunoprecipitation and/or Western blotting of the protein. Single cell clones can be selected by FACS sorting, as previously performed for the avian *CCND1* gene disruptions, after continuous culture in selection drug for a period of 2-3 weeks (Reznitzky *et al.* (1994)).

25 The effect of ablation/haploinsufficiency of cyclin C and/or the truncated cyclin C box protein on cell growth, programmed cell death, and tumorigenesis.

In the event that elimination of both *CCNC* alleles encoding the cyclin C protein is lethal, isolation of resistant colonies containing the second selectable marker gene following disruption, appropriate selection, and analysis of the first homologous
30 recombination event may not be possible. In this case the result can be verified by

switching the order of selectable marker genes used to disrupt these genes, insuring that this result is not due to technical problems or selection protocols, as performed with the *CCND1* gene knockouts. Verification of lethality due to *CCNC* gene disruption would suggest that their function is essential, and these experiments can then be terminated. However, the single allele knockout clones can be analyzed for changes in cell growth, cell death, and tumorigenicity. In the case that disruption of both *CCNC* genes is not lethal, further experiments with these cell lines can be conducted as described below. Once clonal cell lines are obtained with one and/or both *CCNC* genes disrupted, cyclin C protein expression can be verified to be diminished/ablated by immunoprecipitation with the cyclin C-specific antibodies of the present invention, using appropriately metabolically labeled cell lysates and/or Western blot analysis. The ability of parental DT40, *CCNC*^{-/+}, and *CCNC*^{-/-} to progress normally through the cell cycle after synchronization, or undergo apoptosis in response to glucocorticoids and anti-IgM antibodies can be assessed. Cell cycle studies can be performed as described for the *CCND1* gene disruptions. The effect of diminished cyclin C protein expression on the ability of the cells to progress through the cell cycle, as measured by BudR incorporation and mitotic indices, using both asynchronous and synchronously blocked cell populations can be examined. Further, more detailed, analyses of specific cyclin/cdk complexes can be performed. The regulation of programmed cell death can be assayed as described previously (Lahti *et al.* (1995)). DT40 cells are an early B-cell lineage that express surface IgM and can undergo programmed cell death by sIgM cross-linking anti-chicken sIgM antibodies (Ezhevsky *et al.*, *Mol. Biol. Cell* 7:553-564 (1996)). In the case that substantial changes in either cell cycle-progression or the ability of these cell lines to undergo programmed cell death, several different *CCNC*^{-/-} clonal cell lines can be compared to one another to eliminate any effects of clonal variation.

Further, more detailed analysis of the effect of diminished, or abolished (if not lethal), levels of cyclin C on cdk8 protein kinase activity as a function of the cell cycle, and with regard to the ability of the C-terminal domain (CTD) of RNA polymerase II to be

- phosphorylated, can also be examined. RNA polymerase II protein and antibody are available commercially, and can be obtained for these studies (RNA polymerase II is a well conserved protein (Akoulitchev *et al.*, *supra*; Ossipow *et al.*, *Cell* **83**:137-146 (1995)). Generation of appropriate antibodies against avian RNA polymerase II, as described previously for both cyclin C and cdk8 can also be undertaken.
- Immunoprecipitations and kinase assays can be performed as has been done for other cell cycle proteins. This type of analysis allows the determination of whether elimination of cyclin C leads to complete, or partial loss of cdk8 kinase activity; ultimately, these investigations can provide important information regarding the possibility of redundant cyclin, or cyclin-like, regulatory partners for this catalytic subunit in vertebrate cells, as well as its possible relationship with the cdk activating protein kinase (CAK; cdk7) (Desai *et al.* (1992); Solomon *et al.* (1993), reviewed in Morgan (1995).
- Analogous experimental procedures for the selection, cloning, and examination of cell cycle progression and programmed cell death parameters can be performed on targeted disruptions of the truncated cyclin C protein, as well as the simultaneous elimination of both the cyclin C and truncated cyclin C proteins, as has been described above. In the case where significant differences in the parameters of cell growth and/or death are observed the rescue of the phenotype by re-expressing the protein that has been eliminated can be performed. A similar strategy was applied to the *C'ND1* gene knockouts, which successfully rescued these cells (Li *et al.* (1996a)).

Deletion of one C'NC gene in tumor cells.

- Previous studies of the deletion of the C'NC gene in human ALL may need to be re-examined (Li *et al.*, *supra*). In those studies one C'NC allele was found to be deleted in 12/16 ALL patient samples with 6q21 anomalies (deletions and/or translocations), but the remaining allele harbored no apparent mutations within the 12 exons examined. At that time the alternatively transcribed mRNA product of the present invention was not known. Loss of both copies of the normal cyclin C protein could

have devastating consequences on cell growth, particularly in light of the accumulating evidence regarding its involvement in the cell cycle regulation of RNA polymerase II (Akoulitchev *et al.*, *supra*; Leclerc *et al.* (1996); Maldonado *et al.* (1996)). However, since human cells also express this truncated cyclin protein by
5 alternatively splicing of an additional exon, this exon could harbor specific mutations that inactivate its ability to negatively regulate the cyclin C/cdk 8 complex, much like p16^{INK4a} deletion and mutation in human tumors (Cairns *et al.*; Caldas *et al.* *Nature Gen.* 8:27-32 (1994); He *et al.*, *Cancer Res.* 54:5804-5807 (1994); He *et al.*, *Cancer Res.* 55:4833-4836 (1995); Hussussian *et al.*, *Nature Gen.* 8:15-21 (1994); Kamb *et al.*, *Science* 264:436-440 (1994); Kamb *et al.* *Nature Gen.* 8:22-26 (1994); Koh *et al.*,
10 *supra*; Liu *et al.*, *Oncogene* 10:1061-1067 (1995); Lukas *et al.*, *Cancer Res.* 55:4818-4823 (1995); Lukas *et al.*, *Nature*, 375:503-506 (1995); Medema *et al.*, *Proc. Natl. Acad. Sci., USA*, 92:6289-6293 (1995); Parry *et al.*, *EMBO J.*, 14:503-511 (1995). Since studies indicate that this truncated cyclin C protein functions as a CKI
15 and that it is present in human cells, careful evaluation of the integrity of this exon in the previously analyzed ALL patient samples is required. The extensive bank of frozen tumor samples of St. Jude Children's Research Hospital and corresponding database allows for potential correlations to be made between mutations in the *CCNC* gene, tumor progression, and/or therapeutic responsiveness.

20

Mutation of the exon encoding the premature stop codon, leading to truncated cyclin C protein expression, in ALL patient samples with previously identified *CCNC* gene deletions

As mentioned above, demonstration of the existence of an alternatively spliced cyclin
25 C transcript encoding a truncated protein in human cells warrants further examination of the ALL patient samples. A single strand conformational polymorphism (SSCP) analysis of this exonic region and its immediately flanking intronic sequences, can be performed as has been performed by for remainder of the human *CCNC* gene (Li *et al.* (1996a)). PCR-based SSCP analysis has proved to be a reliable method for the rapid
30 detection of point mutations, small deletions or insertions, and polymorphisms in

short fragments of DNA that can be amplified by PCR. Specific oligonucleotides corresponding to the flanking intronic sequences immediately adjacent to this exon can be designed and used in these studies (Li *et al.*, (1996a). The presence of point mutations or other alterations in the alternatively spliced exon can be confirmed by
5 cloning and sequencing of this region of the C'CN' gene by genomic PCR.

In the case when specific point mutations, deletions, and/or insertions are discovered in this region of the C'CN' gene, their effect on the normal function of this gene can be evaluated. For example, if specific point mutations that interfere with the ability of
10 the protein to be normally terminated are found, they can be programmed back into Sf9 insect cell expression system as described herein. Such mutations could lead to the expression of longer, non-specific protein regions at the carboxyl terminus. This would allow the examination of the ability, or inability, of such elongated proteins to bind to the cdk8 catalytic subunit and affect its activity. Similarly, mutations that
15 might alter the ability of this exon to be normally spliced into an mRNA transcript, such as mutations within the canonical splice donor and acceptor sequences, can be examined by transient transfection analysis of appropriate plasmid expression constructs in human cells.

20 C'CN' gene deletion resulting in haploinsufficiency of either the full-length and/or truncated form of the cyclin C protein.

It is possible that deletion of a single allele directly affects the level of cyclin C protein. One approach is to analyze these samples using quantitative competitive RT-PCR, and Western blot analysis of cell lysates. Quantitative competitive RT-PCR
25 allows relatively precise quantitation of specific mRNAs (Gilliland *et al.*, *PCR Protocols*, San Diego, CA: Academic Press, 60-69 (1990)). The procedure involves the co-amplification of a competitive template that uses the same oligonucleotide primers as those of the target cDNA, but this competitive template can be distinguished from the target cDNA after amplification. The tumor samples are
30 examined using 3-glycerol aldehyde phosphate dehydrogenase (3-GAPDH) as a

positive control and p16^{INK4a} as a negative control. The use of the latter as a negative control is based on previous analysis of these same ALL patient samples, many of which contain concomitant loss of one or both alleles of human chromosome 9p21 and the p16^{INK4a} and/or p15^{INK4b} genes (Okuda *et al.*, *Genomics* 29:623-630 (1995)). A potential problem of this approach stems from the fact that primary tumors are contaminated with a variable percentage of normal cells. However, the use of hematopoietic tumors can circumvent this problem, particularly when combined with morphologic examination (% blast cell determinations), direct fluorescence *in situ* hybridization (FISH) analysis (for *CCNC* deletions), and cytogenetic analysis which are well known in the art (Lahti *et al.*, (1994)). These types of analyses can be coordinately used to identify cases with a low percentage of contaminating normal cells and to pinpoint those that have substantial deletions of the *CCNC* locus. When noticeable differences are detected in normal or truncated cyclin C mRNA and/or protein expression, the effect of such alterations on normal cell growth parameters can be assessed using the complementary studies involving targeted disruption of the *CCNC* gene as described above.

The following is a list of documents related to the above disclosure and particularly to the experimental procedures and discussions. These documents, and all others cited above, should be considered as incorporated by reference in their entirety.

Adames *et al.*, *Nature* 318:533-538 (1984).

Akoulitchev, S., Makela, T.P., Weinberg, R.A., and Reinberg, D., *Nature*, 377: 557-560 (1995).

Alexander *et al.*, *Mol. Cell. Biol.* 7:1436-1444 (1984).

Bar *et al.*, *J. Magn. Reson.* 65:355-360 (1985).

- Benoist *et al.*, *Nature* **290**:304-310 (1981).
- Betticher, D.C., Thatcher, N., Altermatt, H.J., Hoban, P., Ryder, W.D.J., and Heighway, J., *Oncogene* **11**:1005-1011 (1995).
- 5 R.A. Brady *et al.*, *Phil. Trans. R. Soc. Land. B* **316**:143-160 (1987).
- Brinster *et al.* *Nature*, **296**:39-42 (1986).
- 10 Buerstedde, J.M. and Takeda, S., *Cell* **67**:179-188 (1991).
- Bunnell, B.A., Heath, L.S., Adams, D.E., Lahti, J.M., and Kidd, V.J., *Proc Natl. Acad. Sci., USA* **87**:7467-7471 (1990).
- 15 Cairns, P., Polascik, T. J., Eby, Y., Tokino, K., Califano, J., Merlo, A., Mao, L., Herath, J., Jenkins, R., Westra, W., Rutter, J. I., Buckler, A., Gabrielson, E., Tockman, M., Cho, K. R., Hedrick, L., Bova, G. S., Isaacs, W., Koch, W., Schwab, D., and D. Sidransky, *Nature Gen.* **11**:210-213 (1995).
- 20 Caldas, S. A. Hahn, I. T. daCosta, M. S. Redston, M. Schutte, A. B. Seymour, C. L. Weinstein, R. H. Hruban, C. J. Yeo, and S. F. Kern, Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma, *Nature Gen.* **8**:27-32 (1994).
- 25 Capecchi, M. R., *Science*, **244**:1288-1292.
- Carpino *et al.*, *J. Org. Chem.* **37**:3403-3409 (1972).
- Chou *et al.*, *Biochemistry* **13**:222 (1974).

Cross, F.R., *Mol. Cell Biol.* **10**:6482-6490 (1990).

Darnell *et al.* (1986) in *Molecular Cell Biology*, pp. 146-148. Scientific American Books, New York.)

5

DeBoer *et al.*, *Proc. Natl. Acad. Sci., USA* **80**:21-25 (1983).

Demetrick, D. J., S. Matsumoto, G. J. Hannon, K. Okamoto, Y. Xiong, H. Zhang, and D. H. Beach, *Cytogenet. Cell Genet.* **69**:190-192 (1995).

10

Desai, D., Gu, Y., and D. O. Morgan, *Mol. Biol. Cell*, **3**:571-582 (1992).

Doetschman, T., Maeda, N., and O. Smithies, *Proc. Natl. Acad. Sci., USA*, **85**:8583-8587 (1988).

15

Dolznic, H., Bartunck, P., Nasmyth, K., Mullner, E.W., and Beug, H., *Cell Growth & Differ.* **6**:1341-1352 (1995).

Eipers, P.G., Lahti, J.M., and Kidd, V.J., *Genomics* **13**:613-621 (1992)

20

Engstrom, *Biochem. Exp. Biol.* **11**:7-13 (1974).

Ezhevsky, S. A., Toyoshim, H., Hunter, T., and D. W. Scott, *Mol. Biol. Cell.*, **7**:553-564 (1996).

25

Fields *et al.*, *Int. J. Pept. Protein Res.* **35**:161-214 (1990).

Gallant, P. and Nigg, E.A., *J. Cell Biol.* **117**:213-224 (1992).

Gold, R., Schmied, M., Rothe, G., Zischler, H., Breitschopf, H., Wekerle, H., and H. Lassman, *Histochem. & Cytochem.*, **41**:1023-1030 (1993).

Gossen, M., and H. Bujard, *Proc. Natl. Acad. Sci., USA*, **89**:5547-5551 (1992).

5

Grosschedl *et al.* *Cell*, **38**:647-658 (1984).

Gu, H., Marth, J. D., Orban, P. C., Mossman, H., and K. Rajewsky, *Science*, **265**:103-106 (1994).

10

Guan, K.-L., Jenkins, W., Li, Y., Nichols, M. A., Wu, X., O'Keefe, C. L., Matcra, A. G., and Y. Xiong, *Genes & Devel.*, **8**:2939-2952 (1994).

Hammer *et al.* *Science* **235**:53-58 (1987).

15

Hanahan, *Nature* **315**:115-122 (1985).

He, J., Allen, J. R., Collins, P., Allalunis-Turner, M. J., Godbout, R., Day, R. S., and C. D. James, *Cancer Res.*, **54**:5804-5807 (1994).

20

He, J., Olson, J. J., and James, C. D., *Cancer Res.*, **55**:4833-4836 (1995).

Hirai, H., Roussel, M. F., Kato, J-Y., Ashmun, R. A., and C. J. Sherr, *Cell. Biol.*, **15**:2672-2681 (1995).

25

Hopp *et al.*, *Proc. Natl. Acad. Sci., USA* **78**:3824 (1981).

Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Tucker, M. A., and N. C. Dracopoli, *Nature Gen.*,

30 **8**:15-21 (1994).

8 / 15

1 MVAPRPLRRVVLFFYQGKLCMAGNFWQSSHYLQWILDKQD

41 LLKERQKDLKFLSEEEYWKLQIFFTNVIQALGEHLKLRQQ

81 VIATATVYFKRFYARYSLKSIDPVLMAPTCVFLASKVEEF

121 GVVSNTRLIAAATSVLKTRFSYAFPKEFPYRMNHILECEF

161 YLLELMDCCCLIVYHPYRPLLQYVQDMGQEDMLLPLAWRIV

201 NDTYRTDLCLLYPPFMIALACLHVACVVQQKDARQWFAEL

241 SVDMEKILEIIRVILKLYEQWKNFDERKEMATILSKMPKP

281 KPPPNSEGEQGPNGSQNSSYSQS/////////////////
-----RNSLSDKAIYCKVTVKESRVQMEVRTLATANLKT
321 /////
FRRIP

FIG.6

9 / 15

FIG. 7A

1 gagcgcggttacggacgggctgggtctatggtcgctccgcgccgctcc

51 gccgctggtgctttttatcagggaagctgtgtccatggcagggaac

101 ttttggcagagctccactatttgcaatggattttggataaacaagatct

151 gttgaaggagcgccaaaaggatttaaagtttctctcagaggaagaatatt

201 ggaagttacaaatatattttacaaatggttatccaagcattaggtgaacat

251 cttaaatgaagacaacaagtattgccactgctacggtatatattcaagag

301 attctatgccagggtatttctctgaaaagtagatcctgtattaatggctc

- Hutchinson, *et al.*, *J. Biol. Chem.* **253**:6551 (1978).
- Hutchinson *et al.*, *Proc. Natl. Acad. Sci., USA* **83**:710 (1986).
- 5 Kamb, A., Gruis, N.-A., Weaver-Feldhaus, J., Liu, Q., harshman, K., Tavtigian, S.-V., Stockert, E., Day III, R.-S., Johnson, B.-E. and Skolnick, M.-H. *Science*. **264**:436-440 (1994).
- Kamb, A., Shattuck-Eidens, D., Eeles, R., Liu, Q., Gruis, N. A., Ding, W., Hussey, C., Tran, T., Miki, Y., Weaver-Feldhaus, J., McClure, M., Aitken, J. F., Anderson, D. E., Bergman, W., Frants, R., Goldgar, D. E., Green, A., MacLennan, R., Martin, N. G., Meyer, L. J., Youl, P., Zone, J. J., Skolnick, M. H., and L. A. Cannon-Albright, *Nature Gen.*, **8**:22-26 (1994).
- 10
- 15 Kato *et al.*, *Genes & Devel.*, **7**:331-342 (1993).
- Kato, J-Y., M. Matsuoka, D. K. Strom, and C. J. Sherr, *Mol Cell. Biol.*, **14**:2713-2721 (1994).
- 20 Kelsey *et al.*, *Genes and Devel.*, **1**:161-171 (1987)
- Keyomarsi, K., Conte, Jr.D., Toyofuku, W., and Fox, M.P., *Oncogene* **15**: 2612-2624 (1995).
- 25 Kidd, V.J., Luo, W., Xiang, J., Tu, F., Easton, J., McCune, S., and Snead, M.L., *Cell Growth & Differ.* **2**:85-93 (1991).
- Kimura *et al.*, *Proc. Natl. Acad. Sci., USA* **77**:1681-1685 (1980).

Kinzler, K.W., Nilbert, M.C., Su, L-K., Vogelstein, B., Bryan, T.M., Levy, D.B., Smith, K.J., Preisinger, A.C., Hedge, P., McKechnie, D., Finniear, R., Markham, A., Groffen, J., Boguski, M.S., Altschul, S.F., Horii, A., Ando, H., Miyoshi, Y., Miki, Y., Nishisho, I., and Nakamura, Y., *Science* **253**:661-665 (1991).

5

Koh, J., Enders, G. H., Dynlacht, D., and E. Harlow, *Nature*, **375**:506-510 (1995).

Kollias *et al.*, *Cell* **46**:89-94 (1986).

- 10 Kowalczyk, J.R., Grossi, M., and Sandberg, A.A., *Cancer Genetics and Cytogenet.* **15**:47-60 (1985).

Krumlauf *et al.*, *Mol. Cell Biol* **5**:1639-1648 (1985).

- 15 Lahti, J.M., Chen, C.-I.H., Tjoelker, L.W., Pickel, J.M., Schat, K.A., Calnek, B.W., Thompson, C.B., and Cooper, M.D., *Proc Natl. Acad. Sci. USA* **88**: 10595-10960 (1991).

Lahti, J.M., Valentine, M., Xiang, J., Joens, B., Amann, J., Grenet, J., Richmond, G.,

- 20 Look, A.T., and Kidd, V.J., *Nature Genetics* **7**, 370-375 (1994).

Lahti, J. M., Xiang, J., Heath, L. S., Campana, D., and V. J. Kidd, *Mol. Cell. Biol.*, **15**:1-11 (1995).

- 25 Lahue, E.E., Smith, A.V., and Orr-Weaver, T.L., *Genes & Development* **5**: 2166-2175 (1991).

Leclerc, V., Tassan, J-P., O'Farrell, P., Nigg, E.A., and Leopold, P., *Molec. Biol. Cell* **7**:505-513 (1996).

30

- Leder *et al.*, *Cell*, **45**:485-495 (1986).
- Lee, M. S., Ogg, O., Xu, M., Parker, L. L., Donoghue, D. J., Maller, J. L., and H. Piwnica-Worms, *Mol. Biol. Cell* **3**:73-84 (1992).
- 5 Lees, E. and E. Harlow, *Mol. Cell. Biol.* **13**:1194-1201 (1993).
- Leopold, P. and O'Farrell, P.H., *Cell*, **66**:1207-1216 (1991).
- 10 Lew, D.J., Dulic, V., and Reed, S.I., *Cell*, **66**:1197-1206 (1991).
- Li, H., Grenet, J., Valentine, M., Lahti, J.M., and Kidd, V.J., *Gene* **153**: 237-242 (1995).
- 15 Li, H., Lahti, J.M., Valentine, M., Saito, M., Reed, S.I., Look, A.T., and Kidd, V.J. *Genomics*, **32**:253-259 (1996a).
- Liao, S-M., Zhang, J., Jeffery, D.A., Koleske, A.J., Thompson, C.M., Chao, D.M., Viljoen, M., vanVuuren, H.J.J., and Young, R.A., *Nature* **374**, 193-196 (1995).
- 20 Lukas, J., L. Aagaard, M. Strauss, and J. Bartek, *Cancer Res.* **55**:4818-4823 (1995).
- Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., and J. Bartek, *Nature*, **375**:503-506 (1995).
- 25 Liu, Q., Neuhausen, S., McClure, M., Frye, C., Weaver-Feldhaus, J., Gruis, N. A., Eddington, K., Allalunis-Turner, M. J., Skolnick, M. H., Fujimura, F. K., and A. Kamb, *Oncogene*, **10**:1061-1067 (1995).
- 30 MacDonald, *Hepatology* **7**:425-515 (1984)).

- Marion *et al.*, *Biochem. Biophys. Res. Comm.* **113**:967-974 (1983).
- Mason *et al.*, *Science* **234**:1372-1378 (1985).
- 5 Matsushime, H., Ewen, M. E., Strom, D. K., Kato, J.-Y., Harks, S. K., Roussel, M. R., and C. J. Sherr, *Cell*, **71**:323-334 (1992).
- Matsushime, H., D. E. Quelle, S. A. Shurtleff, M. Shibuya, C. J. Sherr, and J. Kato,
10 *Mol. Cell. Biol.*, **14**:2066-2076 (1994).
- Medema, R. H., Herrera, R. E., Lam, F., and R. A. Weinberg, *Proc. Natl. Acad. Sci., USA*, **92**:6289-6293 (1995).
- 15 Meloche, S., Pages, G., and Pouyssegur, J., *J. Mol. Biol. Cell*, **3**:63-71 (1992).
- Merrifield, *J. Am. Chem. Soc.* **85**:2149-2154 (1963).
- Minshull, J., R. Golsteyn, C. S. Hill, and T. Hunt, *EMBO J.*, **9**:2865-2875 (1990).
- 20 Mogram *et al.*, *Nature* **315**:338-340 (1985).
- Morgan, D. O., *Nature*, **374**:131-134 (1995).
- 25 Nobori, T., K. Miura, D. -J Wu, A. Lois, K. Takabayashi, and D. A. Carson, *Nature*, **368**:753-756 (1994).
- O'Neill, E.M. and O'Shea, E.K., *Nature*, **374**:121-122 (1995).

- Ohtsubo, M., Theodoras, A.M., Schumacher, J., Roberts, J.M., and Pagano, M., *Mol. Cell. Biol.*, **15**:2612-2624 (1995).
- Okuda, T., Hirai, H., Valentine, V. A., Shurtleff, S. A., Kidd, V. J., Lahti, J. M., Sherr, C. J., and J. R. Downing, *Genomics*, **2**:623-630 (1995).
- Oliphant *et al.*, *Gene* **44**:177 (1986).
- Ornitz *et al.*, *Cold Spring Harbor Symp. Quant. Biol.* **50**:399-409 (1986)
- Ossipow, V., Tassan, J. P., Nigg, E. A., and V. Schibler, *Cell*, **83**:137-146 (1995).
- Parker, I. L., Atherton-Fessler, S., and H. Piwnica-Worms, *Proc. Natl Acad. Sci. USA* **89**:2917-2921 (1992).
- Parry, D., S. Bates, D. J. Mann, and G. Peters, *EMBO J.*, **14**:503-511 (1995).
- Pearson *et al.*, *Proc Natl Acad Sci. USA* **85**:2444-48 (1988).
- Pelech, S. L. and J. S. Sanghera, *TIBS*, **17**:233-238 (1992).
- Pietenpol, J. A., Bohlander, S. K., Sato, Y., Papadopoulos, N., Liu, B., Friedman, C., Trask, B. J., Roberts, J. M., Kinzler, K. W., Rowley, J. D., and B. Vogelstein, *Cancer Res.* **55**:1206-1210 (1995).
- Pinkert *et al.*, *Genes and Devel.* **1**:268-276.
- Polyak, K., Kato, J.-Y., Solomon, M.J., Sherr, C.J., Massague, J., Roberts, J. M., and A. Koff, *Genes & Devel.*, **8**:9-22 (1994).

Prigogina, E.L., Puchkova, G.P., and Mayakova, S.A., *Cancer Genet & Cytogenetics*, **32**:183-195 (1988).

Quelle, D. E., F. Zindy, R. A. Ashmun, and C. J. Sherr, *Cell* **83**:993-1000 (1995).

5

Ranade, K., C. J. Hussussian, R. S. Sikorski, H. E. Varmus, A. M. Goldstein, M. A. Tucker, M. Serrano, G. J. Hannon, D. Beach, and N. C. Dracopoli, *Nature Gen.* **10**:114-116 (1995).

10 Readhead *et al.*, *Cell* **48**:703-712 (1987)).

Reeck *et al.*, *Cell* **50**:667 (1987).

Reed, J. A., F. Loganzo, C. R. Shea, G. J. Walker, J. F. Flores, J. M. Glendening, J. K.

15 Bogdany, M. J. Shiel, F. G. Haluska, J. W. Fountain, and A. P. Albino, *Cancer Res.* **55**:2713-2718 (1995).

Resnitzky, D., M. Gossen, H. Bujard, and S. L. Reed., *Mol Cell Biol.* **14**:1669-1679 (1992)

20

Rickert, P., W. Seghezzi, F. Shanahan, J-P. Tassan, E. A. Nigg, and E. Lees,

Keystone Symp., **1**:61.(Abstract) (1996).

Rosenberg, C. L., H. G. Kim, T. B. Shows, H. M. Kronenberg, and A. Arnold,

25 *Oncogene*, **6**:449-453 (1991).

Rosenberg, C. L., E. Wong, E. M. Petty, A. E. Bale, Y. Tsujimoto, N. L. Harris, and A. Arnold, *Proc. Natl. Acad. Sci., USA*, **88**:9638-9642 (1991).

- Rosenblatt, J., Y. Gu, and D. O. Morgan, *Proc. Natl. Acad. Sci., USA*, **89**:2824-2828 (1992).
- Roy, L. M., K. I. Swenson, D. H. Walker, B. G. Gabrielli, R. S. Li, H. Piwnica
5 Worms, and J. L. Maller, *J Cell Biol.*, **113**:507-514 (1991).
- Sani, *Nature* **314**:283-286 (1985).
- Serrano, M., G. J. Hannon, and D. Beach, *Nature* **366**:704-707 (1993).
- 10 Sherr, C. J., Mammalian G1 cyclins. *Cell*, **73**:1059-1065 (1993).
- Sherr, C. J., *Trends Cell Biol.*, **4**:15-18 (1993).
- 15 Sherr, C. J., *Cell*, **79**:551-555 (1994).
- Sherr, C. J. and J. M. Roberts, *Genes & Devel.*, **9**:1149-1163 (1995).
- Solomon, M. J., Harper, J. W., and J. Shuttleworth, *EMBO J.*, **12**:3133-3142 (1993).
- 20 Stewart and Young, 1984, Solid Phase Synthesis, Second Edition, Pierce Chemical Co., Rockford, IL.
- Swift *et al.*, *Cell* **38**:639-646 (1984).
- 25 Tassan, J-P., Jaquenoud, M., Leopold, P., Schultz, S.J., and Nigg, E.A., *Proc. Natl. Acad. Sci., USA*, **92**:8871-8875 (1995).
- Villa-Kamaroff *et al.*, *Proc. Natl. Acad. Sci., USA* **75**:3727-3731 (1978).
- 30

Wagner *et al.*, *Proc. Natl. Acad. Sci., USA* 78:1441-1445 (1981).

Wu *et al.*, *J. Biol. Chem.* 267:963-967 (1984).

5 Wu *et al.*, *J. Biol. Chem.* 263:14621-14624 (1988).

Xiang, J., Lahti, J.M., Grenet, J., Easton, J., and Kidd, V.J., *J. Biol. Chem.* 269:15786-15794 (1994).

10 Yamamoto *et al.*, *Cell* 22:787-797 (1981).

Zoller *et al.*, *DNA* 3:479-488 (1984).

The present invention is not to be limited in scope by the specific embodiments
15 describe herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

20 It is further to be understood that all base sizes or amino acid sizes, and all molecular weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for description.

Various publications in addition to the immediately foregoing are cited herein, the
25 disclosures of which are incorporated by reference in their entireties.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Lahti, Jill M.
Kidd, Vincent J.
- (ii) TITLE OF INVENTION: CYCLIN-C VARIANT, AND DIAGNOSTIC AND
THERAPEUTIC USES THEREOF
- (iii) NUMBER OF SEQUENCES: 53
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: David A. Jackson, Esq.
 - (B) STREET: 411 Hackensack Ave, Continental Plaza, 4th
Floor
 - (C) CITY: Hackensack
 - (D) STATE: New Jersey
 - (E) COUNTRY: USA
 - (F) ZIP: 07601
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Jackson Esq., David A.
 - (B) REGISTRATION NUMBER: 26,742
 - (C) REFERENCE/DOCKET NUMBER: 1340 1-001 N
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 201-487-5800
 - (B) TELEFAX: 201-343-1684

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1200 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AATTCGCGGC CGCCGGCCGC GGCCGGGGCA GCGGAGGGCC CGGGCCCGTC CCACGGCTCC	60
TCATGGCCGG GAACTTCTGG CAGAGCTCGC ACTATTTACA ATGGATTTTG GATAACAAG	120
ATCTACTGAA GGAGCGCCAA AAAGACTTGA AATTTCTGTC TGAAGAAGAA TATTGGAAGC	180
TACAGATATT TTTTACTAAT GTTATCCAGG CTTTAGGTGA ACATCTTAAA TTAAGACAAC	240
AAGTTATTGC CACTGCTACA GTCTACTTCA AGAGATTCTA TGCCAGATAT TCCCTAAAAA	300
GTATAGATCC AGTATTAATG GCTCCTACGT GTGTGTTTTT GGCATCCAAA GTAGAGGAGT	360
TTGGTGTTGT TTCAAATACA AGGTTGATTT CTGCTGCTAC TTCTGTATTG AAAACTAGGT	420
TTTCATATGC CTTCCCGAAG GAGTTTCCTT ATAGGATGAA CCATATACTA GAATGTGAAT	480
TCTATCTCTT AGAATTAATG GACTGCTGTT TGATAGTGTA TCATCCTTAC AGACCTTTGC	540
TCCAATATGT GCAAGATATG GGCCAAGAAG ACATGCTGCT ACCTCTTGCT TGGAGGATAG	600
TGAATGACAC ATATAGAACT GATCTTTGTC TGCTGTACCC TCCTTTCATG ATAGCTCTAG	660
CTTGCCTACA CGTGGCCTGT GTTGTCCAGC AGAAGGATGC AAGGCAATGG TTTGCTGAGC	720
TATCTGTTGA TATGGAAAAG ATTTTAGAAA TAATCAGGGT TATTCTGAAG CTGTATGAGC	780
AGTGGAAGAA CTTTGATGAG AGGAAAGAGA TGGCTACTAT TCTTAGCAAA ATGCCTAAAC	840
CAAAACCACC TCCAAACAGT GAAGGAGAAC AGGGTCCAAA TGGTAGCCAG AACTCTAGTT	900
ATAGCCAATC TTAAGACATT CCAAAGAATT TCTTTACGGA CCACTTTGAC TCAAGACATC	960
CTGGGATCTT TCCTGTGTTT ATGAAATGGA CGGAATTTTT TTAATAACAT CTTTGACAAA	1020
GAACTTAAAG AGTAAATAGC TTGTTTGTGT CAAGCATTTT GGAAGTTTTT TATTTAAAC	1080
TGCATCATTT TCTCTGAGGC TGGAGCAAAC GTACTAAGAT TTCTCAGTGT AAGGAATCAA	1140
ATGTTAAACC AAGCTGCGAA AGGGTAACGC TATCCACTCT AAAACAAATA GTTCATTACT	1200

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 477 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

AATTCGCGGC CGCCGGCCGC GGCCGGGGCA GCGGAGGGCC CGGGCCCGTC CCACGGCTCC	60
TCATGGCCGG GAACTTCTGG CAGAGCTCGC ACTATTTACA ATGGATTTTG GATAACAAG	120
ATCTACTGAA GGAGCGCCAA AAAGACTTGA AATTTCTGTC TGAAGAAGAA TATTGGAAGC	180
TACAGATATT TTTTACTAAT GTTATCCAGG CTTTAGGTGA ACATCTTAAA TTAAGACAAC	240
AAGTTATTGC CACTGCTACA GTCTACTTCA AGAGATTCTA TGCCAGATAT TCCCTAAAAA	300
GTATAGATCC AGTATTAATG GCTCCTACGT GTGTGTTTTT GGCATCCAAA GTAGAGGATA	360
AAACCAGCGC ACCTTATTGA AGCTCTTTTG ACTGTTTTGT GTGTAGGTTG TTGGCAAAC	420
AATCTTCAGG AGTTTGGTGT TGTTCAAAT ACAAGGTTGA TTTCTGCTGC TACTTCT	477

(2) INFORMATION FOR SEQ ID NO:3:

(1) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 283 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(iv) FRAGMENT TYPE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met	Ala	Gly	Asn	Phe	Trp	Gln	Ser	Ser	His	Tyr	Leu	Gln	Trp	Ile	Leu	1	5	10	15
Asp	Lys	Gln	Asp	Leu	Leu	Lys	Glu	Arg	Gln	Lys	Asp	Leu	Lys	Phe	Leu	20	25	30	
Ser	Glu	Glu	Glu	Tyr	Trp	Lys	Leu	Gln	Ile	Phe	Phe	Thr	Asn	Val	Ile	35	40	45	
Gln	Ala	Leu	Gly	Glu	His	Leu	Lys	Leu	Arg	Gln	Gln	Val	Ile	Ala	Thr	50	55	60	
Ala	Thr	Val	Tyr	Phe	Lys	Arg	Phe	Tyr	Ala	Arg	Tyr	Ser	Leu	Lys	Ser				

92

65		70		75		80									
Ile	Asp	Pro	Val	Leu	Met	Ala	Pro	Thr	Cys	Val	Phe	Leu	Ala	Ser	Lys
				85					90					95	
Val	Glu	Glu	Phe	Gly	Val	Val	Ser	Asn	Thr	Arg	Leu	Ile	Ser	Ala	Ala
			100					105					110		
Thr	Ser	Val	Leu	Lys	Thr	Arg	Phe	Ser	Tyr	Ala	Phe	Pro	Lys	Glu	Phe
		115					120					125			
Pro	Tyr	Arg	Met	Asn	His	Ile	Leu	Glu	Cys	Glu	Phe	Tyr	Leu	Leu	Glu
	130					135					140				
Leu	Met	Asp	Cys	Cys	Leu	Ile	Val	Tyr	His	Pro	Tyr	Arg	Pro	Leu	Leu
145					150					155					160
Gln	Tyr	Val	Gln	Asp	Met	Gly	Gln	Glu	Asp	Met	Leu	Leu	Pro	Leu	Ala
			165						170					175	
Trp	Arg	Ile	Val	Asn	Asp	Thr	Tyr	Arg	Thr	Asp	Leu	Cys	Leu	Leu	Tyr
		180						185					190		
Pro	Pro	Phe	Met	Ile	Ala	Leu	Ala	Cys	Leu	His	Val	Ala	Cys	Val	Val
		195					200					205			
Gln	Gln	Lys	Asp	Ala	Arg	Gln	Trp	Phe	Ala	Glu	Leu	Ser	Val	Asp	Met
	210					215						220			
Glu	Lys	Ile	Leu	Glu	Ile	Ile	Arg	Val	Ile	Leu	Lys	Leu	Tyr	Glu	Gln
225				230					235					240	
Trp	Lys	Asn	Phe	Asp	Glu	Arg	Lys	Glu	Met	Ala	Thr	Ile	Leu	Ser	Lys
			245					250					255		
Met	Pro	Lys	Pro	Lys	Pro	Pro	Pro	Asn	Ser	Glu	Gly	Glu	Gln	Gly	Pro
		260						265					270		
Asn	Gly	Ser	Gln	Asn	Ser	Ser	Tyr	Ser	Gln	Ser					
		275					280								

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 105 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Ala Gly Asn Phe Trp Gln Ser Ser His Tyr Leu Gln Trp Ile Leu
 1 5 10 15

Asp Lys Gln Asp Leu Leu Lys Glu Arg Gln Lys Asp Leu Lys Phe Leu
 20 25 30

Ser Glu Glu Glu Tyr Trp Lys Leu Gln Ile Phe Phe Thr Asn Val Ile
 35 40 45

Gln Ala Leu Gly Glu His Leu Lys Leu Arg Gln Gln Val Ile Ala Thr
 50 55 60

Ala Thr Val Tyr Phe Lys Arg Phe Tyr Ala Arg Tyr Ser Leu Lys Ser
 65 70 75 80

Ile Asp Pro Val Leu Met Ala Pro Thr Cys Val Phe Leu Ala Ser Lys
 85 90 95

Val Glu Asp Lys Thr Ser Ala Pro Tyr
 100 105

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 303 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: No

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met Val Ala Pro Arg Pro Leu Arg Arg Val Val Leu Phe Tyr Gln Gly
 1 5 10 15

Lys Leu Cys Ser Met Ala Gly Asn Phe Trp Gln Ser Ser His Tyr Leu
 20 25 30

Gln Trp Ile Leu Asp Lys Gln Asp Leu Leu Lys Glu Arg Gln Lys Asp
 35 40 45

94

Leu Lys Phe Leu Ser Glu Glu Glu Tyr Trp Lys Leu Gln Ile Phe Phe
 50 55 60
 Thr Asn Val Ile Gln Ala Leu Gly Glu His Leu Lys Leu Arg Gln Gln
 65 70 75 80
 Val Ile Ala Thr Ala Thr Val Tyr Phe Lys Arg Phe Tyr Ala Arg Tyr
 85 90 95
 Ser Leu Lys Ser Ile Asp Pro Val Leu Met Ala Pro Thr Cys Val Phe
 100 105 110
 Leu Ala Ser Lys Val Glu Glu Phe Gly Val Val Ser Asn Thr Arg Leu
 115 120 125
 Ile Ala Ala Ala Thr Ser Val Leu Lys Thr Arg Phe Ser Tyr Ala Phe
 130 135 140
 Pro Lys Glu Phe Pro Tyr Arg Met Asn His Ile Leu Glu Cys Glu Phe
 145 150 155 160
 Tyr Leu Leu Glu Leu Met Asp Cys Cys Leu Ile Val Tyr His Pro Tyr
 165 170 175
 Arg Pro Leu Leu Gln Tyr Val Gln Asp Met Gly Gln Glu Asp Met Leu
 180 185 190
 Leu Pro Leu Ala Trp Arg Ile Val Asn Asp Thr Tyr Arg Thr Asp Leu
 195 200 205
 Cys Leu Leu Tyr Pro Pro Phe Met Ile Ala Leu Ala Cys Leu His Val
 210 215 220
 Ala Cys Val Val Gln Gln Lys Asp Ala Arg Gln Trp Phe Ala Glu Leu
 225 230 235 240
 Ser Val Asp Met Glu Lys Ile Leu Glu Ile Ile Arg Val Ile Leu Lys
 245 250 255
 Leu Tyr Glu Gln Trp Lys Asn Phe Asp Glu Arg Lys Glu Met Ala Thr
 260 265 270
 Ile Leu Ser Lys Met Pro Lys Pro Lys Pro Pro Pro Asn Ser Glu Gly
 275 280 285
 Glu Gln Gly Pro Asn Gly Ser Gln Asn Ser Ser Tyr Ser Gln Ser
 290 295 300

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 267 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

95

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Drosophila melanogaster*

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```

Met Ala Gly Asn Phe Trp Gln Ser Ser His Ser Gln Gln Trp Ile Leu
1           5           10           15
Asp Lys Pro Asp Leu Leu Arg Glu Arg Gln His Asp Leu Leu Ala Leu
20           25           30
Asn Glu Asp Glu Tyr Gln Lys Val Phe Ile Phe Phe Ala Asn Val Ile
35           40           45
Gln Val Leu Gly Glu Gln Leu Lys Leu Arg Gln Gln Val Ile Ala Thr
50           55           60
Ala Thr Val Tyr Phe Lys Arg Phe Tyr Ala Arg Asn Ser Leu Lys Asn
65           70           75           80
Ile Asp Pro Leu Leu Leu Ala Pro Thr Cys Ile Leu Leu Ala Ser Lys
85           90           95
Val Glu Glu Phe Gly Val Ile Ser Asn Ser Arg Leu Ile Ser Ile Cys
100          105          110
Gln Ser Ala Ile Lys Thr Lys Phe Ser Tyr Ala Tyr Ala Gln Glu Phe
115          120          125
Pro Tyr Arg Thr Asn His Ile Leu Glu Cys Glu Phe Tyr Leu Leu Glu
130          135          140
Asn Leu Asp Cys Cys Leu Ile Val Tyr Gln Pro Tyr Arg Pro Leu Leu
145          150          155          160
Gln Leu Val Gln Asp Met Gly Gln Glu Asp Gln Leu Leu Thr Leu Ser
165          170          175
Trp Arg Ile Val Asn Asp Ser Leu Arg Thr Asp Val Cys Leu Leu Tyr
180          185          190
Pro Pro Tyr Gln Ile Ala Ile Ala Cys Leu Gln Ile Ala Cys Val Ile
195          200          205
Leu Gln Lys Asp Ala Thr Lys Gln Trp Phe Ala Glu Leu Asn Val Asp
210          215          220

```

96

Leu Asp Lys Val Gln Glu Ile Val Arg Ala Ile Val Asn Leu Tyr Glu
 225 230 235 240

Leu Trp Lys Asp Trp Lys Glu Lys Asp Glu Ile Gln Met Leu Leu Ser
 245 250 255

Lys Ile Pro Lys Pro Lys Pro Pro Pro Gln Arg
 260 265

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "Oligonucleotides C-1"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

TCCAGCAGAA GGATGCAA

18

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "Oligonucleotides C-2"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CTCCAGCACA CAGTCAAC

18

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

97

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Oligonucleotides C-3"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

AGGTGAACAT CTAAATT

18

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Oligonucleotides C-4"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

TAGGAGCCAT TAATACTG

18

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Oligonucleotides C-5"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GACCACTTTG ACTCAAGA

18

(2) INFORMATION FOR SEQ ID NO:12:

98

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "Oligonucleotides C-6"
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CTGCAGAATC ACTATACA

18

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "Oligonucleotides C-7"
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GTCCATTTCA TGAACACA

18

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "Oligonucleotides C-8"
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

AGCCATCTCT TTCCTCTC

18

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "Oligonucleotides C-9"

(iii) HYPOTHETICAL: NO

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CAAGCTAGAG CTATCATG

18

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "Oligonucleotides C-10"

(iii) HYPOTHETICAL: NO

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CGCTCCTTCA GTAGATCTTG

20

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "Oligonucleotides C-11"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

TTGAAATTTT TGTCTGAA

18

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Oligonucleotides C-12"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

AAACTCCTTC GGGAAGGC

18

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Oligonucleotides C-13"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

ATCAACAGAT AGCTCAGC

18

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

101

(A) DESCRIPTION: /desc = "Oligonucleotides C-14"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GTCTTCTTGG CCCATATC

18

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Oligonucleotides C-15"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

GTAGACTGTA GCAGTGGC

18

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Oligonucleotides C-16"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

GCATCCAAAG TAGAGGAG

18

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

102

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Oligonucleotides C-17"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

CCTTTGCTCC AATATGTG

18

(2) INFORMATION FOR SEQ ID NO:24:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Oligonucleotides C-18"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

TAGAGAATAT TCGCTTGAG

19

(2) INFORMATION FOR SEQ ID NO:25:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Oligonucleotides C-19"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

TAGTGCGAGC TCTGCCAGA

19

103

(2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "Oligonucleotides C-20"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

GAGATAGAAT TCACATTC

18

(2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "Oligonucleotides C-21"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

CTAAAAAGTA TAGATCCAGT

20

(2) INFORMATION FOR SEQ ID NO:28:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "Oligonucleotides C-22"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

TAGTGCGAGC TCTGCCAGAA GTTCC

25

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Oligonucleotides C-23"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

AACTTCTGGC AGAGCTCGCA C

21

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Oligonucleotides C-24"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

CAATGGATTT TGGATAAAC

19

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Oligonucleotides C-25"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

CTCTACTTTG GATGCCAA

18

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Oligonucleotides C-26"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

GAGTTTGGTG TTGTTTCA

18

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Oligonucleotides C-27"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

GCTCTATGCA GGTGGATT

18

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

106

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Oligonucleotides C-28"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

GAAACTACAG GTGCTGAG

18

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Oligonucleotides C-29"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

AGCTATCATG AAAGGAGG

18

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Oligonucleotides C-30"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

AGGATAGTGA ATGACACA

18

(2) INFORMATION FOR SEQ ID NO:37:

107

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "Oligonucleotides C-31"
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

ATAATCAGGG TTATTCTG

18

(2) INFORMATION FOR SEQ ID NO:38:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "Oligonucleotides C-41-1"
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

GCACCTTATT GAAGCTCT

18

(2) INFORMATION FOR SEQ ID NO:39:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "Oligonucleotides C-41-2"
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

GTTTGCCAAC AACCTACA

18

(2) INFORMATION FOR SEQ ID NO:40:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "Oligonucleotides C-41-3"
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

GATAAAACCA GCGCACCT

18

(2) INFORMATION FOR SEQ ID NO:41:

- (1) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "Oligonucleotides C-41-4"
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

CTGAAGATTA GTTTGCCA

18

(2) INFORMATION FOR SEQ ID NO:42:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: other nucleic acid
 - (A) DESCRIPTION: /desc = "Oligonucleotides CPP-1"
- (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

AGCGCACCTT ATTGAAGCTC TT

22

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Oligonucleotides CPP-2"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

AGGCAAGCTA GAGCTATCAT GA

22

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Oligonucleotides CPP-3"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

AGATCTACTG AAGGAGCGCC AA

22

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

110

(A) DESCRIPTION: /desc = "Oligonucleotides CPP-4"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

AGATTAGTTT GCCAACAACC TACA

24

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Oligonucleotides PRIMER 1"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

GACTTGCTGG CTGCCTCATA

20

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Oligonucleotides PRIMER 2"

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

ATATATGAAA GGTATTACAG CCACAA

26

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:

111

- (A) LENGTH: 1508 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

GAGCGCGGTT ACCGGACGGG CTGGGTCTAT GGTGCTCCG CGGCCGCTCC GCCGCGTGGT	60
GCTTTTTTAT CAGGGCAAGC TGTGTTCCAT GGCAGGGAAC TTTTGCCAGA GCTCCCACTA	120
TTTGCAATGG ATTTTGGATA AACAAGATCT GTTGAAGGAG CGCCAAAAGG ATTTAAAGTT	180
TCTCTCAGAG GAAGAATATT GGAAGTTACA AATATTTTTT ACAAATGTTA TCCAAGCATT	240
AGGTGAACAT CTTAAATTAA GACAACAAGT TATTGCCACT GCTACGGTAT ATTTCAAGAG	300
ATTCTATGCC AGGTATTCTC TGAAAAGTAT AGATCCTGTA TTAATGGCTC CTACATGTGT	360
GTTTTTGGCA TCCAAAGTAG AGGAATTGG AGTAGTTTCA AATACAAGAT TGATTGCTGC	420
TGCTACTTCT GTATTAAAAA CTAGATTTTC ATATGCCTTT CCAAAGGAAT TTCCTTATAG	480
GATGAATCAT ATATTAGAAT GTGAATTCTA TCTGTTAGAA CTAATGGATT GTTGCTTGAT	540
AGTGTATCAT CTTTATAGAC GTTTGCTCCA GTATGTGCAG GACATGGGCC AAGAAGACAT	600
GTTGCTTCCC CTTGCATGGA GGATAGTGAA TGATACCTAC AGAACGGATC TTTGCCTACT	660
GTATCCTCCT TTCATGATAG CTTTAGCTTG CCTACATGTA GCCTGTGTTG TACAGCAGAA	720
AGATGCCAGG CAATGGTTTG CTGAGCTTTC TGTGGATATG GAAAAGATTT TGGAAATAAT	780
CAGGGTTATT TTAAACTAT ATGAGCAGTG GAAGAATTTC GATGAGAGAA AAGAGATGGC	840
AACCATTCTT AGTAAGATGC CAAAACCAAA ACCACCTCCA AACAGTGAAG GAGAGCAGGG	900
TCCAAATGGA AGTCAGAACT CTAGCTACAG CCAATCTTAA AACATTCCGA AGAATTCCAT	960
AGTGGACCAC TTGGAAATAA ACCATTGGAC AGATTTCACT AATGTCTTCA GTGGAACACA	1020
AATGAAAATG AATAGCTTGT TTCTGTCAAG CATATTGGAA AGTGATTTTA TTTTTCAGAA	1080
TAGTTTTTCT TTAATATGAT TCTAGTACAT AATTGATTGA TTAAATCTCT TGATTATAAA	1140
TGTTTGAAAA GGTCTAAGG GGACCTACAG ACAGACATAC ATAGACATTT CAAAATTAAT	1200

AGCTTTTGAT TAGTATAATA TTTCTTAATT TGGATAATAA AAATTGTAGC TTTTATTAA	1260
GCCAGGAAAC ATGAAGCATA ATTTGTTTAA AATTCTCTTT GGTCATTGAG GGACCAAAAA	1320
AGGACGTAAA ATTTACAGTC AATCTATGAG GGTTTTTTTC CCTCCATAAG TTAACTTTA	1380
AAACTGTATT TAAGGAATCA AATCTTACAA AATCCTGGAA GATTTTGGTA ATGATGTTGA	1440
TAATTTTCAGG GAAATTAATC AAGTACCGTA TATTGATTAA AAAGTGTATT TTATTCAGTA	1500
GTTTGAGG	1508

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1006 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

GAGCGCGGTT ACCGGACGGG CTGGGTCTAT GGTGCTCCG CGGCCGCTCC GCCGCGTGGT	60
GCTTTTTTAT CAGGGCAAGC TGTGTTCCAT GGCAGGGAAC TTTTGGCAGA GCTCCCACTA	120
TTTGCAATGG ATTTTGGATA AACAAGATCT GTTGAAGGAG CGCCAAAAGG ATTTAAAGTT	180
TCTCTCAGAG GAAGAATATT GGAAGTTACA AATATTTTTT ACAAATGTTA TCCAAGCATT	240
AGGTGAACAT CTTAAATTAA GACAACAAGT TATTGCCACT GCTACGGTAT ATTTCAAGAG	300
ATTCTATGCC AGGTATTCTC TGAAAAGTAT AGATCCTGTA TTAATGGCTC CTACATGTGT	360
GTTTTTGGCA TCCAAAGTAG AGGAATTTGG AGTAGTTTCA AATACAAGAT TGATTGCTGC	420
TGCTACTTCT GTATTAAAAA CTAGATTTTC ATATGCCTTT CCAAAGGAAT TTCCTTATAG	480
GATGAATCAT ATATTAGAAT GTGAATTCTA TCTGTTAGAA CTAATGGATT GTTGCTTGAT	540
AGTGTATCAT CTTTATAGAC CTTTGCTCCA GTATGTGCAG GACATGGGCC AAGAAGACAT	600
GTTGCTTCCC CTTGCATGGA GGATAGTGAA TGATACCTAC AGAACGGATC TTTGCCTACT	660
GTATCCTCCT TTCATGATAG CTTTAGCTTG CCTACATGTA GCCTGTGTTG TACAGCAGAA	720

113

AGATGCCAGG CAATGGTTTG CTGAGCTTTC TGTGGATATG GAAAAGATTT TGGAAATAAT 780
 CAGGGTTATT TTAAAACTAT ATGAGCAGTG GAAGAATTTT GATGAGAGAA AAGAGATGGC 840
 AACCATTCTT AGTAAGATGC CAAAACCAAA ACCACCTCCA AACAGAAATT CCCTGAGTGA 900
 TAAGGCAATA ATCTATTGCA AAGTTACTGT GAAGGAGAGC AGGGTCCAAA TGGAAGTCAG 960
 AACTCTAGCT ACAGCCAATC TTAAACATT CCGAAGAATT CCATAG 1006

(2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 325 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

Met Val Ala Pro Arg Pro Leu Arg Arg Val Val Leu Phe Tyr Gln Gly
 1 5 10 15
 Lys Leu Cys Ser Met Ala Gly Asn Phe Trp Gln Ser Ser His Tyr Leu
 20 25 30
 Gln Trp Ile Leu Asp Lys Gln Asp Leu Leu Lys Glu Arg Gln Lys Asp
 35 40 45
 Leu Lys Phe Leu Ser Glu Glu Glu Tyr Trp Lys Leu Gln Ile Phe Phe
 50 55 60
 Thr Asn Val Ile Gln Ala Leu Gly Glu His Leu Lys Leu Arg Gln Gln
 65 70 75 80
 Val Ile Ala Thr Ala Thr Val Tyr Phe Lys Arg Phe Tyr Ala Arg Tyr
 85 90 95
 Ser Leu Lys Ser Ile Asp Pro Val Leu Met Ala Pro Thr Cys Val Phe
 100 105 110
 Leu Ala Ser Lys Val Glu Glu Phe Gly Val Val Ser Asn Thr Arg Leu
 115 120 125
 Ile Ala Ala Ala Thr Ser Val Leu Lys Thr Arg Phe Ser Tyr Ala Phe
 130 135 140

114

Pro Lys Glu Phe Pro Tyr Arg Met Asn His Ile Leu Glu Cys Glu Phe
 145 150 155 160
 Tyr Leu Leu Glu Leu Met Asp Cys Cys Leu Ile Val Tyr His Pro Tyr
 165 170 175
 Arg Pro Leu Leu Gln Tyr Val Gln Asp Met Gly Gln Glu Asp Met Leu
 180 185 190
 Leu Pro Leu Ala Trp Arg Ile Val Asn Asp Thr Tyr Arg Thr Asp Leu
 195 200 205
 Cys Leu Leu Tyr Pro Pro Phe Met Ile Ala Leu Ala Cys Leu His Val
 210 215 220
 Ala Cys Val Val Gln Gln Lys Asp Ala Arg Gln Trp Phe Ala Glu Leu
 225 230 235 240
 Ser Val Asp Met Glu Lys Ile Leu Glu Ile Ile Arg Val Ile Leu Lys
 245 250 255
 Leu Tyr Glu Gln Trp Lys Asn Phe Asp Glu Arg Lys Glu Met Ala Thr
 260 265 270
 Ile Leu Ser Lys Met Pro Lys Pro Lys Pro Pro Pro Asn Arg Asn Ser
 275 280 285
 Leu Ser Asp Lys Ala Ile Ile Tyr Cys Lys Val Thr Val Lys Glu Ser
 290 295 300
 Arg Val Gln Met Glu Val Arg Thr Leu Ala Thr Ala Asn Leu Lys Thr
 305 310 315 320
 Phe Arg Arg Ile Pro
 325

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 854 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

115

GAGCGCGGTT ACCGGACGGG CTGGGTCTAT GGTGCTCCG CGGCCGCTCC GCCGCGTGGT	60
GCTTTTTTAT CAGGGCAAGC TGTGTTCCAT GGCAGGGAAC TTTTGGCAGA GCTCCCACTA	120
TTTGCAATGG ATTTTGGATA AACAAGATCT GTTGAAGGAG CGCCAAAAGG ATTTAAAGTT	180
TCTCTCAGAG GAAGAATATT GGAAGTTACA AATATTTTTT ACAAATGTTA TCCAAGCATT	240
AGGTGAACAT CTTAAATTAA GACAACAAGT TATTGCCACT GCTACGGTAT ATTTCAAGAG	300
ATTCTATGCC AGGTATTCTC TGAAAAGTAT AGATCCTGTA TTAATGGCTC CTACATGTGT	360
GTTTTTGGCA TCCAAAGTAG AGGAATTTGG AGTAGTTTCA AATACAAGAT TGATTGCTGC	420
TGCTACTTCT GTATTAAAAA CTAGATTTTC ATATGCCTTT CCAAAGGAAT TTCCTTATAG	480
GATGAATCAT ATATTAGAAT GTGAATTCTA TCTGTTAGAA CTAATGGTAA GTAAATCTTC	540
TGTGATTAAT AGATTAAAC ATTTTAAAT TAAATGAAGT TGGAAATTAT TTAAAGAAAT	600
GATTTTAGAG AGGTACATTT TAAACCATC CACCTAATAT GTGATGGTGA AATCATGGTA	660
GCCTATTTAT ATTAGCACCT AGAGTCTCTC TGAAGCCTGT AAAATAATTT GTATATCCTA	720
CTTAGGATGG GAAAATTTTT CTGTTCTATA GTAAGTAACT ATAATGAAAG GATTACAAAC	780
AGACAAGTCA GGACATTAAA CCACCATAAA TTATGTGCAC AATTTGTGTG TGCGTGCAGT	840
GTTATTTAAA GATA	854

(2) INFORMATION FOR SEQ ID NO:52:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 179 amino acids
- (B) TYPE amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

Met	Val	Ala	Pro	Arg	Pro	Leu	Arg	Arg	Val	Val	Leu	Phe	Tyr	Gln	Gly
1					5				10					15	
Lys	Leu	Cys	Ser	Met	Ala	Gly	Asn	Phe	Trp	Gln	Ser	Ser	His	Tyr	Leu
			20					25					30		

116

Gln Trp Ile Leu Asp Lys Gln Asp Leu Leu Lys Glu Arg Gln Lys Asp
 35 40 45
 Leu Lys Phe Leu Ser Glu Glu Glu Tyr Trp Lys Leu Gln Ile Phe Phe
 50 55 60
 Thr Asn Val Ile Gln Ala Leu Gly Glu His Leu Lys Leu Arg Gln Gln
 65 70 75 80
 Val Ile Ala Thr Ala Thr Val Tyr Phe Lys Arg Phe Tyr Ala Arg Tyr
 85 90 95
 Ser Leu Lys Ser Ile Asp Pro Val Leu Met Ala Pro Thr Cys Val Phe
 100 105 110
 Leu Ala Ser Lys Val Glu Glu Phe Gly Val Val Ser Asn Thr Arg Leu
 115 120 125
 Ile Ala Ala Ala Thr Ser Val Leu Lys Thr Arg Phe Ser Tyr Ala Phe
 130 135 140
 Pro Lys Glu Phe Pro Tyr Arg Met Asn His Ile Leu Glu Cys Glu Phe
 145 150 155 160
 Tyr Leu Leu Glu Leu Met Val Ser Lys Ser Ser Val Ile Asn Arg Leu
 165 170 175
 Lys His Phe

(2) INFORMATION FOR SEQ ID NO:53:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 815 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

AAACCATCT AATATTCTGT TCCATAAATA TACCTATTAA AATTAATTTT ATAACAAAAC 60
 ACAGACTGTA AACATAAAAA TTAAGGACAA GTTNTCTTTA AAGTAATCAG GATACTTTTT 120
 GGTACTCTGC AACATACAT ATAAATTTAC TGTATAATTT CTGGTTTTTT AATTGATTT 180

TTCTGATTTT TAAAAAATTA GAAAAATGTG TTTATAATTT GTTATGAGAT TTTGAAATTT	240
AAAATATATT TAGCTGTAAT TTTATTCATT GATATGTGCT TATTTGTTGT CACATTCATG	300
TATCCATCCT TTGTCCTTGA TGTTTTCACT TTTATAGCTG TGCTTCAGTA GTATAAAAGG	360
AAATAAATGT GTGCAAAGAT GGGAAATCTG GCCCTCTCTG GAGGAAATAT ACAATCAGAT	420
GAGGTAGTTC TGCTTTCAGT AATAATATGA TTTACATTTT TATAGGAGGA TAGTGAATGA	480
TACCTACAGA ACGGATCTTT GCCTACTGTA TCCTCCTTTC ATGATAGCTT TAGCTTGCCT	540
ACATGTAGCC TGTGTTGTAC AGCAGAAAGA TGCCAGGCAA TGGTTTGCTG AGCTTTCTGT	600
GGATATGGAA AAGATTTTGG AAATAATCAG GGTATTTTAA AACTATATG AGCAGTGGAA	660
GAATTTTCGAT GAGAGAAAAG AGATGGCAAC CATTCTTAGT AAGATGCCAA AACCAAAACC	720
ACCTCCAAAC AGTCAAGGAG AGCAGGGTCC AAATAAGGCA ATAATCTATT GCAAAGTTAC	780
TTGGAAGTCA GAACTCTAGC TACAGCCAAT CTTAA	815

WHAT IS CLAIMED IS:

- 1 1. An isolated amino acid polymer corresponding to a peptide or protein that is
2 encoded by an alternatively spliced cyclin C mRNA, wherein said amino acid
3 polymer hinders the formation of an active cyclin C-cdk8 complex.
- 1 2. The amino acid polymer of Claim 1 that, in addition, has a binding affinity for
2 cdk8.
- 1 3. The amino acid polymer of Claim 1 which is a truncated form of cyclin C.
- 1 4. The amino acid polymer of Claim 3 wherein the truncated form of cyclin C
2 comprises at least about 20% of the amino acid sequence encoded by the cyclin-box
3 region.
- 1 5. The amino acid polymer of Claim 4 having an amino acid sequence of SEQ ID
2 NO:4.
- 1 6. The amino acid polymer of Claim 1 which is *Human*.
- 1 7. The amino acid polymer of Claim 6 having the amino acid sequence of SEQ
2 ID NO:52.
- 1 8. The amino acid polymer of Claim 1 labeled with a detectable label.
- 1 9. An isolated amino acid polymer corresponding to a human cyclin C that does
2 not encode a PEST sequence rich carboxy terminal domain.
- 1 10. The amino acid polymer of Claim 9 having the amino acid sequence of SEQ
2 ID NO:50.

- 1 11. An antibody for the amino acid polymer of Claim 1 wherein said antibody
2 binds said amino acid polymer preferentially over the full-length form of cyclin C.
- 1 12. The antibody of Claim 11 which is selected from the group consisting of a
2 polyclonal antibody, a monoclonal antibody and a chimeric antibody.
- 1 13. An immortal cell line that produces a monoclonal antibody according to Claim
2 12.
- 1 14. An isolated nucleic acid that encodes the amino acid polymer of Claim 1.
- 1 15. The nucleic acid of Claim 14 encoding an amino acid polymer having an
2 amino acid sequence selected from the group consisting of a SEQ ID NO:4; and SEQ
3 ID NO:52.
- 1 16. The nucleic acid of Claim 15 comprising a nucleotide sequence selected from
2 the group consisting of the coding region of SEQ ID NO:2 and the coding region of
3 SEQ ID NO:51.
- 1 17. A transformed unicellular host comprising the nucleic acid of Claim 14.
2 wherein said nucleic acid is a recombinant DNA operatively linked to an expression
3 control sequence.
- 1 18. An expression vector comprising the nucleic acid of Claim 14 operatively
2 linked to an expression control sequence, wherein the nucleic acid is DNA.
- 1 19. A transgenic animal comprising the expression vector of Claim 18
2 homologously recombined in a chromosome.

- 1 20. A transgenic animal in which the gene encoding the amino acid polymer of
2 Claim 1 has been disrupted, wherein the transgenic animal cannot express the amino
3 acid polymer in a functional form.
- 1 21. A pharmaceutical composition for treating oncogenesis comprising:
2 a therapeutically effective amount of a material selected from the group
3 consisting of the amino acid polymer of Claim 1, an agent capable of promoting the
4 production and/or activity of said amino acid polymer, an agent capable of mimicking
5 the activity of said amino acid polymer, an agent capable of inhibiting the production
6 and/or activity of said amino acid polymer, and mixtures thereof.
- 1 22. An isolated amino acid polymer having the amino acid sequence of SEQ ID
2 NO:3.
- 1 23. An isolated nucleic acid that encodes the amino acid polymer of Claim 22.
- 1 24. An isolated nucleic acid encoding an amino acid polymer having an amino
2 acid sequence of SEQ ID NO:50.
- 1 25. The nucleic acid of Claim 24 comprising the coding region of the nucleotide
2 sequence of SEQ ID NO:49.
- 1 26. An antibody to the amino acid polymer of Claim 9 wherein said antibody
2 binds to said amino acid polymer preferentially relative to binding to the full-length
3 form of cyclin C.
- 1 27. A method of preventing and/or treating oncogenesis, comprising administering
2 to an animal a therapeutically effective amount of a material selected from the group
3 consisting of the amino acid polymer of Claim 1, an agent capable of promoting the
4 production and/or activity of said amino acid polymer, an agent capable of mimicking

5 the activity of said amino acid polymer, an agent capable of inhibiting the production
6 of said amino acid polymer, and mixtures thereof.

1 28. A method of delivering the recombinant DNA molecule of Claim 14 to a
2 target cell which comprises providing a virus-derived vector that has been modified to
3 comprise the recombinant DNA molecule and causing said vector to transduct said
4 cell.

1 29. The method of Claim 28 wherein the recombinant DNA molecule comprises a
2 gene that is transcribed in said target cell either constitutively or under regulatable
3 conditions.

1 30. The method of Claim 29 wherein the target cell is a human cell.

1 31. A nucleotide probe for screening for the nucleic acid of Claim 14 prepared
2 from a nucleotide sequence selected from the group consisting of nucleotides 527-771
3 of SEQ ID NO:51; nucleotides 357-429 of SEQ ID NO:2; and SEQ ID NO:53.

1 32. A nucleotide probe for screening for the nucleic acid of Claim 24 prepared
2 from nucleotides 885-928 of SEQ ID NO:49

AATTCGGCGCCGCGCGCGCGAGCGGAGCGGCCCGCTCCTCATGGCCGGGAACCTTCTGGCAGAGCTCGCACTATTTTACAATGGATTTTGATATAACAAG
M A G N F W Q S S H Y L Q W I L D K Q D

V

21 ATCTACTGAGGAGCGCCAAAGAAGACTTGAATTTCTGTCTGAAGAAGAATNTTGGARGCTACAGATATTTTTTACTAATGTTATCCAGGCCTTTAGGTGAACATCTTAATTAATTAAGACAAC
L L K E R Q K D L K F L S E E E Y W K L Q I F F T N V I Q A L G E H L K L R Q Q

V

41 AAGTTATTGCCACTGCTACAGCTACTTCAAGAGATTCTATGCCAGATATTCCTAAAAGTATAGATCCAGTATTAATGGCTCCTACGTGTGTGTTTTTGGCATCCCAAAGTAGAGCAGT
V I A T A T V Y F K R F Y A R Y S L K S I D P V L M A P T C V F L A S K V E E F

V

61 TTGGTGTGTTTCAAATACAAAGGTTGATTTCTGTCTACTTCTGTATTTGAAAAGTAGGTTTTTCATATGCCTTCCGAAAGGAGTTTTCCTTATAGGATGAACCATATATACTAGAAATCTGAAT
G V V S N T R L I S A A T S V L K T R F S Y A F P K E F P Y R M N H I L E C E F

V

81 TCTATCTCTTAGAATTAATGCACTGCTGTTTGATAGTGTATCATCTTACAGACCTTTTGCTCCAATATGTGCAAGATATGGGCCAAGAGACATGCTGCTACCTCTTGCTTGGAGGATAG
Y L L E L M D C C L I V Y H P Y R P L L Q Y V Q D M G Q E D M L L P L A W R I V

V

01 TGAATGACACATATAGAACTGATCTTTGTCTGCTGTACCCTCTTTCATGATAGCTCTAGCTTGCTCACAGTGGCCTGTGTTGTCCAGCAGAAGGATGCAAGGCAATGGTTTGTCTGAGC
N D T Y R T D L C L L Y P P F M I A L A C L H V A C V V Q Q K D A R Q W F A E L

V

21 TATCTGTTGATATGGAACATTTTAGAATAATCAGGGTTATTCTGAAGCTGTATGAGCAGTGGAGCACTTTGATGAGAGGADAGAGATGGCTACTATTCTTAGCAAAATGCCTAAC
S V D M E K I L E I I R V I L K L Y E Q W K N F D E R K E M A T I L S K M P K P

V

41 CAAAACCACTCCAAACAGTGAAGGAGAACAGGGTCCAAATGGTAGCCAGAACTCTAGTTATAGCCAAATCTTAAGACATTCCTAAAGAAATTTCTTTACGGACCACTTTGACTCAAGACATC
K P P P N S E G E Q G P N G S Q N S S T S Q S

V

51 CTGGGATCTTCTGTGTTTCAATGAATGGACGGAAATTTTTTAATAACATCTTTTGACAAAGAACTTAAAGAGTAAATAGCTTGTGTTGTCTAAGCATTTTGGAAAGTTTTTCTTTAAAAAC

081 TGCAATCAATTTCTCTGAGGCTGGAGCAACGTAAGATTTCTCAGTGTAAAGGAATCAAAATGTTAAACCAAGCTGCGAAAGGGTAAACGCTATCCACTCTAAACAAATAGTTTCATTAT/

FIG. 1A

2 / 1 5


FIG. 1B

3 / 15

	M	V	A	P	R	P	L	R	R	V	V	L	F	Y	Q	G	K	L	C	S	M	M	A	G	N	F	W	Q	S	S	H	Y	L	Q	W	I	L	D	K	Q	D
11	L	L	K	E	R	Q	K	D	L	K	F	L	S	E	E	E	Y	W	K	L	Q	I	F	F	T	N	V	I	Q	A	L	G	E	H	L	K	L	R	Q	Q	
11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
11	-	-	R	-	-	-	H	-	-	L	A	-	N	-	D	-	Q	-	V	F	-	-	-	A	-	-	-	-	-	V	-	-	-	Q	-	-	-	-	-	-	
11	V	I	A	T	A	T	V	Y	F	K	R	F	Y	A	R	Y	S	L	K	S	I	D	P	V	L	M	A	P	T	C	V	F	L	A	S	K	V	E	E	F	
11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	-	-	I	L	-	-	-	-	-	-	-	-		
01	G	V	V	S	N	T	R	L	I	S	A	A	T	S	V	L	K	T	R	F	S	Y	A	F	P	K	E	F	P	Y	R	M	N	H	I	L	E	C	E	F	
21	-	-	-	-	-	-	-	-	-	A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
01	-	-	I	-	-	S	-	-	-	S	I	C	Q	-	A	I	-	-	K	-	-	-	-	Y	A	Q	-	-	-	-	-	T	-	-	-	-	-	-	-	-	
41	Y	L	L	E	L	M	D	C	C	L	I	V	Y	H	P	Y	R	P	L	L	Q	Y	V	Q	D	M	G	Q	E	D	M	L	L	P	L	A	W	R	I	V	
61	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
41	-	-	-	-	N	L	-	-	-	-	-	-	-	Q	-	-	-	-	-	-	-	L	-	-	-	-	-	-	-	-	Q	-	-	T	-	S	-	-	-		
81	N	D	T	Y	R	T	D	L	C	L	L	Y	P	P	F	M	I	A	L	A	C	L	H	V	A	C	V	V	Q	Q	K	D	A	-	R	Q	W	F	A	E	
01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
81	-	-	S	L	-	-	-	V	-	-	-	-	-	-	Y	Q	-	-	I	-	-	-	Q	I	-	-	-	-	I	L	-	-	-	T	K	-	-	-	-		
20	L	S	V	D	M	E	K	I	L	E	I	I	R	V	I	L	K	L	Y	E	Q	W	K	N	F	D	E	R	K	E	M	A	T	I	L	S	K	M	P	K	
40	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
21	-	N	-	-	L	D	-	V	Q	-	-	-	-	-	-	-	-	-	-	-	L	-	-	-	D	W	K	-	K	D	-	I	Q	M	L	-	-	-	-	-	
60	P	K	P	P	P	N	S	E	G	E	Q	G	P	N	G	S	Q	N	S	S	T	S	Q	S	*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
80	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
61	-	-	-	-	-	-	Q	R	*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		

FIG.1C

FIG. 2



5' / 15

FIG. 3A





FIG. 3B



6 / 15

FIG. 4A




FIG. 4B



FIG. 4C




FIG. 4D




FIG. 4E

	0	2	4	6	8	10	12	14	Asynch.
%G1	2	46	34	13	7	27	33	42	20
%S	36	10	43	73	61	33	43	38	60
%G2/M	62	44	23	14	32	40	24	20	20

7 / 15

FIG. 5A





FIG. 5B



10 / 15

FIG. 7B

351 ctacatgtgtgtttttggcatccaaagtagaggaatttgagtagtttca

401 aatacaagattgattgctgctgctacttctgtattaaaaactagatttc

451 atatgcctttccaaaggaaatttccttataggatgaatcatatatagaat

501 gtgaattctatctgttagaaactaatggattgttcttgatagtgatcat

551 ccttatagacctttgctccagtatgtgcaggacatgggccaagaagacat

601 gttgctcccccttgcatggaggatagtgaaatgataacctacagaacggatc

651 tttgcctactgtatcccttccttcatgatagctttagcttgccctacatgta

11 / 15

FIG. 7C

```
701  gcctgtgtgtgtacagcagaaagatgccaggcaatgggtttgctgagctttc
-----
751  tgtggatatggaaaagattttggaaataatcagggttatTTTaaactat
-----
801  atgagcagtggaaagaatttcgatgagagaaaaagagatggcaaccattctt
-----
851  agtaagatgccaaaaccaaaaccacctccaaca//////////
-----gaaattccctgagtga
901  ////////////////////////////////////gtgaaggagagcagggccaaa
taaggcaataatcttatTgcaaagtTact-----
951  tggaaagtcagaactctagctacagccaatcttaaaacattccgaagaatt
-----
1001 ccatag
-----
```

12 / 15

1 MVAPRPLRRVVLFYQGKLCMAGNFWQSSHYLQWILDKQD

41 LLKERQKDLKFLSEEEYWKLOIFFTNVIQALGEHLKLRQQ

81 VIATATVYFKRFYARYSLKSIDPVLMAPTCVFLASKVEEF

121 GVSNTRLIAAATSVLKTRFSYAFPKEFPYRMNHILECEF

161 YLLELM//////////DCCLIVYHPYRPLLQYVQDMG
-----VSKSSVINRLKHF*
201 QEDMLLPLAWRIVNDTYRTDLCLLYPPFMIALACLHVACV
241 VQOKDARQWFAELSVDMEKILEIIRVILKLYEQWKNFDER
281 KEMATILSKMPKPKPPPNSEGEQGPNGSQNSSYSQS

FIG.8

13 / 15

1 gagcgcggttaccggacgggctgggtctatggctcgctccgcgggccgctcc

51 gccgcgtggtgcttttttatcagggcaagctgtgttccatggcaggggaac

101 ttttggcagagctcccactatttgcaatggattttggataaacaagatct

151 gttgaaggagcgccaaaaggatttaaagtttctctcagaggaagaatatt

201 ggaagttacaaatattttttacaaatgttatccaagcattaggtgaacat

251 cttaaattaagacaacaagttattgccactgctacgggtatatttcaagag

301 attctatgccagggtatttctctgaaaagtatagatcctgtattaatggctc

351 ctacatgtgtgttttttggcatccaaagtagaggaatttggagtagtttca

401 aatacaagattgattgctgctgctacttctgtattaaaaactagattttc

451 atatgcctttccaaaggaatttccttataggatgaatcatatattagaat

Exon 7

501 gtgaattctatctgttagaactaatg////////////////////////////////////
-----gtaagtaaattcttctgtgattaat
////////////////////////////////////
agattaaaacatttttaaattaaatgaagttggaaattatttaaagaaat
////////////////////////////////////
gatttttagagaggtacattttaaaaccatccacctaatatgtgatggtga
////////////////////////////////////
aatcatggtagcctatttatattagcacctagagtctctctgaagcctgt

FIG.9A

14 / 15

////////////////////////////////////
aaaataatttgatatatcctacttaggatgggaaaatttttctgttctata

////////////////////////////////////
gtaagtaactataatgaaaggattacaaacagacaagtcaggacattaaa

////////////////////////////////////
ccaccataaattatgtgcacaatttgtgtgtgcgtgcagtgttatttaaa

//// : : : : : : : :
gata : : : : : : : :

Exon 8

527 gattgttgcttgatagtgatcatccttatagacctttgctccagtgatgtg
: :

caggacatgggccaagaagacatggttgcttcccttgcat: : : : : : : : : :
: :

////////////////////////////////////
aaaccattctaataattctgttccataaataacattataaaattaatttt

////////////////////////////////////
ataacaaaacacagactgtaaataaaaaattaaggacaagttntcttta

////////////////////////////////////
aagtaatcaggatactttttggtagtgctgcaaatacatataaaatttac

////////////////////////////////////
tgtataatttctggttttttaatttgatttttctgatttttaaaaaatta

////////////////////////////////////
gaaaaatgtgtttataatttggtatgagattttgaaatttaaaatatatt

////////////////////////////////////
tagctgtaattttattcattgatatgtgcttatttggtgtcacattcatg

////////////////////////////////////
tatccatccttttgcttgatgttttcacttttatagctgtgcttcagta

////////////////////////////////////
gtataaaaggaaataaatgtgtgcaaagatgggaaatctggccctctctg

////////////////////////////////////
gaggaaatatacaatcagatgaggtagttctgctttcagtaataatatga-

FIG.9B

15 / 15

/////////
tttacatttctata

Exon 9

590 ggaggatagtgaatgatacctacagaacggatc

622 ttgcctactgtatcctcctttcatgatagctttagcttgcctacatgta

673 gcctgtgttgtagcagcagaaagatgccaggcaatggtttgctgagctttc

724 tgtggatatggaaaagattttggaaataatcagggttatttttaaactat

775 atgagcagtggagaattttcgatgagagaaaagagatggcaaccattctt

826 agtaagatgccaaaaccaaaccacctccaaacagtcaaggagagcaggg

877 tccaaataaggcaataatctattgcaaagttacttggaagtcagaactct

928 agctacagccaatcttaa

FIG.9C

INTERNATIONAL SEARCH REPORT

Intern. Appl. No.

PCT/US 97/09709

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/465 C07K14/47 C07K16/18 C12N5/10
A01K67/027 A61K38/17 A61K31/70 A61K48/00 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A01K A61K C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EMBL Database entry GG40873; Accession number U40873; 20.11.1995; Li H. et al.: 'Gallus gallus cyclin C mRNA.' XP002039161 see abstract	22,23
A	CELL, vol. 66, 1991, pages 1197-1206, XP002039130 LEW D.J. ET AL.: "Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast." cited in the application see the whole document, especially Fig. 3A and from page 1199, right column, last paragraph to page 1200, right column, bottom line	1-32

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

2 September 1997

Date of mailing of the international search report

16.09.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Mandl, B

INTERNATIONAL SEARCH REPORT

Interr. Application No
PCT/US 97/09709

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 666 270 A (BRISTOL-MYERS SQUIBB COMPANY) 9 August 1995 see the whole document, especially page 4, lines 46-58 and page 7, lines 44-57 ---	1-32
A	WO 93 24514 A (MITOTIX) 9 December 1993 see the whole document, especially page from 6, line 27 to page 7, line 14 and from page 20, line 16 to page 21, line 11 ---	1-32
A	PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 8871-8875, XP002039131 TASSAN J.-P. ET AL.: "Identification of human cyclin-dependent kinase 8, a putative protein kinase partner for cyclin C." cited in the application ---	1-32
A	SCIENCE, vol. 240, 1988, pages 1544-1546, XP002039132 JASKULSKI D. ET AL.: "Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNA cyclin." see the whole document ---	21,27
P,X	ONCOGENE, vol. 13, no. 4, 15 August 1996, pages 705-712, XP002039133 LI H. ET AL.: "Alternatively spliced cyclin C mRNA is widely expressed, cell cycle regulated, and encodes a truncated cyclin box." see the whole document ----- ---	1-32

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/09709

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely.
Please see Further Information sheet enclosed.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows.

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 97/09709

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

Remark : Although claim 27 and claims 28-30 partially, as far as they concern an in vivo method, are directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/09709

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0666270 A	09-08-95	US 5625031 A	29-04-97
		CA 2140379 A	09-08-95
		JP 7316196 A	05-12-95
WO 9324514 A	09-12-93	NONE	